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1 Summary 
Melanoma is the deadliest form of skin cancer with over 20,000 deaths alone in Europe 
each year. Novel therapeutic strategies targeting mutated kinases in the mitogen-
activated protein kinase (MAPK) signaling pathway as well as the blockade of immune 
checkpoints lead to significantly improved response and survival rates compared to 
standard chemotherapies. However, not all patients profit from these new therapeutics 
and acquired resistance remains an unsolved problem. Therefore, discovering new 
potential targets for therapy is still in focus of basic melanoma research. 
Melanoma develops from malignant transformation of melanocytes. During embryonic 
development melanocytes derive from multipotent neural crest cells (NCCs). Typical 
features of NCCs are a high proliferation rate, an enormous plasticity, and a strong 
migratory ability along defined routes. 
A key factor for proliferation and survival of NCCs and subsequent differentiation to 
melanocytes is the transcription factor sex determining region-Y (SRY)-box 10 (SOX10). 
SOX10 is not only expressed during embryonic development of melanocytes but also 
serves as a specific marker of the melanocytic lineage. Characteristic features during 
embryonic development of melanocytes resemble key features in tumor initiation and 
progression. It stands to reason that SOX10 may regulate similar capacities during 
melanoma progression. Therefore, this study focused on investigating the role of 
SOX10 in melanoma. 
Expression of SOX10 and the closely related transcription factor SOX9 were examined 
in human skin and melanoma cells. SOX10 expression was found abundantly in 
melanocytes and most melanoma cell lines but not in fibroblasts, whereas SOX9 
expression was weak in melanocytes and fibroblasts and highly variable in melanoma 
cell lines. In a subset of melanoma cell lines, SOX10 and SOX9 expression correlated 
inversely. 
Inhibition of SOX10 expression in melanoma cells by RNA interference induced cell 
cycle arrest, reduced cell viability and led to onset of (intrinsic) apoptosis. Moreover, 
SOX10 inhibition significantly reduced melanoma cell invasion in two- and three-
dimensional invasion models, independent of onset of cell death. It was discovered that 
the reduced invasion capacity was mediated by melanoma inhibitory activity (MIA). MIA 
is a well-described secreted protein in melanoma cells that promotes migration and 
invasion and negatively correlates with patient’s prognosis. Direct transactivation of MIA 
by SOX10 was found in this study. 
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Moreover, another novel target gene of SOX10 was detected by RNA sequencing 
studies and verified by promoter binding studies: peripheral myelin protein 2 (PMP2). 
PMP2 is a small, lipid-binding, and membrane-associated β-barrel protein that is one of 
the most important proteins in the composition of the myelin sheath of Schwann cells. In 
this study, PMP2 expression was found in a subset of melanoma cell lines, along with 
other myelin proteins. Strikingly, PMP2 overexpression was able to enhance melanoma 
cell invasion. 
In summary, this study shows that SOX10 is a key regulator of the invasion capacity of 
melanoma cells and activates invasion-promoting proteins such as MIA and PMP2. 
Therefore, SOX10 seems to be not only essential for the development of melanocytes 
but also critical for their neoplastic transformation and melanoma progression. 
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Zusammenfassung 
Das Melanom ist die tödlichste Form des Hautkrebses mit jährlich über 20.000 
Todesfällen allein in Europa.  
Neue Therapiemöglichkeiten, insbesondere die Blockade von mutierten Kinasen des 
mitogenassoziierte Proteinkinase-Signalwegs und von Immun-Kontrollstellen, haben zu 
signifikant verbesserten Ansprech- und Überlebensraten verglichen mit Standard-
Chemotherapien geführt. Jedoch profitieren nicht alle Patienten von den neuen 
Therapien und das häufige Auftreten erworbener Resistenzen bleibt weiterhin ein 
ungelöstes Problem. Daher stellt die Identifizierung neuer potenziell therapierbarer 
Faktoren im Melanom weiterhin einen wesentlichen Forschungsschwerpunkt dar. 
Melanomzellen stammen von entarteten Melanozyten ab. Während der 
Embryonalentwicklung entstehen Melanozyten aus multipotenten Neuralleistenzellen. 
Charakteristische Eigenschaften der Neuralleistenzellen sind eine hohe 
Proliferationsrate, eine ausgeprägte Plastizität und eine Migrationsfähigkeit entlang 
definierter Wege. 
Ein wesentlicher Faktor, der die Proliferation und das Überleben der Neuralleistenzellen 
sowie ihre Differenzierung zu Melanozyten sicherstellt, ist der Transkriptionsfaktor sex 
determining region-Y (SRY)-box 10 (SOX10). SOX10 wird nicht nur während der 
Embryonalentwicklung von Neuralleistenzellen exprimiert, sondern stellt auch einen 
spezifischen Marker für melanozytäre Zellen dar. 
Charakteristische Schritte bei der Embryonalentwicklung von Melanozyten ähneln 
denen der Tumorentstehung und Progression. Es liegt nahe, dass SOX10 ähnliche 
Funktionen bei der Melanomentstehung regulieren könnte. Deshalb konzentrierte sich 
diese Arbeit auf die Erforschung der Rolle von SOX10 im Melanom. 
Die Expression von SOX10 und dem nah verwandten Transkriptionsfaktor SOX9 wurde 
in humanen Haut- und Melanomzellen untersucht. Während SOX10 ausgeprägt in 
Melanozyten und in den meisten Melanom-Zelllinien, aber nicht in Fibroblasten 
nachgewiesen werden konnte, war die Expression von SOX9 in Fibroblasten und 
Melanozyten schwach und sehr variabel in Melanom-Zelllinien. In einigen Melanom-
Zelllinien wurde eine inverse Expression von SOX10 und SOX9 festgestellt. 
Eine Hemmung der SOX10-Expression in Melanomzellen mittels RNA-Interferenz führte 
zu Zellzyklus-Arrest, reduzierter Zellvitalität und (intrinsischer) Apoptose. Darüber 
hinaus wurde die Invasivität von Melanomzellen nach SOX10-Hemmung signifikant 
herabgesetzt und zwar unabhängig vom Einsetzen des Zelltods. Dies wurde in zwei- 
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und drei-dimensionalen Invasionsmodellen gezeigt. Als Vermittler dieser reduzierten 
Migrationsfähigkeit wurde melanoma inhibitory activity (MIA) entdeckt. MIA ist ein 
bereits gut beschriebenes sezerniertes Protein im Melanom, welches Migration und 
Invasivität fördert und einen negativen prognostischen Faktor für Melanompatienten 
darstellt. Die direkte Transaktivierung von MIA durch SOX10 konnte in dieser Studie 
gezeigt werden. 
Darüber hinaus wurde peripheral myelin protein 2 (PMP2) als weiteres neues Zielgen 
von SOX10 mittels RNA-Sequenzierung entdeckt und durch Promotor-Bindestudien 
verifiziert. 
PMP2 ist ein kleines, Lipid-bindendes und Membran-assoziiertes β-Fass-Protein, 
welches eines der wichtigsten Proteine beim Aufbau der Myelinscheide von Schwann-
Zellen darstellt. In dieser Studie konnten PMP2 und andere Myelin-Proteine in wenigen 
Melanom-Zelllinien nachgewiesen werden. Eine Überexpression von PMP2 erhöhte die 
Melanomzell-Invasivität. 
Zusammenfassend konnte gezeigt werden, dass SOX10 maßgeblich die Invasions-
Kapazität von Melanomzellen reguliert und Invasions-fördernde Proteine wie MIA und 
PMP2 direkt reguliert. Somit scheint SOX10 nicht nur essenziell für die Entwicklung von 
Melanozyten zu sein, sondern auch eine entscheidende Rolle bei ihrer neoplastischer 
Transformation und der Melanomprogression zu spielen. 
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2 Introduction 
Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths and 
14.1 million new cases in 2012 [269]. A substantive increase in cancer-related deaths is 
estimated due to growth and ageing of the global population. In Germany, 25% of death 
cases are related to cancer, which makes it the second common cause of death behind 
cardiovascular diseases (www.destatis.de). 
Over 25 years of research have focused on the issue of how a normal human body cell 
can transform into a malignant one. The basis of this research has been set by the 
discovery of specific mutations: oncogenes with gain-of-function or suppressors with 
loss-of-function, which cause cancer phenotypes in experimental models. Hence, it 
seems that most types of human cancer share a small number of molecular, 
biochemical, and cellular changes that drive the progressive malignant conversion [95].  
Cancer cells are characterized by their potential to proliferate indefinitely. They grow 
independent from growth signals and are resistant to growth inhibitors. Furthermore 
they show a high resistance against controlled cell death (apoptosis). They provide their 
own nutrition and oxygen by sustaining angiogenesis and are capable to overcome 
natural borders by invading in the surrounding tissue. Thereby they can spread to other 
organs, a process that is called metastasis.  
Melanoma, the black skin cancer, is one of the deadliest types of cancer due to its rapid 
potential to progress, metastasize, and its high resistance against standard radio- and 
chemotherapies. Melanoma originates from neoplastically transformed melanocytes, the 
pigment cells of the skin. 
2.1 Melanocyte Development 
Pigment-producing melanocytes populate in the integument, inner ear, and eyes of 
vertebrate organisms. They originate as melanoblasts from the neural crest, which is 
formed at the edge of the neural plate on the border between the neural and non-neural 
ectoderm [131], [223]. Neural crest cells (NCCs) constitute a multipotent, highly 
migratory cell population that has the ability of self-renewal and is unique to vertebrate 
embryos. During or after neural tube closure, NCCs undergo epithelial-to-mesenchymal 
transition (EMT), start to migrate on distinct ways throughout the body and give rise to 
many cell derivatives (Figure 1). The fate of NCCs mostly depends on where they 
locally originate along the neuraxis, migrate and settle.  
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Cranial NCCs migrate dorsolaterally to produce the craniofacial mesenchyme that 
differentiates into cartilage, bone, cranial neurons, glia, and connective tissue of the 
face [233]. Cells from the vagal and sacral neural crest generate the parasympathetic 
(enteric) ganglia of the gut. The cardiac neural crest lies between the cranial and trunk 
neural crest and gives rise to smooth muscle cells from the heart outflow tract.  
 
Figure 1: Embryonic development of neural crest cells.  
After neurulation NCCs migrate out and differentiate into multiple cell types. While ventrolaterally 
migrating trunk NCCs differentiate to neurons and glial cells, dorsolaterally migrating cells become 
melanocytes. 
Cells originating from the trunk neural crest after closure of the neural tube take two 
different pathways: ventrally and ventrolaterally migrating NCCs, between the somites 
and neural tube, form the sensory (dorsal root) and sympathetic neurons, 
adrenomedullary cells, and glial cells. On the other hand, cells migrating dorsolaterally 
into the ectoderm and continue toward the ventral midline of the belly become 
melanoblasts. While some studies demonstrate that melanocyte specification occurs in 
multipotent neural crest stem cells, others propose that lineage segregation already 
occurs in a premigratory stage [34], [138]. Non-melanoblast cells migrating along the 
dorsolateral pathway are eliminated by apoptosis [280]. However, it was shown that a 
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fraction of melanoblasts arises from NCCs migrating ventrally along the nerves that 
innervate the skin to acquire the melanocytic fate after detaching from these nerves at 
around embryonic stage 11 in mice [2]. 
The induction and specification of the neural crest depends on a strictly regulated 
network of signaling molecules and transcription factors. Neural crest formation, initiated 
during gastrulation by formation of a neural plate border, is dependent on fibroblast 
growth factor (FGF), bone morphogenic protein (BMP), Notch, and wingless (Wnt) 
signaling [66], [79], [142]. These signaling pathways activate transcription factors that 
define the neural plate border, e.g., zinc finger protein 1 (ZIC1), msh homeobox 1 
(MSX1), MSX2, distal-less homeobox 3 (DLX3), DLX5, paired box protein 3 (PAX3), 
PAX7, and activator protein 2 (AP-2) [224]. To acquire the capability to emigrate from 
the neuroepithelium during EMT, NCCs undergo changes in their cytoskeleton, 
morphology, and cell contact molecules. Thereby they interact differently with other cells 
and their environment in comparison to non-migratory cells. These events are 
orchestrated by another class of transcription factors termed neural crest specifiers 
such as Snail, Slug, sex determining region Y (SRY)-box E (SoxE), forkhead box D3 
(FOXD3), AP-2, Twist, avian myelocytomatosis viral oncogene homolog c (c-Myc), and 
inhibitor of DNA-binding protein (ID) family members. They furthermore regulate NCC 
proliferation, cell cycle control, and differentiation into several derivatives as mentioned 
before.  
NCCs, designated to become melanoblasts, express specific markers like the receptor 
tyrosine kinase c-KIT. KIT signaling is required for melanoblast proliferation, survival, 
and migration [290]. A further marker is microphthalmia-associated transcription factor 
(MITF). Its expression is a key event in melanocyte specification [154], [190]. MITF 
regulates melanoblast proliferation through its target gene T-box 2 (TBX2) and survival 
through the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) [273]. Furthermore, it drives 
differentiation by activating enzymes for melanogenesis, i.e., tyrosinase, tyrosinase-
related protein 1 (TYRP1), and dopachrome tautomerase (DCT), melanocytic surface 
proteins, i.e., silver, melanocortin 1 receptor (MC1R) and melanoma antigen (MLANA) 
as well as the tumor suppressor absent in melanoma 1 (AIM1). It has also been 
suggested that MITF transcriptionally activates Slug [221], a transcription factors that 
promotes EMT as mentioned before. MITF expression itself is regulated by PAX3, 
lymphoid enhancer-binding factor-1 (LEF1) through canonical Wnt signaling, cyclic 
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adenosine monophosphate (cAMP) response element-binding protein (CREB) via 
MC1R signaling, and sex determining region Y (SRY)-box 10 (SOX10) [273].  
Melanoblast specification and proliferation is further regulated by transcription factors as 
FOXD3, SOX9, SOX10, PAX3, Slug, AP-2, and transcription factor AP-2 alpha 
(TCFAP2α) [88], [179], [249]. 
At their target sites, the fully specified melanocytes produce melanin and transfer the 
pigment in melanosomes to adjacent keratinocytes. This pigment transfer leads to hair 
and skin coloring and protects the skin cells from damage by ultraviolet (UV) radiation 
[120]. Defects in NCC migration, proliferation and/or differentiation can cause genetic 
disorders, like Hirschsprung disease with reduced enteric ganglia, Waardenburg 
Syndrome (reduced melanocytes and hypopigmentation), and a number of cancers 
including melanoma.  
2.2 From melanocytes to melanoma 
One hallmark of cancer is the ability to reproduce indefinitely. Normal cells require 
mitogenic growth signals to change from a quiescent state into an active proliferative 
state. For cancer cells, three common molecular strategies are evident for achieving 
autonomy: altering extracellular growth signals, transcellular transducers of these 
signals, or intracellular circuits that translate those signals into action [95]. 
Malignant transformation of melanocytes to melanoma cells requires several 
simultaneous or sequential steps. Some melanomas develop de novo in the dermis or 
in association with congenital nevi [93], [287]. Others arise within the epidermis and 
invade across the basement membrane. 
Wallace H. Clark described a classical histopathological pathway for the progression of 
melanocytes to melanoma [50] (Figure 2). The initiating step is the deregulated 
proliferation of melanocytes forming benign nevi followed by the formation of dysplatic 
nevi (clinical atypical nevus) occurring in pre-existing nevi or at new locations. Following 
transformation, melanocytes require the ability to proliferate intraepidermally and 
therefore this state is termed radial growth phase (RGP). The critical step in 
melanomagenesis is the progression of radial to vertical growth phase (VGP), where 
melanoma cells gain the ability to invade the dermis. This deep invasion enhances the 
potential of melanoma cells to disseminate via lymphatic or hematogenous routes, 
spread to distant organs and form distant tumors (metastases).  
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Figure 2: Clark model describing the development of malignant melanoma.  
Typical genetic changes leading to progression of the stages nevus to metastasis are depicted within the 
figure and described in the text. BM = basement membrane, RGP = radial growth phase, VGP = vertical 
growth phase. 
Under normal conditions, melanocyte proliferation in the epidermis is strictly regulated 
by their symbiotic relationship with keratinocytes. Melanocytes and keratinocytes are 
physically attached to each other with E-cadherin as the major adhesion molecule being 
expressed on both cell types [113], [264]. During melanoma progression, changes in 
expression of adhesion molecules contribute to deregulated proliferation and 
transformation. E-cadherin, P-cadherin, and desmoglein are downregulated through 
autocrine secretion of growth factors (GFs) or altered secretion of GFs by keratinocytes 
and fibroblasts upon ultraviolet (UV) irradiation [13], [14], [117], [156]. E-cadherin loss is 
a crucial event in the progression from RGP to VGP and is likely mediated by Snail, 
which is expressed in melanoma cells but not in melanocytes [202]. Furthermore, 
upregulation of receptors and signaling molecules such as N-cadherin and melanoma 
cell adhesion molecule (Mel-CAM) as well as altered expression of cell-matrix adhesion 
molecules and metalloproteases enhances self-assembly and decoupling from the 
basement membrane in transformed melanocytes [98], [113]. Thus, the 
microenvironment influences melanoma progression distinctively and its alteration is 
mediated by UV irradiation.  
An important signaling pathway in melanocyte transformation and melanoma 
progression is the mitogen-activated protein kinase (MAPK) pathway. This pathway is 
activated by GFs that are recognized by cell surface receptors. Upon binding of these 
GFs, an intracellular signaling chain of kinases is turned on, that eventually activates 
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factors, which promote cell growth and proliferation. Mutations of mediators in this 
pathway lead to constitutive activation and thereby deregulated cell cycle progression.  
The first oncogene identified in melanoma was neuroblastoma rat sarcoma viral 
oncogene homolog (NRAS) [61], [192]. It is a membrane-associated guanosine 
triphosphate (GTP)-binding protein, which can trigger a number of intracellular signaling 
pathways including the MAPK and phospoinositide 3-kinase (PI3K) / protein kinase B 
(PKB also known as AKT) / mammalian target of rapamycin (mTOR) pathways. The 
PI3K pathway is an intracellular signaling pathway that regulates quiescence and 
proliferation. 
V-Raf murine sarcoma viral oncogene homolog B (BRAF), a serine/threonine kinase in 
the MAPK pathway, is mutated in around 50-60% of melanomas [110]. BRAF mutations 
occur also in benign nevi suggesting that they represent an early event in the 
progression of neoplastically transformed melanocytes to melanoma [57], [201], [236]. 
Notwithstanding, additional genetic changes are required for malignant transformation 
of nevus cells. Another early event in the neoplastic progression are mutations within 
the telomerase reverse transcriptase (TERT) promoter that causes lengthening of 
telomeres in DNA strands [236]. Thereby, cells of early neoplastic lesions are dividing 
rather than being senescent presumably with reduced proliferation due to counteracting 
events e.g. replicative stress. 
Mutations in the cyclin-dependent kinase N2A (CDKN2A) gene locus, encoding for 
inhibitor of cyclin-dependent kinase 4a (p16INK4A) and alternative reading frame 
(p14ARF), eliminate tumor suppressive pathways. CDKN2A mutation carriers have a 
higher risk of developing melanoma [16]. In a well established melanoma mouse model, 
overexpression of NRAS together with loss of p16INK4A  has resulted in melanoma 
formation, whereas loss of p16INK4A alone was not sufficient for malignant transformation 
[1]. 
It was suggested that BRAF and phosphatase and tensin homolog (PTEN) cooperate in 
melanoma progression [270]. PTEN is an inhibitor of the PI3K. Loss of PTEN activates 
the PI3K/AKT/mTOR pathway, promoting cell growth and survival.  
Inactivation of the tumor suppressor p53 is a general event in cancer development. 
Although mutations in the tumor protein 53 (TP53) gene are rare in melanoma, 
functional inactivation of p53 has been shown through several alternative mechanisms 
such as amplification of mouse double minute 2 homolog (MDM2), which abrogates p53 
functions [181]. 
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Another signaling pathway that is highly susceptible for mutations in melanocytes is the 
pathway of melanogenesis. Upon UV radiation, keratinocytes produce and secret α-
melanocyte stimulating hormone (α-MSH) binding to MC1R on melanocytes and 
thereby upregulating MITF via cAMP and CREB [177]. Genetic variants of MC1R and 
MITF are associated with pigmentary phenotypes and an increased melanoma risk. 
MITF gene amplification and mutations have been found in metastatic melanoma and 
overexpression of MITF together with BRAF V600E contributes to melanocyte 
transformation [54], [80]. 
In summary, multiple events act together in the progression from melanocytes to 
melanoma, including genetic aberrations and influences from the microenvironment, 
which both can be induced by UV irradiation. 
2.3 Malignant melanoma 
Over 90% of melanoma cases evolve from a primary tumor that develops from 
melanocytes in the skin as the most common site of origination (cutaneous melanoma). 
Less common sites are the choroidal and retina layer of the eye (uveal melanoma) as 
well as respiratory, gastrointestinal, and genitourinary mucosal surfaces. In 1969, Clark 
and colleagues described criteria for clinical and histological subtypes of malignant 
melanoma with the main types superficial spreading, nodular, lentigo maligna, and acral 
lentiginous melanoma (ALM) [51]. These types allow a clinical diagnosis according to 
the ABCDE rule (A=asymmetry, B=border, C=color, D=diameter > 6mm, E=evolving) in 
80% of cases [74].  
So far, early detection and surgical excision remain the best gold standard of tumor 
therapy. Once the primary tumor has metastasized, the prognosis worsens dramatically. 
For evaluation of prognosis, appropriate therapy and follow-up, melanoma is classified 
in stages and subcategories according to the American Joint Committee on Cancer 
(AJCC). These implicate thickness, ulceration, and mitotic rate (mitoses per mm2) of the 
primary tumor, affection of lymph nodes, and distant metastases [9]. While the 10-year 
survival rate of patients with a small primary tumor (< 1mm) is about 90%, the 5-year 
survival rate of patients with distant metastasis is only about 17%. 
Risk factors for the development of melanoma include a history of sunburns and 
intermittent exposure to strong sunlight, i.e., UV radiation. UVB (290-320 nm) can 
directly induce DNA damage, resulting in the formation of highly genotoxic cyclobutane 
pyrimidine dimers and pyrimidine(6-4)pyrimidone photoproducts. UVA (320-400 nm) 
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can generate free radicals, in particular reactive oxygen species, which also can cause 
DNA damage. Besides of these direct effects on DNA, indirect effects of UV radiation 
such as immunosuppression and stimulation of GFs, as mentioned before, contribute to 
melanoma development [12]. 
A family history of melanoma occurs in about 10% of melanoma patients and confers an 
approximately two-fold increase in melanoma risk [78]. Also phenotypical aspects like 
fair skin, red hair, freckles, numerous nevi, and atypical nevi are associated with 
increased melanoma risk. 
Melanoma is an immunogenic tumor, i.e., a healthy immune system generates a strong 
immune response to melanoma cells. As a consequence the risk for melanoma is 
higher in immunocompromised patients like organ transplant recipients and acquired 
immune deficiency syndrome (AIDS) patients [175]. 
Considering the risk factors for melanoma and the ability of early detection of primary 
lesions, preventive measures such as sun protection and regular skin examinations 
have been propagated for many years. This may be the reason why in spite of 
increasing incidences the melanoma mortality rate remains rather constant. 
2.4 Melanoma therapy and resistance 
The first-line therapies of melanoma are surgical excision of the primary tumor and 
biopsy of the sentinel lymph node, the first draining lymph node of the site of the primary 
tumor. Advanced metastatic melanoma is characterized by high resistance against 
radiation and chemotherapy with a median survival of only 6-9 months and a 3-year 
survival rate of only 10-15% of patients [9]. Therefore, the development of novel 
therapeutical strategies against malignant melanoma is of utmost importance. 
Although melanoma is an immunogenic tumor, cytokine-based immunotherapy with 
interferon (IFN) and interleukin-2 (IL-2) has only shown limited benefit.  
Nevertheless, novel immunotherapeutic strategies targeting the blockade of T-cell 
activation with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-
programmed cell death ligand 1 (PD-L1), and anti-programmed cell death 1 receptor 
(PD1) antibodies showed promising efficacy [109], [217], [298]. CTLA-4 is a 
transmembrane inhibitory receptor expressed on activated T-lymphocytes that 
downregulates T-cell activation upon binding to antigen presenting cells (APCs) [114]. 
PD-1 is expressed on T-cells and its ligand PD-L1 on melanoma cells and both act as 
negative regulators of T-cells. CTLA-4 antibody ipilimumab and PD-1 antibodies 
  Introduction 
 
13 
nivolumab and pembrolizumab have been approved for treatment of metastatic 
melanoma by the Food and Drug Administration (FDA) and the European medicines 
agency (EMA) in 2011 and 2014/2015, respectively. 
A milestone of melanoma treatment was set by the discovery of activating somatic point 
mutations in the BRAF gene driving melanoma cell proliferation and transformation via 
the MAPK-pathway (Figure 3) [57]. About 50% of all cutaneous melanomas carry a 
BRAF mutation, with V600E as the most common in about 80% and V600K in about 12-
20% of cases [162], [163]. The frequency of BRAF mutations is higher in melanoma 
than in other human cancers. It has become an ideal target for therapy. Indeed, the 
treatment of patients with a BRAF V600-mutated melanoma with the BRAF-specific 
inhibitor vemurafenib (PLX4032) showed unprecedented objective response rates and a 
significant increase in overall survival in comparison to standard chemotherapy [42], 
[174]. Vemurafenib has been approved for melanoma therapy in 2011 in the USA and 
2012 in Europe. Despite of the great success of this targeted monotherapy, about 50% 
of patients relapsed after about 7-8 months due to acquired resistance to therapy. 
Investigations of the underlying resistance mechanisms demonstrated that the MAPK 
signaling pathway is reactivated in 70-80% of cases most commonly by RAS mutations, 
BRAF amplifications, BRAF alternative splicing, or by mutations in mitogen-activated 
protein kinase kinases (MEK) or MITF [216], [272]. Other resistance mechanisms 
include the activation of the PI3K/AKT pathway, an upregulation of receptor tyrosine 
kinase (RTK) signaling (e.g. fibroblast growth factor receptor 3 [FGFR3], platelet-
derived growth factor receptor β [PDGFRβ], insulin-like growth factor 1 receptor 
[IGF1R]), and a downregulation of Bcl-2 homology (BH3)-only proteins [184], [240], 
[242], [277], [300]. 
Recent studies have demonstrated that the combination of BRAF-specific inhibitors 
(vemurafenib or dabrafenib) with MEK inhibitors (cobimetinib or trametinib) could further 
increase response rates, progression-free survival and overall survival in comparison to 
BRAF inhibitor monotherapy in advanced BRAF-mutated melanoma patients [147], 
[161]. The dabrafenib/trametinib combination has been approved by the FDA 2014 and 
by the EMA 2015, while the vemurafenib/cobimetinib combination has been approved 
2015. However, also these combined therapies show relapses after around 11-12 
months due to acquired resistance, especially by reactivation of the MAPK pathway 
[160]. Thus, new therapeutic strategies are based on a combination of inhibitors that 
abrogate resistance [106]. 
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Although the majority of therapeutic strategies have been focused on mutations in 
BRAF, NRAS was the first identified oncogene in melanoma [192]. NRAS mutations are 
present in about 20% of melanoma cases with the most common mutations in codon 61 
[150]. NRAS and BRAF mutations are mutually exclusive and 75% of melanomas have 
either mutation [85]. However, mutated NRAS is not targetable with drugs competing for 
the catalytic site, because NRAS activating mutations impair GTPase activity and an 
inhibitor would have to restore the GTPase activity, which has not been found yet. Thus, 
an alternative therapeutic strategy for NRAS mutant melanoma patients is targeting the 
downstream signaling of RAS including MEK, extracellular signal-related kinase (ERK), 
PI3K, and cyclin-dependent kinase 4 and 6 (CDK4/6) [7], [209].  
In uveal melanoma BRAF and NRAS mutations are very rare, while 46% of cases show 
a mutation in the heterotrimeric guanine nucleotide binding protein Q (GNAQ) gene at 
position Q209, leading to an active Gα protein that activates the MAPK pathway via 
BRAF [189]. Another mutation in this family of receptor molecules is the mutation of 
guanine nucleotide binding protein 11 (GNA11), which is mutually exclusive to the 
GNAQ mutation and occurs in 32% of uveal melanoma cases [274].  
Further common mutations in malignant melanoma include activating mutations in the 
receptor tyrosine kinase c-KIT (20-30 % of ALM, mucosal melanomas and melanomas 
on chronically sun-damaged skin), inactivation of PTEN (30-50% of melanomas), 
mutations in the PI3K/AKT pathway (PI3K subunit phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha [PIK3CA] and AKT3), and loss-of-function 
mutations in neurofibromin 1 (NF1) - a negative regulator of RAS-signaling - in 
approximately 25% of BRAF/NRAS-wild type melanomas [48], [56], [85], [110], [232], 
[270]. 
In summary, a lot of achievements have been made in terms of melanoma therapy 
especially regarding immune checkpoint blockade and targeted mutation-based 
therapy. However the complex network of oncogenes and signal transduction requires 
interventions at multiple sites and therefore the identification of novel therapeutical 
targets is still a requisite for the successful treatment of melanoma. 
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Figure 3: Mutation-prone signaling pathways in melanoma.  
Illustrated is the MAPK pathway, activated via RTKs and mediated by GTP-coupled NRAS or GNAQ/11, 
leading to activation of BRAF that in turn activates MEK and ERK by phosphorylation. NRAS also 
activates the PI3K/AKT pathway. CDK4/6, which can be blocked by p16INK4A, drives cell cycle progression 
from G1- to S-phase. Several mediators of these pathways are commonly mutated in melanoma as 
described in the text (section 2.4). TF = transcription factor. 
2.5 Linking melanomagenesis to the embryonic development of 
melanocytes 
Fundamental processes of embryonic melanocyte development and regeneration share 
a great deal of cellular and genetic events with their malignant transformation [294]. 
During early embryonic development, NCCs represent a highly proliferative and 
multipotent cell population before specification into certain cell types. Melanoblasts 
migrate along the dorsolateral axis of the embryo while they continue to expand and 
promote their own survival. They possess an almost unlimited capacity of self-renewal, 
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which can be also found in regenerative processes of adult melanocytes, e.g., during 
hair and skin coloration. 
In contrast to malignant progression, embryogenesis and regenerative processes are 
strictly regulated. Regenerative melanocytic stem cells can be found in the bulge of hair 
follicles. During the hair follicle cycle, differentiated melanocytes are generated in the 
bulge region and migrate from the bulge to the bulb where they transfer melanin to hair-
producing keratinocytes and thereby induce hair coloring [244]. The process of hair 
graying can be linked to a gradual failure to maintain the melanocyte stem cell self-
renewal in the hair follicle bulge and can be analyzed in mouse models with defects in 
hair pigmentation [186], [187].  
Characteristics of embryonic and adult stem cells, which are the potential of self-
renewal, differentiation, and almost unlimited proliferation [213] have also been 
described in a subpopulation of cancer cells that are extremely aggressive, resistant to 
radiation and chemotherapy, and have a specific capacity for tumor initiation: the cancer 
stem cells. This subpopulation has also been characterized in melanoma and can be 
detected by the expression of stem cell markers like CD133 (also known as prominin-1), 
ATP binding cassette sub-family B member 5 (ABCB5), CD271 (also known as p75 
neurotropin receptor or nerve growth factor receptor), and the enzyme aldehyde 
dehydrogenase [19], [23], [73], [225].  
Another feature that melanoma cells share with developing melanoblasts is the ability to 
migrate extensively, since NCCs migrate out, and „metastasize“ to numerous sites of 
the body. Strikingly, melanoma cells express a number of lineage-specific markers that 
are typical for embryonic and regenerating melanocytes like endothelins and their 
corresponding receptor endothelin receptor type B (EDNRB), and c-KIT [143], [183]. 
Interestingly, transcription factors commonly expressed in melanoma cells are also 
required specifically during melanocyte development, especially in migratory NCCs. The 
transcription factor Slug, which plays an important role in EMT in NCCs, promotes 
metastasis of transformed melanocytes [91]. Another example is MITF, which is the key 
factor for melanocyte differentiation during embryogenesis, and which has been shown 
to be involved in melanoma initiation and progression [154]. Therefore, studies of 
lineage specific transcription factors, which regulate developmental programs that are 
recapitulated during melanomagenesis, can provide insight into the genetic causes of 
melanoma and its progression. 
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2.6 SOX transcription factors in development and disease 
The SOX transcription factor family comprises approximately 30 vertebrate and over a 
dozen invertebrate gene or gene fragment members, with 20 orthologous pairs of SOX 
genes in human and mice, which are named after the original member SRY (sex-
determining region-Y) [29], [227]. All Sox members share a similar DNA-binding high-
mobility group (HMG) domain that recognizes the consensus sequence 5’-
(A/T)(A/T)CAA(A/T)G-3’. The HMG domain contains two nuclear localization signals 
and a nuclear export signal for shuttling the protein between nucleus and cytoplasm. 
With this domain, SOX transcription factors bind to the minor groove of the DNA and 
induce a strong structural bend, indicating that they exert structural roles on regulatory 
DNA regions [289]. SOX factors can bind the DNA as monomers or hetero- and 
homodimers [164], [197], [255]. They often function in cooperation with other 
transcription factors that influence their activity. SOX proteins are involved in a diverse 
range of developmental processes, reflecting their evolutionary history in metazoans. 
They can be divided into nine subgroups: A, B1, B2, C, D, E, F, G, and H (Table 1). 
SOX group Genes and major known or deduced functions 
A SRY (testis determination) 
B1 SOX1 (lens development, neural determination), SOX2 (neural 
induction, lens induction, pluripotency), SOX3 (neural determination, 
lens induction) 
B2 SOX14 (interneuron specification, limb development), SOX21 (central 
nervous system patterning) 
C SOX4 (heart, lymphocyte, thymocyte development), SOX11 (neuronal, 
glial maturation), SOX12 (ortholog SOX22; development of many 
tissues) 
D SOX5 (chondrogenesis), SOX6 (chondrogenesis, cardiac myogenesis), 
SOX13 (development of arterial wall, pancreatic islets) 
E SOX8 (development of many tissues), SOX9 (chondrogenesis, sex 
determination), SOX10 (neural crest specification) 
F SOX7 (development of vascular and many other tissues), SOX17 
(endoderm specification), SOX18 (vascular and hair follicle 
development) 
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G SOX15 (ortholog SOX20; myogenesis) 
H SOX30 (male germ cell maturation) 
Table 1: SOX groups with according genes and their major known or deduced functions. 
Modified from Bowles et al. and Schepers et al. [29], [227]. 
In general, SOX-transcription factors play a key role in embryonic development of NCCs 
and are also major determinants of stem cell behavior [222]. SoxE transcription factors, 
comprising SOX8, SOX9, and SOX10, are major players in the neural crest 
development [223]. As mentioned before (section 2.1), they are neural crest specifiers, 
i.e., they regulate effector genes that mediate terminal differentiation of the derivative 
cell. Structurally they share highly conserved domains, which are a DNA-dependent 
dimerization domain, the DNA-binding HMG domain, a K2 domain, and a C-terminal 
transactivation domain [288]. The K2 domain provides an additional transactivation 
capacity in selected cell types and under specific developmental conditions. It still needs 
to be clarified how SoxE factors are modulated to allow such functional diversity and 
nuclear/cytoplasmatic translocation [92]. Many mechanisms might be involved, including 
post-translational modifications as phosphorylation, acetylation, and small ubiquitine like 
modifier (SUMO)ylation, as well as context-dependent interactions with other factors. 
The interaction with other transcription factors is mediated by the HMG domain [297]. In 
several organ systems each of the SoxE member’s function is likely to be redundant 
und possibly compensated by other family members.  
SOX8 is expressed in various tissues during embryonic development but is often turned 
off in the mature stage of the cell, while its expression continues in the brain, spinal 
cord, and testis [199], [226], [245]. During embryogenesis and in tissue development, it 
rather plays an auxiliary role, e.g., by reinforcing SOX9 in testis differentiation [40] and 
SOX10 during adrenal gland and enteric nervous system development [169], [212].  
Another SoxE family member, SOX9, has specific functions in the development of 
chondrocytes and in testis formation by regulating extracellular matrix proteins like 
collagen type II α1 [153] and the anti-Müllerian hormone [59]. Heterozygous loss-of-
function mutations in the SOX9 gene causes campomelic dysplasia, a human disorder 
characterized by defective chondrogenesis, male-to-female sex reversal, and other 
variable organ defects [279]. SOX9 is also expressed in various adult tissues where it 
maintains stem cell homeostasis and regeneration [77]. However, dysregulation of 
these qualities promotes neoplasia and SOX9 has been implicated in the formation and 
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growth of tumors in the prostate, central nervous system, skin, pancreas, ovary, and 
esophagus [121]. 
Furthermore, SOX9 plays a crucial role during the embryonic development in the neural 
crest together with the structurally related factor SOX10. During melanocyte 
development, SOX9 and SOX10 come up in different developmental stages with SOX9 
particularly expressed in pre-migratory NCCs and shot off soon after EMT, and SOX10 
expressed in early delaminating and migrating NCCs [101]. Both factors control 
multipotency, survival, and proliferation of NCCs and promote their differentiation into 
glial cells and melanocytes but not into the neuronal lineage at later stages [46]. While 
SOX9 expression continues in glial cells [46], [257], SOX10 expression persists in glial 
cells of the peripheral nervous system (including Schwann cells), in oligodendrocytes of 
the central nervous system, and in melanocytes [47], [101], [126]. 
SOX10-deficient mice loose most or all of their melanocytes [31], [107], [125], [248], 
emphasizing the crucial role of SOX10 for melanocyte differentiation. As mentioned in 
section 2.1, SOX10 transactivates MITF expression with which it controls DCT, an 
enzyme that is essential for the synthesis of melanin, and other melanogenic enzymes 
like TYRP1 and tyrosinase [119], [164], [180], [207]. 
Furthermore, in vivo analyses of transgenic mice showed that SOX10 is also expressed 
in melanocyte stem cells (McSCs) in hair follicles [102]. SOX10 knockout led to loss of 
McSCs and melanocytes while SOX10 overexpression led to premature differentiation 
and loss of McSCs causing hair graying. Thus, SOX10 levels seem to be critical for 
McSC function and maintenance.  
SOX10 also plays a role in fate determination of other neural crest derivatives such as 
sympathetic neurons by regulating the achaete-scute homologue ash1 (MASH1) and 
paired like homeobox 2b (PHOX2B) [128], the sensory neurons via neurogenin-1 [126], 
and Schwann cells by activating Schwann-cell specific genes like myelin protein zero 
(MPZ), myelin basic protein (MBP), and proteolipid protein 1 (PLP1) [196], [256]. 
Furthermore, it regulates differentiation of the enteric nervous system by activating the 
RTK c-RET together with PAX3 [145], [146], and EDNRB in collaboration with 
endothelin-3 [253], [306]. 
Since SOX10 regulates the development of several cell lineages, loss of SOX10 causes 
different phenotypic manifestation in disorders. Homozygous deletion of SOX10 in mice 
leads to embryonic lethality, while SOX10 haploinsufficiency causes pigmentary 
defects, and a dominant megacolon [31], [248]. In zebrafish, all pigment cells are absent 
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when SOX10 expression is abrogated [64]. In humans, heterozygous mutations of 
SOX10 cause Waardenburg syndrome Type 2, which is characterized by partial 
depigmentation of the hair, skin or iris, and sensory deafness due to melanocyte loss 
from the stria vascularis of the inner ear, as well as Waardenburg-Hirschsprung disease 
or Waardenburg-Shah syndrome (a combination of Waardenburg syndrome and 
Hirschsprung disease) causing aganglionosis of the colon [20], [200]. Additionally, 
truncating mutations of SOX10 can cause Peripheral demyelinating neuropathy, central 
dysmyelination, Waardenburg syndrome, and Hirschsprung disease (PCWH), in which 
Waardenburg-Hirschsprung disease is combined with peripheral demyelinating 
neuropathy and central dysmyelinating leukodystrophy [20], [115]. 
In context of melanomagenesis, the distinct roles of SOX9 and SOX10 remain widely 
unclear so far. SOX10 is expressed in melanocytes, congenital nevi, primary and 
metastatic melanoma, while SOX9 expression has been found present and absent in 
melanocytes, nevi, and melanoma [4], [8], [52], [195], [238], [239]. Other data 
demonstrate that upregulation of SOX9 reduces melanoma cell growth but increases 
invasion [44], [195]. A recent study suggests that SOX9 and SOX10 are functional 
antagonists in postnatal melanocyte and melanoma development [238]. Besides this 
potential antagonistic role, SOX9 and SOX10 both regulate factors like MITF and DCT 
in melanocytes or the intermediate filament nestin in melanoma cells [72], [194]. 
Several recent studies indicate that SOX10 appears to be oncogenic and is responsible 
for melanoma initiation as well as survival and proliferation [53], [239]. Furthermore, low 
frequencies of intragenic mutations in the SOX10 gene suggest that SOX10 wild type 
function is required for melanoma formation and maintenance [53], [54]. SOX10 also 
appears to play a role in reversible and adaptive resistance to BRAF inhibition in 
melanoma [261]. Therefore, a crucial relation of SOX10 to melanomagenesis is 
suggested. 
However, targeting SOX10 or other transcription factors that are dysregulated in 
melanoma is difficult as these proteins lack an enzymatic domain, which would allow the 
development of allosteric or competitive small molecule inhibitors. Agents that block 
association to coregulators or the binding region of these transcription factors in target 
genes would be necessary. On the other hand, pleiotropic effects on the expression of a 
multitude of genes resulting in unacceptable toxicity by the inhibition of a specific 
transcription factor are most likely. Therefore understanding the biological contribution 
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of its target genes is of utmost importance and might lead to the discovery of alternative 
targets that are amenable to pharmacologic therapy. 
2.7 Aims of this study 
SOX10 seems to play an important role in melanoma initiation, progression and 
survival. However, the distinct functions of this transcription factor in melanoma remain 
unclear. To elucidate the function of SOX10 in comparison to SOX9, following issues 
have been addressed: 
 
1. Analysis of the expression of SOX10 and SOX9 in melanoma cell lines at 
different progression stages and in in-house generated short term cultures on 
messenger ribonucleic acid (mRNA) and protein levels as well as in human skin 
cells (primary fibroblasts and melanocytes).  
 
2. Phenotypic effects of SOX10 inhibition via RNA interference and SOX10 ectopic 
overexpression on cell morphology, invasion capacity, proliferation, and cell 
death.  
 
3. Identification of SOX10 target genes that could mediate the observed phenotypic 
effects based on literature and on RNA sequencing analysis.  
 
4. Evaluating direct transcriptional activation/repression of these identified targets 
and analyzing their functions in melanoma cells.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Media 
Melanocyte growth medium 
Medium 254CF (Gibco® by Life Technologies; 
Carlsbad, California, USA) 
500 ml 
CaCl2 (0.2 M; Gibco® by Life Technologies) 0.5 ml 
HMGS-2 (Gibco® by Life Technologies) 5 ml 
 
Fibroblast growth medium 
DMEM (Gibco® by Life Technologies) 500 ml 
Fetal bovine serum (FBS superior; 
Millipore/Merck, Darmstadt, Germany) 
50 ml 
L-glutamine (200 mM, Gibco® by Life 
Technologies) 
5 ml 
 
Fibroblast-conditioned medium 
Fibroblast-conditioned medium as required for Matrigel invasion assays was 
generated by incubating a confluent T75 flask of primary human fibroblasts with 10 ml 
DMEM/1% L-glutamine at 37°C and 5% CO2 for 24 hours. The supernatant containing 
the conditioned medium was centrifuged at 1000 rpm and room temperature for 3 
minutes. This supernatant was aliquoted in 1.5 ml tubes and stored at -20°C. 
 
Tumor 2% (TU2%) 
MCDB153 (Sigma, Taufkirchen, Germany, in H2O 
bidestilled); pH 7.4 adjusted with NaHCO3 
(Gibco® by Life Technologies) 
500 ml 
Leibovitz L-15 (Gibco® by Life Technologies) 50 ml 
FBS 10 ml 
Insulin (10 µg/ml, Sigma) 0.25 ml 
CaCl2 (2 M, Sigma) 0.42 ml 
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Luria-Bertani Broth (LB) Medium 
12.5 g LB powder (Sigma) in 500 ml H2O bidestilled, autoclaved 
 
Agar plates 
7.5 g Select-Agar (Life Technologies) in 500 ml LB medium, autoclaved 
 
Antibiotics for selection 
Ampicillin (100 mg/ml, Sigma) 100x 
Kanamycin (10 mg/ml, Gibco® by Life 
Technologies) 
100x 
Puromycin (10 mg/ml, Life Technologies) cell line dependent 
 
Further solutions for cell culture usage 
0.05% Trypsin-EDTA in HBSS (Gibco® by Life 
Technologies) 
for cell detachment 
0.2% EDTA in PBS (phosphate-buffered saline; 
Pharmacy of the University Hospital of Munich) 
for gentle detachment of cells 
ABAM (100x, Gibco® by Life Technologies) antibiotics, antimycotics 
Deep-freezing solution (FBS + 10% DMSO, 
Sigma) 
for cell storage in liquid nitrogen 
HBSS (Hank’s balanced salt solution; Gibco® by 
Life Technologies) 
for cell washing 
 
10x Digestion solution for preparation of primary melanoma cells 
Collagenase (Sigma) 0.5% 
Dispase (Sigma) 0.73% 
Hyaluronidase (Sigma) 1% 
in HBSS  
3.1.2 Buffers and solutions 
If not otherwise stated, buffers and solutions were prepared with bidestilled H2O from 
the Pharmacy of the University Hospital of Munich or with aqua ad injectabilia (Braun, 
Melsungen, Germany). 
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3.1.2.1 Buffers and solutions for immunoblotting 
Cold Spring Harbor (CSH) buffer for whole cell lysate preparation 
Tris-HCl pH 7.4 (Sigma) 50 mM 
NaCl (Sigma) 250 mM 
EDTA (Sigma) 1 mM 
TritonX-100 (Sigma) 0.1 % 
Protease inhibitors complete mini (Roche, 
Penzberg, Germany) 
1x 
PhosStop phosphatase inhibitors (Roche) 1x 
 
RIPA buffer for whole cell lysate preparation 
Tris-HCl pH 7.4 (Sigma) 50 mM 
NaCl 150 mM 
SDS (Sigma) 0.1% 
Deoxycholic acid sodium salt (Merck) 1% 
Triton X-100 1% 
Protease inhibitors complete mini (Roche) 1x 
PhosStop phosphatase inhibitors (Roche) 1x 
 
Running buffer 
NuPAGE® MES SDS Running Buffer (Life 
Technologies) 
1x 
NuPAGE® Antioxidant (Life Technologies) 0.25% 
 
Transfer buffer 
NuPAGE® Transfer buffer (Life Technologies) 1x 
NuPAGE® Antioxidant (Life Technologies) 0.1% 
Methanol pro analysi (p.a.) ≥ 99.8% (Merck) 10% (20% for blotting two gels 
at one time) 
 
Ponceau S staining solution 
Ponceau S (Sigma) 0.1%  
Acetic acid (Merck) 5%  
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Blocking buffer 
Western blocking reagent, solution (Roche) 10% 
Sodium fluoride (Sigma) 50 mM 
in PBS  
 
Washing buffer 
0.1% Tween20 (Calbiochem/Merck) in PBS 
3.1.2.2 Buffers and solutions for fluorescence-activated cell sorting 
ANPI staining buffer 
HEPES pH 7.4 (Sigma) 10 mM 
NaCl 140 mM 
CaCl2 (Sigma) 5 mM 
 
Annexin V-staining solution for one sample 
Annexin V-Fluos (Roche) 1 µl 
ANPI staining buffer 49 µl 
 
Propidium iodide staining solution for one sample 
Propidium iodide (Sigma, 0.5 mg/ml in PBS) 10 µl 
ANPI staining buffer 50 µl 
 
Fixing solution for cell cycle analysis 
75% Ethanol p.a. (VWR, Fontenay-sous-Bois cedex, France) in H2O bidestilled 
 
Washing buffer for cell cycle analysis 
1% BSA (w/v, Sigma) in PBS 
 
Cell cycle staining solution for one sample 
Propidium iodide (Sigma, 5 mg/ml)  0.8 µl 
RNAse A (Sigma, 10 mg/ml in PBS) 0.8 µl 
Washing buffer 300 µl 
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3.1.2.3 Buffers and solutions for luciferase reporter assay 
Lysis buffer 
5x passive lysis buffer (Promega, Madison, Wisconsin, USA) diluted to 1x with PBS 
 
TE buffer 
Tris-HCl pH 8 1% 
EDTA pH 8 0.2% 
 
Luciferase reporter solution 
50% ATP substrate (in TE buffer; Biothema, Handen, Switzerland) 
50% Luciferin substrate (in TE buffer; Biothema) 
 
Renilla Substrate 
1 µl Coelenterazine (Promega; 1 µg in 1 ml Methanol p.a.) in 800 ml H2O bidestilled 
3.1.2.4 Buffers and solutions for electrophoretic mobility shift assay 
10x Binding buffer 
HEPES (pH 7.4) 100 mM 
NaCl 500 mM 
EDTA pH 8 1 mM 
Glycerol (Merck) 50% 
MgCl2 (Merck) 50 mM 
 
1x TBE 
Trizma® base (Sigma) 89 mM 
Boric acid (Sigma) 89 mM 
EDTA 2 mM 
3.1.2.5 Buffer for immunohistochemistry 
Tris buffer 
0.5 M Tris-HCl buffer pH 7.6 10% 
1.5 M NaCl 10% 
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3.1.2.6 Buffers for chromatin immunoprecipitation 
Cell lysis buffer 
PIPES pH 8 (Sigma) 5 mM 
KCl (Fluka/Sigma) 85 mM 
NP-40 (Sigma) 0.5% 
Protease inhibitors complete mini 1x 
 
Nuclear lysis buffer 
Tris-HCl pH 8 50 mM 
EDTA pH 8 10 mM 
SDS 1% 
Protease inhibitors complete mini 1x 
 
IP dilution buffer 
Tris-HCl pH 8 16.7 mM 
NaCl 167 mM 
EDTA pH 8 1.2 mM 
Triton X-100 1% 
SDS 0.01% 
Protease inhibitors complete mini 1x 
 
Low salt wash buffer 
Tris-HCl pH 8 20 mM 
NaCl 150 mM 
EDTA pH 8 2 mM 
Triton X-100 1% 
SDS 0.1% 
 
High salt wash buffer 
Tris-HCl pH 8 20 mM 
NaCl 500 mM 
EDTA pH 8 2 mM 
Triton X-100 1% 
SDS 0.1% 
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LiCl wash buffer 
Tris-HCl pH 8 10 mM 
EDTA pH 8 1 mM 
LiCl (Sigma) 0.25 mM 
NP-40 1% 
Deoxycholic acid sodium salt (Merck) 1% 
 
Elution buffer 
SDS 1% 
NaHCO3 (Merck) 0.1 M 
3.1.2.7 Further buffers and solutions 
RNase free water (H2O/DEPC) 
0.1% (w/v) Diethylpyrocarbonat (Sigma) in H2O bidestilled, autoclaved 
 
Collagen mix (for spheroid assay) 
10x EMEM (Lonza, Basel, Switzerland) 420 µl 
L-glutamine (100x) 38 µl 
FBS 462 µl 
NaHCO3 (Gibco® by Life Technologies, 7.5%) 78 µl 
Collagen (Type I, rat tail; BD Biosciences, Bedford, 
Massachusetts, USA; adjusted to 1.3 mg/ml with 
0.05% acetic acid) 
3.5 ml 
The collagen mix was prepared on ice and adjusted to an orange/red color by adding 
further NaHCO3. 
3.1.3 Commercial kits 
Buffers and solutions from commercial kits are not listed separately. 
Name Supplier Application 
Amersham™ ECL™ 
Prime Western Blot 
Detection Reagent 
GE Healthcare 
(Buckinghamshire, 
Great Britain) 
immunoblot detection 
Bio-Rad Protein Assay Bio-Rad (Munich, 
Germany) 
measuring protein concentration 
according to Bradford [30] 
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Pierce™ BCA Protein 
Assay Kit 
ThermoFisher 
Scientific (Bonn, 
Germany) 
measuring protein concentration 
CellTiter-Blue® Cell 
Viability Assay 
Promega determination of cell viability 
Dako REAL™ Detection 
System 
Dako (Glostrup, 
Denmark) 
detection of 
immunohistochemistry (IHC) 
DIG luminescent 
detection kit 
Roche Electrophoretic mobility shift 
assay (EMSA), detection of 
digoxygenin (DIG)-labeled 
oligonucleotides 
Gateway® LR Clonase® 
II enzyme mix 
Life Technologies in vitro recombination 
LightCycler® TaqMan® 
Master 
Roche quantitative real-time polymerase 
chain reaction (qRT-PCR) 
LIVE/DEAD® 
viability/cytotoxicity kit 
Life Technologies staining of viable cells with 
calcein AM and dead cells with 
ethidium homodimer-1 (EthD-1) 
Venor® GeM Minerva Biolabs 
(Berlin, Germany) 
detection of mycoplasm 
contamination in cell culture 
Nuclear extract kit Active Motif (La Hulpe, 
Belgium) 
purification of nuclear proteins 
NucleoSpin® Plasmid 
Kit 
Macherey-Nagel 
(Düren, Germany) 
plasmid extraction 
NucleoSpin® Gel and 
PCR Clean-up (with 
NTB buffer) 
Macherey-Nagel purification of DNA from PCR, 
agarose gels, and chromatin 
immunoprecipitation (ChIP) 
QuikChange Lightning 
Site-Directed 
Mutagenesis Kit 
Agilent Technologies 
(Santa Clara, 
California, USA) 
introducing point mutations in 
plasmids 
Rapid DNA Ligation Kit Roche DNA ligation for cloning 
Reverse transcriptase Roche reverse transcription to generate 
copy DNA (cDNA) from mRNA 
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RNeasy™ Mini Kit Qiagen (Hilden, 
Germany) 
RNA extraction 
SIGMA FAST™ Fast 
Red TR/Naphthol AS-
MX 
Sigma Alkaline Phosphatase Substrate 
Tablets Set for IHC detection 
Table 2: Commercial kits. 
3.1.4 Transfection reagents 
Lipofectamin™ RNAiMAX (Life Technologies) for small interfering RNA (siRNA) 
transfection. 
FuGENE® 6 Transfection Reagent (Promega) for plasmid transfection. 
3.1.5 Oligonucleotides 
Productions of oligonucleotides as well as sequencing analyses were performed by 
Eurofins Genomics, Ebersberg, Germany. 
3.1.5.1 Primers for quantitative real-time PCR 
Primers for mRNA quantification from cDNA after reverse transcription 
Gene Forward (5’→3’) 
 
Reverse (5’→3’) 
 
Probe 
CtBP1 CGAGTCGGAACCCTTCAG CAGATGAGGTTGGGTGCA #81 
GJB1 TGCAGACATTCTCTGGGAAA ATCCTGCCTCATTCACACCT #71 
GJC2 AGGGCTCTGAGGGAGACTG CAGCTCATGTTGGTCATAGG
G 
#80 
ERBB3 CACAATGCCGACCTCTCCC CACGAGGACATAGCCTGTCA #86 
FTL GCTGAACCAGGCCCTTTT TCCAGGAAGTCACAGAGATG
G 
#37 
GH1 TCACCTAGCTGCAATGGCTA AGGCACTGCCCTCTTGAA #13 
H1FX-
AS1 
TTTTTGTTGAAGCCGTTGC CCTCAACGTTGTCCTGTGC #60 
HMG1 CATTGAGCTCCATAGAGACA
GC 
GGATCTCCTTTGCCCATGT #73 
HPRT TGACCTTGAATTTATTTTGC
ATACC 
CGAGCAAGACGTTCAGTCCT #73 
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ITGA3 GAGGACATGTGGCTTGGAG
T 
GTAGCGGTGGGCACAGAC #13 
ITGA4 GATGAAAATGAGCCTGAAA
CG 
GCCATACTATTGCCAGTGTTG
A 
#22 
ITGAV ACTTGACTGTGGTGAAGAC
AATG 
GGGTTGTCATCCCCAATATA
GA 
#11 
ITGB1 CGATGCCATCATGCAAGT ACACCAGCAGCCGTGTAAC #65 
ITGB3 CGCTAAATTTGAGGAAGAAC
G 
GAAGGTAGACGTGGCCTCTT
T 
#76 
KLF10 TCTGAAGGCCCACACGAG ACCTCCTTTCACAACCTTTCC #2 
MIA GGGCCAAGTGGTGTATGTC
T 
CAGATCTCCATAGTAATCTCC
CTGA 
#16 
M-MITF CATTGTTATGCTGGAAATGC
TAGA 
TGCTAAAGTGGTAGAAAGGT
ACTGC 
#62 
MPZ TATCCTGGCTGTGCTGCTC TGTCGGTGTAAACCACGATG #56 
NR1D1 AACTCCCTGGCGCTTACC GAAGCGGAATTCTCCATGC #17 
PLP1 CTGCCAGTCTATTGCCTTCC AGCATTCCATGGGAGAACAC #53 
PMP2 TTGACGATTACATGAAAGCT
CTG 
GCTGATGATCACAGTGGGTT
T 
#48 
PPP1R15
A 
GCTTCTGGCAGACCGAAC GTAGCCTGATGGGGTGCTT #24 
RPL27a CGATACCTCGCGAGACTTG 
 
CCTAAGTTTCCGGGTCTTCC 
 
#26 
SOX9 GTACCCGCACTTGCACAAC TCGCTCTCGTTCAGAAGTCTC #61 
SOX10 GACCAGTACCCGCACCTG CGCTTGTCACTTTCGTTCAG #61 
TIPARP GGAAATTCTTCTGTAGGGAC
CA 
AATCAATCGAATGACAGACTC
G 
#58 
Primers for DNA quantification after ChIP 
Name Forward (5’→3’) 
 
Reverse (5’→3’) 
 
Probe 
MIAChIP
_Set3 
TGGGCTGTTTCTGGTAATC
A 
CACCTTGGAATTTCCTGTGC 
 
#43 
PMP2_ TGCTCTGCTGCAATCGACT GAAGGCTTGGCATAGTTCACA #13 
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ChIP1 GAC 
PMP2_ 
ChIP2 
GCAGGGTAAGATCATGGT
TCA 
AAATTGCTCCCAAAAGTTGAAT #55 
hActin 
intron 2 
CGCCCTTTCTCACTGGTTC TCCAAAGGAGACTCAGGTCAG #29 
Table 3: Primers for mRNA and ChIP-DNA quantification.  
Primers for qRT-PCR were designed with the open software “Assay Design Center” from Roche 
(www.universalprobelibrary.com) including an intron spanning assay. For design of primers for DNA 
quantification after ChIP, the intron spanning was excluded. Probes derived from the “Universal Probe 
Library, Human” from Roche. 
3.1.5.2 Primers for polymerase chain reaction 
Name Sequence (5’→3’) Purpose 
KpnI_SOX9_fwd AGGAGGTACCAAATGAATCTC
CTGGACC 
Cloning of SOX9 into 
pENTRY4-flag. 
XhoI_SOX9_rev AGGACTCGAGTCAAGGTCGAG
TGAG 
Cloning of SOX9 into 
pENTRY4-flag. 
KpnI_SOX10_fwd ATTAGGTACCAAATGGCGGAG
GAGCAG 
Cloning of SOX10 into 
pENTRY4-flag. 
XhoI_SOX10_rev ATTACTCGAGTTAGGGCCGGG
ACAGT 
Cloning of SOX10 into 
pENTRY4-flag. 
KpnI_PMP2_fwd ATTAGGTACCGCAAAATAGCA
ACAAATTC 
Cloning of PMP2 into 
pENTRY4-flag. 
XhoI_PMP2_rev ATTACTCGAGCTGGACCTTCT
CATAGA 
Cloning of PMP2 into 
pENTRY4-flag. 
pMIA_ATtoCGfwd CTTTGGACCTTATCTGGGACG
TTCCTTGGGCTTACAGCC 
Mutation of SOX binding 
site G1/G2 (AT to CG) in 
the MIA promoter. pMIA_ATtoCGrev AGGCTGTAAGCCCAAGGAACG
TCCCAGATAAGGTCCAAAG 
MIAmutV2fwd CTGCTTTGGACCTTATCTGCG
TCGACCCTTGGGCTTACAGCC
TTT 
Mutation of SOX binding 
site G1/G2 based on the 
previous mutation AT to 
CG in the MIA promoter. MIAmutV2rev AAAGGCTGTAAGCCCAAGGGT
CGACGCAGATAAGGTCCAAAG
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CAG 
MIAmutV3fwd CCTTATCTAGGCCTCTGTCAG
GGTTGAGGAGGGGGCTGGTC 
Mutation of SOX binding 
site G3/J6 in the MIA 
promoter. MIAmutV3rev GACAGCCCCCTCCTCAACCCT
GACAGAGGCCTAGATAAGG 
MIAmutV4fwd GGCTGGGCTGTTTCTGGTAAT
CGGAGGGCTGCCTTGTT 
Mutation of SOX binding 
site J9 in the MIA promoter. 
MIAmutV4rev AACAAGGCAGCCCTCCGATTA
CCAGAAACAGCCCAGCC 
MIAmutV5fwd CTGGTAATCAAAGGGCTGCCG
GTGTCTCCTGCCCCACAGCAC
AG 
Mutation of SOX binding 
site G4/J8 in the MIA 
promoter. 
MIAmutV5 rev CTGTGCTGTGGGGCAGGAGA
CACCGGCAGCCCTTTGATTAC
CAG 
MIAmutV6_fwd TCACTGGGAAAGTTGTGAGCT
GCGGGTGACCTTATCTGGGAA
TTTCCTTG 
Mutation of SOX binding 
site J5 in the MIA promoter. 
MIAmutV6_res CAAGGAAATTCCCAGATAAGG
TCACCCGCAGCTCACAACTTT
CCCAGTGA 
MIAcDNA_fwd GGACAAGACCAAGAACACAAG Amplification of MIA cDNA 
and subsequent 
sequencing. 
MIAcDNA_rev AAAGCCAAGGAGGGGAAAC 
PMP2_R106E_fwd GGATGGCAAAGAGACAACCAT
AAAGGAAAAGCTAGTGAATGG
GAAAATG 
Introducing a point 
mutation (R106E) in pLenti-
PMP2-R126E-Y128F. 
PMP2_R106E_rev CATTTTCCCATTCACTACCTTT
TCCTTTATGGTTGTCTCTTTGC
CATCC 
Introducing a point 
mutation (R106E) in pLenti-
PMP2-R126E-Y128F. 
PMP2_R126E_Y12
8F_fwd 
AGGGCGTGGTGTGCACCGAA
ATCTTTGAGAAGGTCTAGGAC
C 
Introducing two point 
mutations (R126E and 
Y128F) in pLenti-PMP2. 
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PMP2_R126E_ 
Y128F_rev 
GGTCCTAGACCTTCTCAAAGA
TTTCGGTGCACACCACGCCCT 
Introducing two point 
mutations (R126E and 
Y128F) in pLenti-PMP2. 
PMP2_L27D_fwd AAGCTCTGGGTGTGGGGGAT
GCCACCAGAAAACTGGG 
Introducing a point 
mutation (L27D) in pLenti-
PMP2. 
PMP2_L27D_rev CCCAGTTTTCTGGTGGCATCC
CCCACACCCAGAGCTT 
Introducing a point 
mutation (L27D) in pLenti-
PMP2. 
SOX10cDNA_fwd1 ATGGCGGAGGAGCAGGAC Amplification of SOX10 
cDNA and subsequent 
sequencing performed with 
two overlapping fragments. 
SOX10cDNA_rev1 GGTACTGGTCCAACTCAGCC 
SOX10cDNA_fwd2 CCATGTCAGATGGGAACCCC 
SOX10cDNA_rev2 AGTGTGGGTGCAACAGTCAA 
Table 4: Primers for PCR.  
Primers for introducing point mutations were designed with the QuikChange primer design software from 
Agilent Technologies (http://www.genomics.agilent.com/primerDesignProgram.jsp). Other PCR primers 
were designed with the primer3web suite (http://primer3.ut.ee/). 
3.1.5.3 Oligonucleotides for electrophoretic mobility shift assay 
Name Sense (5’→3’) Antisense (5’→3’) 
DIG_SOX10pMIA TGGTAATCAAAGGGCTGCC
TTGTTCTCCTGC 
GCAGGAGAACAAGGCAGCCC
TTTGATTACCA 
PMP2_EMSA_P1 TTGGAGACAAAGGGAAGTA
TTATGTG 
CACATAATACTTCCCTTTGTCT
CCAA 
PMP2_EMSA_P2 CAATAGACTGACTTCTTTGT
CTGCCT 
AGGCAGACAAAGAAGTCAGTC
TATTG 
PMP2_EMSA_P3 TTCTAGCTGAAAATCTTTGT
TGTGCT 
AGCACAACAAAGATTTTCAGC
TAGAA 
SOX consensus 
(according to 
Cook et al. [52]) 
AGACTGAGAACAAAGCGCT
CTCACAC 
GTGTGAGAGCGCTTTGTTCTC
AGTCT 
Table 5: Oligonucleotides for EMSA.  
Oligonucleotides were labeled with DIG at the 5’ end. 
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3.1.5.4 Small interfering ribonucleic acids 
Name Gene Sequence (5’→ 3’) 
siEGR2 EGR2 GAUCCACCUGAGACAGAAA(dT)(dT) 
siMIA MIA GCCAAGUGGUGUAUGUCUU(dT)(dT) 
siRELA RELA GCCCUAUCCCUUUACGUCA(dT)(dT) 
siPMP2a PMP2 CCACAGCUGACAAUAGAAA(dT)(dT) 
siPMP2b PMP2 GUGAGAACUUUGACGAUUA(dT)(dT) 
siSOX9a SOX9 GGAGGAAGUCGGUGAAGAA(dT)(dT) 
siSOX9b SOX9 CAGCGAACGCACAUCAAGA(dT)(dT) 
siSOX10a SOX10 CCGUAUGCAGCACAAGAAA(dT)(dT) 
siSOX10b SOX10 GUAUGCAGCACAAGAAAGA(dT)(dT) 
siControl - GCGCAUUCCAGCUUACGUA(dT)(dT) 
Table 6: Small interfering RNAs (siRNAs) for gene silencing.  
Small interfering RNAs were designed according to 3.2.2.1.1. 
3.1.6 Plasmids and vectors 
Name Backbone Description 
pCDNA4/to (Life Technologies) Control vector (pControl) 
pCMV6 pCMV6-XL5 Generated from pCMV6- SOX10 by Not1 
digestion and re-ligation of the vector 
backbone. Control vector for RNA 
sequencing. 
pCMV6-SOX9 pCMV6-AC (Origene 
Technologies, 
Rockville, USA) 
Vector for constitutive ectopic SOX9 
overexpression. 
pCMV6-
SOX10 
pCMV6-XL5 (Origene 
Technologies) 
Vector for constitutive ectopic SOX10 
overexpression. 
pCMV-PAX6 pCMV-Sport6 Vector for constitutive ectopic PAX6 
overexpression. 
pCMX-MIA pCMX-PL1 Vector for constitutive ectopic MIA 
overexpression. 
pDONR221-
PMP2 
pDONR221 (Harvard 
plasmid 
Donor vector including the coding 
sequence of PMP2. 
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HsCD00043524) 
pDONR221-
PMP2-L27D 
pDONR221-PMP2 Donor vector including the coding 
sequence of PMP2 with the mutation 
L27D. 
pDONR221-
PMP2-Mut3 
pDONR221-PMP2 Donor vector including the coding 
sequence of PMP2 with the mutations 
R106E, R126E, and Y128F. 
pENTRY4-flag (Addgene) Entry vector for in vitro recombination. 
pENTRY4-
flag-SOX9 
pENTRY4-flag Ligation of PCR fragment containing the 
SOX9 coding sequence via restriction 
enzyme digestion (KpnI/XhoI) into 
pENTRY4-flag. 
pENTRY4-
flag-SOX10 
pENTRY4-flag Ligation of PCR fragment containing  the 
SOX10 coding sequence via restriction 
enzyme digestion (KpnI/XhoI) into 
pENTRY4-flag. 
pENTRY4-
flag-PMP2 
pENTRY4-flag Ligation of PCR fragment containing the 
PMP coding sequence via restriction 
enzyme digestion (KpnI/XhoI) into 
pENTRY4-flag. 
pGL2-MIA-493 pGL2-basic (Promega) Encodes the firefly luciferase coding 
sequence under control of a part of the 
MIA promoter (-493bp). 
pGL2-MIA-275 pGL2-basic Encodes the firefly luciferase coding 
sequence under control of a part of the 
MIA promoter (-275bp). 
pGL2-MIA-212 pGL2-basic Encodes the firefly luciferase coding 
sequence under control of a part of the 
MIA promoter (-212bp). 
pGL2-MIA-200 pGL2-basic Encodes the firefly luciferase coding 
sequence under control of a part of the 
MIA promoter (-200bp). 
pGL2-MIA-160 pGL2-basic Encodes the firefly luciferase coding 
  Materials and Methods 
 
37 
sequence under control of a part of the 
MIA promoter (-160bp). 
pGL3-MIA pGL3-basic (Promega) Encodes the firefly luciferase coding 
sequence under control of the full-length 
MIA promoter (-1376bp). 
pLenti CMV 
Puro dest 
(Addgene) Lentiviral expression vector with CMV 
promoter and puromycin selection, 
destination vector for pENTRY. Also for 
control vector pLenti-Control. 
pLenti-flag-
SOX9 
pLenti CMV Puro dest In vitro recombination of pENTRY4-flag-
SOX9 into pLenti CMV Puro dest. 
pLenti-flag-
SOX10 
pLenti CMV Puro dest In vitro recombination of pENTRY4-flag-
SOX10 into pLenti CMV Puro dest. 
pLenti-PMP2 pLenti CMV Puro dest In vitro recombination of pDONR221-
PMP2 into pLenti CMV Puro dest. 
pLenti-flag-
PMP2 
pLenti CMV Puro dest In vitro recombination of pENTRY4-flag-
PMP2 into pLenti CMV Puro dest. 
pLenti-PMP2 
L27D 
pLenti CMV Puro dest In vitro recombination of pDONR221-
PMP2 L27D into pLenti CMV Puro dest. 
pLenti-PMP2 
Mut3 
pLenti CMV Puro dest In vitro recombination of pDONR221-
PMP2 Mut3 into pLenti CMV Puro dest. 
Table 7: Plasmids and vectors used or established in this study.  
Vectors containing MIA promoter and promoter fragments for reporter assays as well as for MIA 
overexpression were kind gifts from Professor Anja-Katrin Bosserhoff. 
3.1.7 Enzymes and polypeptides 
Herculase II Fusion DNA Polymerase (Agilent Technologies, Waldbronn, Germany) 
IgG goat (1.7 mg/ml in 150 nM NaCl, Sigma) 
IgG rabbit (0.5 mg/ml in 150 nM NaCl, Sigma) 
poly(dG:dC) (2 mg/ml in sterile H2O bidestilled; InvivoGen, San Diego, USA) 
MB Taq DNA polymerase (Minerva Biolabs) 
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3.1.8 Antibodies 
3.1.8.1 Primary antibodies 
Name Source Supplier Dilution 
Anti--Actin mouse Sigma 1:5000 
Anti-Bak rabbit Cell Signaling 
(Denvers, 
Massachusetts, 
USA) 
1:1000 
Anti-Bax mouse Santa Cruz 1:200 
Anti-Bid rabbit Cell Signaling 1:1000 
Anti-Bcl-2 mouse Calbiochem 
(Merck/Millipore) 
1:1000 
Anti-caspase 3 rabbit Cell Signaling 1:1000 
Anti-caspase 8 Mouse (1C12) Cell Signaling 1:1000 
Anti-caspase 9 rabbit Cell Signaling 1:1000 
Anti-ERBB3 rabbit Cell Signaling 1:1000 
Anti-HMG1 rabbit Cell Signaling 1:1000 
Anti-p21 mouse Santa Cruz 
(Santa Cruz, 
California, USA) 
1:200 
Anti-p65 rabbit Cell Signaling 1:1000 
Anti-phospho-p65 rabbit Cell Signaling 1:1000 
Anti-PMP2 mouse Santa Cruz 1:200 
Anti-PMP2 rabbit Bioss Antibodies 
(Woburn, 
Massachusetts, 
USA) 
1:200 
Anti-MITF mouse Thermo 
Scientific 
(Waltham, 
Massachusetts, 
USA) 
1:100 
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Anti-SOX9 pSer181 rabbit Anaspec Inc. 
(San Jose, USA) 
1:200 
Anti-SOX9 rabbit Millipore/Merck 1:2000 
Anti-SOX9 rabbit Zytomed 
Systems (Berlin, 
Germany) 
1:1000 
Anti-SOX9 rabbit Chemicon 
(Temecula, CA, 
Germany) 
1:1000 
Anti-SOX10 sc-17342x Goat Santa Cruz 1:2000 
Anti-SOX10  rabbit Medac 
Diagnostika, 
Wedel, Germany 
1:25 (for IHC) 
Table 8: List of primary antibodies used in this study.  
The MIA antibody (source: rabbit, dilution 1:2000) was a kind gift from Professor Anja-Katrin Bosserhoff. 
3.1.8.2 Secondary antibodies 
Name Source Supplier Dilution 
Anti-mouse IgG HRP-linked Horse Cell Signaling 1:5000 
Anti-rabbit IgG HRP-linked Goat Cell Signaling 1:2000 
Anti-goat IgG HRP-linked Donkey Santa Cruz 1:30000 
Table 9: List of secondary antibodies used in this study. 
3.1.9 Cell lines 
Human melanoma cell lines were a kind gift from Meenhard Herlyn (Wistar Institute, 
Philadelphia, USA). Cells were isolated from primary tumors or metastases and 
classified according to their growth state as RGP, VGP, or metastasis [108]. Tissue 
origins of metastatic melanoma cell lines were lymph nodes (WM239A, WM9, WM1158, 
and WM1232) and lungs (451Lu and 1205Lu). Melanoma cells were cultivated as 
described under 3.2.1.1. Short term-cultured melanoma cells from patient’s tissue were 
prepared as described in section 3.2.1.2. Primary melanocytes and fibroblasts had been 
in-house isolated from human foreskins and cultivated in melanocyte or fibroblast 
medium, respectively. 
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3.1.10 Appliances 
Name Supplier 
Biological safety cabinet Class II Type A/B3 NuAire (Plymouth, Massachussetts, 
USA) 
Centrifuge RC-5B Sorvall (Bad Homburg, Germany) 
Centrifuge Rotixa 50 RS Hettich AG (Baech, Switzerland) 
CO2 incubator Heracell Heraeus (Hanau, Germany) 
EpiShear™ Probe Sonicator Active Motif 
KODAK RP X-OMAT Developer and 
Replenisher 
Kodak (Stuttgart,Germany) 
Flow cytometer FACScan Becton Dickinson (Franklin Lakes, 
New Jersey, USA) 
Fluorescence microscope Axioskop with 
cameras Mrc and Mrc 5 
Zeiss (Munich, Germany) 
Fluorimeter Cytofluor 2350 Millipore/Merck 
Gel Doc 2000 Bio-Rad 
HERAsafe biological safety cabinet Heraeus 
Horizontal Gel Electrophoresis System Life Technologies 
LightCycler® Instrument Roche (Penzberg, Germany) 
Luminometer GloMax® 96 Promega 
Microcentrifuge 5415 R Eppendorf (Hamburg, Germany) 
Microcentrifuge 5415 C Eppendorf 
Microscope Olympus BX51 with camera DP21 Olympus, Hamburg, Germany 
Photometer SmartSpec 3000 Bio-Rad 
PS500XT DC Power Supply Hoefer Scientific Instruments (San 
Francisco, California, USA) 
Power supply model 200/2.0 and Pac300 Bio-Rad 
RoboCycler® Thermal Cycler Stratagene/Agilent Technologies 
(Santa Clara, California, USA) 
Stratalinker® UV Crosslinker Stratagene 
TissueFAXS TissueGnostics (Vienna, Austria) 
Ultraviolet Crosslinker Amersham Life Science/GE 
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Healthcare 
XCell II™ Blot Module Invitrogen/Life Technologies 
XCell SureLock™ mini-cell electrophoresis 
system 
Invitrogen/Life Technologies 
Table 10: List of appliances. 
3.1.11 Consumables 
Name Supplier 
6-, 24-, and 96-well plates Greiner bio-one (Frickenhausen, 
Germany) 
10 cm2 dish TPP (Trasadingen, Switzerland) 
25 and 75 cm2 filter cap cell culture flasks Greiner bio-one 
Amicon® Ultra 0.5 ml centrifugal filters 3K Millipore/Merck 
Biocat® 25 cm2 collagen vented flasks Becton Dickinson 
Carbon steel safety scalpel Braun 
Cell scrapers 24 cm TPP 
Cell strainer 100µm Nylon BD Falcon™ (Franklin Lakes, New 
Jersey, USA) 
Cryo tubes 2 ml Greiner bio-one 
Disposable cuvettes 1.5 ml semi-micro PMMA Brand (Wertheim, Germany) 
Disposable safety scalpels Braun (Tuttlingen, Germany) 
Disposable serological pipettes, 10 ml Corning (New York, USA) 
Disposable syringe discardit Becton Dickinson 
DNA retardation gel (6%), 1 mm, 10 well Life Technologies 
EpiShear™ Probe Sonicator Active Motif 
FACS-PE tubes 5 ml Falcon/Becton Dickinson 
Filtered pipette tips Kisker (Steinfurt, Germany) 
Filtropur BT50 500 ml bottle filter 0.2 µm pore 
size 
Sarstedt (Nuembrecht, Germany) 
High performance chemiluminescence film GE Healthcare (Solingen, Germany) 
LightCycler capillaries Roche 
Microscope slides and cover glasses Menzel-Glaeser (Braunschweig, 
Germany) 
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NuPAGE® Novex® 4-12% Bis Tris Gel, 1.0 
mm, 10 well 
Invitrogen/Life Technologies 
Nylon membrane, positively charged Roche 
Parafilm Bemis (Soignies, Belgium) 
Pasteur pipettes Hirschmann (Eberstadt, Germany) 
PCR tubes 0.6 ml thin well Agilent Technologies 
Petri dishes 94x16 mm Greiner bio-one 
Pipette tips Sarstedt 
Rotilabo®-syringe filters 0.22 µm pore size Roth (Karlsruhe, Germany) 
Round bottom tubes 12 ml Greiner bio-one 
Safe-lock tubes 2 ml Eppendorf 
Safe Seal Micro Tubes 1.5 ml Sarstedt 
ThinCerts™ cell culture inserts, 8 µm pore size Greiner bio-one 
Tubes 15 ml Greiner bio-one 
Tubes 50 ml Sarstedt 
Table 11: List of consumables. 
3.1.12 Software 
Name Supplier 
AxioVision rel. 4.7.2 
microscope software 
Zeiss 
Assay Design Center Roche; www.universalprobelibrary.com 
CellQuest software Becton Dickinson, Heidelberg, Germany 
CpG Island searcher http://www.cpgislands.usc.edu 
EMBOSS Cpgplot http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/ 
Fiji ImageJ http://Fiji.sc 
immunoblot quantification was performed as described in 
http://www.yorku.ca/yisheng/Internal/Protocols/ImageJ.pdf 
HeatMapper Version 13 GenePattern http://genepattern.broadinstitute.org/gp/) 
Human Gene Atlas 
 
www.proteinatlas.org/ 
MIA expression data: 
http://www.proteinatlas.org/ENSG00000261857-
MIA/cancer 
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SOX9 expression data: 
http://www.proteinatlas.org/ENSG00000125398-
SOX9/tissue 
http://www.proteinatlas.org/ENSG00000125398-
SOX9/cancer 
SOX10 expression data: 
http://www.proteinatlas.org/ENSG00000100146-
SOX10/tissue 
http://www.proteinatlas.org/ENSG00000100146-
SOX10/cancer 
PMP2 expression data: 
http://www.proteinatlas.org/ENSG00000147588-
PMP2/tissue 
Illustrator CS5 http://www.adobe.com 
JASPAR version 
5.0_alpha 
http://jaspar.genereg.net/ 
MatInspector, 
ModelInspector 
Genomatix Software GmbH, Munich 
https://www.genomatix.de/ 
Microsoft Office 2010 Department for medical technique and IT, LMU Munich 
ModFit LT software Verity Software, Topsham, USA 
PhotoShop CS2 Adobe / Department for medical technique and IT, LMU 
Munich 
Primer3 web suite http://primer3.ut.ee/ 
Prism 5 v 5.04 GraphPad Software, San Diego, CA 
www.graphpad.com 
QuikChange primer 
design software 
Agilent Technologies 
http://www.genomics.agilent.com/primerDesignProgram.jsp 
Table 12: List of software used in this study.  
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3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Cultivation of human melanoma cell lines 
Human melanoma cell lines were isolated from primary tumors or melanoma 
metastases at the Wistar Institute, Philadelphia, USA. Cells were cultivated in TU2% in 
T75 flasks at 37°C and 5% CO2. At about 90% confluence, adherent cells were washed 
with HBSS and dissolved with 2 ml trypsin/EDTA for about 3 minutes. The trypsin 
digestion was stopped with 3 ml TU2% medium and the cell suspension was transferred 
into a 50 ml tube. Cells were spun down at 1000 rpm and room temperature for 3 
minutes. According to their density, cells were diluted into a new T75 flask with fresh 
TU2% medium, generating a new cell passage, termed splitting. Cells were splitted 
twice a week. Antibiotics and antimycotics were not used for standard cell cultivation. 
Cell lines were analyzed for mycoplasm contamination using Venor® GeM (Minerva 
Biolabs) PCR control frequently. For further experiments, the cell number was 
calculated with a Neubauer counting chamber (Marienfeld, Lauda-Königshofen, 
Germany) and cells were seeded to a confluence of 60-70% in 6-, 24-, or 96-well plates.  
For cell storage, 1/3 of cells from a confluent T75 flask were spun down as described 
above, resuspended in 1 ml deep-freezing medium, and transferred into Cryo tubes. 
These tubes were instantly stored in a freezing box at -80°C. For long-term storage, 
cells were stored in a tank with liquid nitrogen. For cell thawing, deep-frozen Cryo tubes 
were thawed at 37°C and the cell suspension was mixed with 4 ml TU2%. Cells were 
spun down at 1000 rpm and room temperature for 3 minutes, resuspended in fresh 
TU2% medium with ABAM and transferred into a T75 flask. Twenty-four hours later, the 
medium was exchanged with fresh TU2% medium. Cells were splitted at least one time 
before starting experiments. 
3.2.1.2 Isolation of melanoma cells from patient samples 
Fresh tumor samples from primary or metastatic melanoma were washed with HBSS. In 
a 10 cm² dish, excessive skin, connective, and adipose tissue were removed with a 
scalpel and the tumor was transferred in a fresh 10 cm² dish and covered with 5 ml 1x 
digestion solution, a mixture of collagenase, dispase, and hyaluronidase. The tumor 
was cut into small pieces of about 1 mm³ size and incubated for 1 hour at 37°C to allow 
the decomposition of extracellular matrix and thereby discharge the melanoma cells. 
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The proteolytic digestion was stopped 
with 5 ml DMSO/10% FBS and the cell 
suspension was pressed through a cell 
strainer to separate the cells. The cells 
were spun down with 2000 rpm at room 
temperature for 5 minutes and the cell 
pellet was resuspended in 5 ml TU2% 
with ABAM. Fresh isolated melanoma 
cells were cultivated in Biocat® 25 cm2 
collagen vented flasks to facilitate the 
cell attachment and the medium was changed 24 hours after the isolation. When freshly 
isolated cells reached about 80-90% confluence, they were transferred and further 
cultivated in flasks without collagen surface. 
3.2.1.3 Cultivation of primary skin cells 
Primary fibroblasts and melanocytes were in-house isolated from human foreskins 
according to [15]. Fibroblasts were cultivated in fibroblast growth medium containing 
DMEM, FBS, and L-glutamine. Melanocytes were cultivated in melanocyte growth 
medium containing 254CF, CaCl2, and human melanocyte growth supplements (HMGS-
2). Primary fibroblasts were cultivated to a maximum of 20 passages, melanocytes up to 
10 passages in T75 flasks at 37°C and 5% CO2. Cell splitting, freezing, and thawing has 
been performed as described in section 3.2.1.1. 
3.2.2 Molecular biological methods 
3.2.2.1 Gene silencing using RNA interference 
3.2.2.1.1 Design of small interfering RNAs 
All siRNAs used in this study were designed according to published algorithms from 
Reynolds [214] and Ui-Tei [271]. The control siRNA was designed in terms of not to 
interfere with the human transcriptome. 
3.2.2.1.2 Transfection of siRNAs 
Cells were transfected at a confluence of about 70% 24 hours after seeding. For cells in 
a 6-well plate, 1.5 µl siRNA (concentration 20 µM) were mixed with 125 µl Opti-MEM® 
Figure 4: Isolation of tumor cells from patient 
samples. 
(a) Removal of skin, adipose, and connective tissue 
from cutaneous melanoma samples washed with 
HBSS. (b) Dissected melanoma tissue in digestion 
solution. 
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reduced serum medium (Life Technologies). One µl Lipofectamine® RNAiMAX were 
mixed in the same volume Opti-MEM. After a short incubation of 2 minutes, both 
solutions were combined and mixed by inversion. An incubation for 15-20 minutes at 
room temperature allowed complex formation between siRNA and Lipofectamine. 
Meanwhile, the medium covering the cells was exchanged with 1.25 ml fresh medium. 
After the incubation, the mixture containing Lipofectamine-complexed siRNAs was 
added dropwise to the cells. The final siRNA concentration was 20 nM per well. Gene 
silencing after siRNA transfection was assessed by qRT-PCR and immunoblotting. If 
cell death was blocked by caspase and necroptosis inhibitors, 100 µM Z-VAD (N-
Benzyloxicarbonyl-Val-Ala-Asp[O-ME]-fluoromethyl ketone, stock 100 mM in methanol, 
Sigma Aldrich) or 50 µM Nec-1 (necrostatin-1, stock 50 mM in DMSO, Sigma Aldrich) 
were added prior to siRNA transfection. 
3.2.2.2 Transient and stable transfection of plasmid DNA 
FuGENE® 6 transfection reagent was used to insert plasmid DNA into cells. For 
transfection of a 6-well plate well, 3 µl FuGENE reagent were mixed with 50 µl Opit-
MEM and incubated at room temperature for 5 minutes. One µg plasmid DNA was 
added, mixed by inversion, and incubated for 30 minutes at room temperature. The cell 
medium was exchanged with 1 ml fresh medium and the mixture containing 
DNA/reagent complexes was added dropwise. For a T25 flask, 2.6 µg plasmid DNA 
were transfected using 7.8 µl FuGENE reagent in 122.2 µl Opti-MEM and 3 ml medium 
on top of the cells, for a T75 flask using 7.8 µg plasmid DNA with 23.4 µl FuGENE 
reagent in 366 µl Opti-MEM and 7.8 ml medium on top of the cells. 
If the DNA transfection followed a siRNA transfection, the DNA transfection was 
performed 24 hours later and cells were washed with HBSS before adding the 
DNA/reagent mixture into the new medium. 
For stable plasmid DNA transfection, the medium was exchanged to medium containing 
antibiotics for selection (e.g. 0.5 µg/ml puromycin for pLenti-PMP2 and WM3211 cells, 
0.25 µg/ml puromycin for WM278) 48 hours after plasmid transfection. 
3.2.2.3 Cell invasion assays 
3.2.2.3.1 Matrigel invasion assay 
For the Matrigel invasion assay, ThinCert™ cell culture inserts for 24-well plates 
(Greiner bio-one) were coated with 50 µl cold PBS-diluted Matrigel matrix (Matrigel™ 
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Basement Membrane Matrix, BD Biosciences; 39 mg per well), incubated at 37°C and 
5% CO2 for 3 hours, and dried under the clean bench overnight. Twenty-four hours after 
siRNA or plasmid transfection, melanoma cells were harvested by trypsinization, 
washed with TU medium without FBS, and counted. 150,000 cells in case of inhibition 
and 120,000 cells in case of overexpression studies were resuspended in 200 µl TU 
medium without FBS and seeded on top of the Matrigel-coated ThinCert™ inserts. The 
well below the inserts was filled with 600 µl fibroblast-conditioned medium (for 
preparation see section 3.1.1). The assay was performed for 5 hours at 37°C and 5% 
CO2. Afterwards, non-invasive cells and the remaining Matrigel matrix were removed 
with cotton swabs and the invaded cells on the lower side of the ThinCert™ insert were 
fixed and stained with a Diff-Quik® staining set (Medion Diagnostics, Duedingen, 
Switzerland). Invaded cells were counted from whole inserts with microscopical 
magnification. Macroscopical pictures of stained inserts were taken with a Canon G11 
camera (Canon, Krefeld, Germany). 
3.2.2.3.2 Spheroid assay 
To form spheroids, 5,000 melanoma cells per well in 100 µl TU2% medium were 
seeded on an agar-coated 96-well plate. Coating was performed directly before seeding 
the cells, by pipetting 50 µl sterilized liquid agar solution (1.5% agar noble from Beckton 
Dickinson Difco™, New Jersey, USA, in PBS) per well and letting the agar solidify by 
cooling down to room temperature for 45 min. After seeding, cells were incubated at 
37°C with 5% CO2 for 48 to 96 hours (depending on cell line), to allow aggregation and 
spheroid formation. Spheroids were harvested with a 1,000 µl pipette and transferred 
into a 1.5 ml reaction tube. After 5 to 10 minutes, spheroids settled down at the bottom 
of the reaction tube. Meanwhile, wells of a 24-well plate were covered with 300 µl 
collagen mix and incubated at 37°C, 5% CO2, for 15-30 min to solidify. The medium on 
top of the spheroids was removed. Spheroids were resuspended in 300 µl collagen mix 
per well and added on top of the previous layer, followed by further incubation at 37°C 
and 5% CO2. The cell invasion was monitored by light microscopy. In case of 
investigating cell viability, spheroids were stained with calcein AM and EthD-1 from the 
LIVE/DEAD® viability/cytotoxicity kit according to the manufacturer’s protocol and 
fluorescence microscopy had been performed 45 minutes later. The cell invasion was 
quantified using FIJI ImageJ software by determination of the complete area covered 
with cells and subtracting the non-invasive spheroid core. 
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3.2.2.3.3 Chick embryo invasion assay 
Chick embryo invasion assay was performed in collaboration with Dr. Christian Busch at 
the Section Dermato-Oncology, University of Tübingen, Tübingen. Fertilized eggs of 
chicken from a local farmer were incubated in a water-filled incubator at 38°C for 60 
hours. The upper side of each egg was marked. When the chick embryos had reached 
embryonic stage 12-13 according to Hamburger and Hamilton [94] (Figure 5 d), the egg 
was prepared for melanoma cell injection with the marked side facing up. Two ml of egg 
white were removed with a syringe after tapping the egg on one side to lower the 
embryo. A window was carefully cut in the egg shell with a small hacksaw (Figure 5 a 
and b) and 2 ml PBS were injected to lift the embryo up again. For a better contrast, a 
bit of writing ink was injected with a mouth pipette behind the embryo (Figure 5 c). 
1205Lu melanoma cells of a T75 flask were harvested by trypsinization and washed 
twice with PBS. The supernatant was removed and 10 µl of the cell suspension were 
injected in the rhomboid fossa, in the hindbrain of the chick embryo, using a mouth 
pipette. The window in the egg was closed with a tape and the embryo was incubated 
for further 96 hours at 38°C before fixation, paraffin embedding, and serial sectioning. 
For quantification of melanoma cell invasion, the three middle sections with the largest 
tumor diameters were analyzed in each embryo by counting the invading mindbomb E3 
ubiquitin protein ligase 1 (MIB1)–positive melanoma cells. The mean value represented 
the number of invading melanoma cells per embryo. The maximum diameter of each 
tumor on the same section was measured in two dimensions using an Olympus BX51 
microscope with a DP21 camera (Olympus, Hamburg, Germany). 
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Figure 5: Chick embryo invasion assay.  
(a) Windowed chick egg with embryo in the middle surrounded by blood vessels. (b) Tools for the assay. 
(c) Ink injected behind the chick embryo for better visualization of the injection side. (d) Chick embryos in 
the developmental stages 12 and 13 according to Hamburger and Hamilton (modified from [94]). 
3.2.2.4 Cell viability assay 
The viability of cells in multiwell plates was determined with the CellTiter-Blue® Cell 
Viability Assay (Promega). In case of a 6-well format, the cell medium was exchanged 
with 750 µl medium and 150 µl of the dark blue CellTiter-Blue® reagent were added and 
mixed, followed by incubation at 37°C, 5% CO2, for one hour. A control containing 
medium without cells plus the reagent was included as reference for the fluorescence 
signal. After the incubation, 100 µl of the cell supernatant (1 to 3 technical replicates) as 
well as from the control were transferred into a 96-well plate and measured at a 
Cytofluor 2350 Fluorimeter (Millipore) with an excitation of 560 nm and emission at 590 
nm. 
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3.2.2.5 Flow cytometry 
3.2.2.5.1 Cell cycle analysis 
For cell cycle analysis, the supernatant of a 6-well plate well was transferred into a 2 ml 
tube and the adherent cells were washed twice with PBS before detachment by 
trypsinization. The detached cells were added to the supernatant and washed twice with 
PBS with centrifugation at 2000 rpm, 4°C, for 5 minutes in between. PBS was reduced 
to a volume of 100 µl and 1.4 ml ice-cold 75% ethanol (end concentration 70%) was 
added dropwise while gentle mixing to permeabilize the cell membrane and fix the DNA. 
The fixed cells were incubated at 4°C overnight and then washed again twice with 500 
µl washing buffer (PBS/0.5% BSA). Cell pellets were resuspended in 300 µl cell cycle 
staining solution followed by RNAse A (Sigma) digestion with incubation at 37°C for 15 
minutes. The samples were transferred into fluorescence-activated cell sorting (FACS) 
tubes and the amount of DNA was detected with a FACScan flow cytometer (Becton 
Dickinson) and evaluated with the ModFit LT software.  
3.2.2.5.2 Cell death analysis 
The supernatant of one 6-well plate well was transferred into a 1.5 ml tube and adherent 
cells were washed twice with PBS and detached with 0.2% EDTA in PBS at 37°C for 10 
minutes. Cells were transferred to the supernatant-containing tube and washed again 
twice with PBS and centrifugation at 2,600 rpm, 4°C, 3 minutes in between. Cells were 
resuspended in 50 µl Annexin staining solution and incubated in dark at room 
temperature for 15 minutes. During this incubation time, 60 µl PI staining solution were 
pipetted into a FACS tube and Annexin V-Fluos-stained cells were added and mixed. 
Samples were immediately analyzed with a FACScan flow cytometer and evaluated 
with the CellQuest software (Becton Dickinson, Heidelberg, Germany). 
3.2.2.6 Luciferase reporter assay 
Cells in a 6-well plate were transfected with 800 ng luciferase reporter vector and 200 
ng renilla vector per well as described in 3.2.2.2. Twenty-four hours later, cells were 
washed twice with PBS and lysed by adding 250 µl 1x lysis buffer (Promega) and 
incubating at 4°C for 10 minutes. The cell lysate was transferred into a 1.5 ml tube. 
Twenty-five µl of the cell lysate were transferred into a white 96-well plate. Twenty-five 
µl of a 1:1 mixture of luciferin and ATP substrate (Biothema) for the firefly luciferase 
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reaction or 25 µl coelenterazine substrate (1:800 in H2O bidestilled, Promega) for the 
renilla luciferase reaction were added and mixed by shaking. The bioluminescence was 
immediately measured in a GloMax® luminometer (Promega). Firefly and renilla 
luciferase reactions were measured in triplicates. 
MIA promoter activity was tested with the full length promoter in pGL3 (-1376bp, in 
relation to the protein start ATG) or promoter fragments (-493bp, -275bp, -212bp, -
200bp, and -160bp) in a pGL2 reporter vector backbone (kindly provided by Prof. Anja-
Katrin Bosserhoff [25], [203], [204]). SOX-binding sites were predicted using Genomatix 
software (Genomatix Software GmbH, Munich, Germany) and JASPAR version 
5.0_alpha (http://jaspar.genereg.net/) with the MIA promoter sequence according to 
>gi|224589810|ref|NC_000019.9|:41279500-41280875 Homo sapiens chromosome 19, 
GRCh37.p5. Mutations in predicted SOX-binding sites in the MIA promoter were 
introduced using the QuikChange Lightning Site-Directed mutagenesis kit (Agilent 
Technologies) by exchanging A to C or T to G and vice versa. In case of measuring MIA 
reporter activity after SOX10 inhibition, siRNA transfection was carried out as described 
in section 3.2.2.1.2 twenty-four hours prior to reporter plasmid transfection. 
3.2.2.7 Cloning of expression vectors 
PCR with a proofreading Herculase II Fusion DNA polymerase (Agilent Technologies) 
was carried out with the following composition and PCR program in a RoboCycler® 
Thermo cycler (Stratagene): 
Template DNA 10-30 ng plasmid DNA or 2 µl cDNA 
DMSO (Agilent Technologies) 0-8% 
MgCl2 (Agilent Technologies) 2-4 mM 
Primers 0.25 µM each 
Deoxyribonucleotide triphosphates 
(dNTPs; Agilent Technologies) 
250 µM each dNTP 
Herculase II Fusion DNA polymerase 1 µl 
 total volume 50 µl 
Concentration of DMSO and MgCl2 were varied to optimize the PCR. 
PCR program: 
Initial denaturation 95°C, 5 minutes 1 cycle 
Denaturation 95°C, 1 minute 30 cycles 
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Primer annealing Primer melting 
temperature minus 5°C, 
1 minute 
Extension 72°C, 30 seconds per kb 
Final extension 72°C, 5 minutes 1 cycle 
PCR products were controlled on a 1% agarose gel (1 g w/v peqGold Universal 
Agarose, Peqlab, Erlangen, Germany, in 100 ml TBE, microwaved for dissolving) and 
detected on a Gel Doc 2000 apparatus (Bio-Rad). If fragments had to be cut out of the 
agarose gel, these fragments were purified with a NucleoSpin® Gel and PCR Clean-up 
Kit (Macherey-Nagel) according to the manufacturer’s protocol. 
Restriction enzyme digestion was carried out with corresponding restriction enzymes 
from NEB (Ipswitch, Massachusetts, USA) according to the manufacturer’s protocol. 
For assemble vector insert and backbone, the Rapid DNA Ligation Kit (Roche) was 
used. Therefore, vector and insert DNA were mixed in a molecular ratio of 3:1 or 5:1 
with DNA dilution buffer in a final volume of 10 µl. Ten µl T4 DNA ligase buffer as well 
as 1 µl T4 DNA ligase were added and mixed. The reaction mixture was incubated at 
room temperature for 10 minutes. Five µl of the ligation was transformed in chemical 
competent DH5α bacteria cells according to section 3.2.2.8. 
Entry or donor vectors were recombined in a pLenti Puro CMV Dest vector with a 
Gateway® LR Clonase® II enzyme mix (Life Technologies) by mixing 75 ng of each 
vector in a final volume of 6 µl in TE buffer (pH 8). One µl of the LR Clonase® II enzyme 
was added and incubated at room temperature for 3 hours. Three µl were transformed 
in chemical competent StBl3 bacteria cells as described in section 3.2.2.8. Successful 
cloning was monitored by restriction enzyme digestion and sequencing (1.7 µg plasmid 
DNA and 10 µM sequencing primer in 20 µl H2O, performed by Eurofins genomics). 
3.2.2.8 Transformation and conservation of chemical competent Escherichia coli 
For transformation of plasmid DNA in chemical competent Escherichia coli bacteria, 200 
µl One Shot StBl3 (Life Technologies) or DH5α were thawed in a 12 ml round bottom 
tube on ice. Ten ng plasmid DNA were added, mixed, and further incubated for 30 
minutes on ice. At the heat shock step, the tube was dipped in a water bath at 42°C for 
90 seconds followed by a further incubation on ice for 2 minutes. Eight-hundred µl SOC 
medium (Life Technologies) were added and the bacteria suspension was incubated at 
37°C, 300 rpm, for one hour. One-hundred µl of the suspension were streaked on an 
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agar plate with the appropriate selection antibiotic and incubated at 37°C overnight. For 
long-term storage, one colony was inoculated in 5 ml LB medium containing antibiotics 
for selection at 37°C, 300 rpm overnight. Eight-hundred µl of the bacteria suspension 
were mixed with 200 µl glycerol and stored at -80°C. 
3.2.3 Biochemical methods 
3.2.3.1 Isolation of nucleic acids 
3.2.3.1.1 Plasmid isolation 
To isolate plasmid DNA from bacteria, 5 ml of an overnight culture were spun down at 
13,000 rpm, room temperature, for 30 seconds. The pellet was either stored at -20°C or 
directly used for plasmid DNA isolation with the NucleoSpin® Plasmid Kit (Macherey-
Nagel) according to the manufacturer’s protocol. Plasmid DNA was eluted with 50 µl AE 
buffer (5 mM Tris-HCl, pH 8.5) and a 1:40 dilution of the DNA was prepared. The 
absorbance of this dilution was measured in a quartz cuvette in a SmartSpec 3000 
photometer (Bio-Rad) at 260 and 280 nm with AE buffer as reference. The quotient 
A260/A280 determines the purity of isolated DNA and should range between 1.6 and 2 
(with a value of 1.8 for pure DNA and 2 for pure RNA). Lower values indicate protein 
contamination with absorption of aromatic amino acids at 280 nm. The DNA 
concentration was then calculated using the following formula:        
  
       
                       
  
  
                    . 
Plasmid DNA was stored at -20°C. 
3.2.3.1.2 RNA isolation 
For RNA isolation, cells cultivated in a 6-well plate were washed twice with PBS. One ml 
phenol-containing QIAzol (Qiagen) was added and incubated at room temperature for 5 
minutes. The lysed cells were scratched with a cell scraper and transferred into a 1.5 ml 
tube. Two-hundred µl chloroform (Sigma) were added and mixed by strong shaking for 
15 seconds. The mixture was incubated for 2 minutes. To separate the two phases, the 
mixture was centrifuged at 4°C and 13,200 rpm for 15 minutes. The upper liquid phase 
was transferred into a new 1.5 ml tube containing 700 µl 70% ethanol in RNase-free 
water and mixed. Further RNA purification was performed with an RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s protocol and eluted with 35 µl RNase-free 
water. The concentration of RNA was measured in a 1:20 dilution with a SmartSpec 
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3000 photometer and RNase-free water as reference as described in section 3.2.3.1.1. 
The concentration was calculated using the following formula:        
  
        
                          
  
                       
The isolated RNA was stored at -80°C. 
3.2.3.2 Quantification of gene expression 
3.2.3.2.1 Copy DNA synthesis 
Gene expression can be measured by the relative amount of copies of an mRNA 
transcript of a gene in a sample. To quantify gene expression, isolated single-stranded 
mRNA was first transcribed into cDNA with a RNA-dependent DNA polymerase called 
reverse transcriptase. Oligo-deoxythymidine (dT) was used as primer for the 
transcription because it specifically hybridizes with the poly-adenosine-tailed mRNA, 
allowing only mRNA but no other RNA species to be transcribed. Therefore, 300–1,000 
ng isolated RNA was incubated with 500 ng poly-dT (15 dTs, Eurofins Genomics) in a 
final volume of 10.5 µl with RNase-free water for 10 minutes at 65°C in a RoboCycler® 
Thermo Cycler (Stratagene) for denaturating the RNA and cooled down immediately 
afterwards for total hybridization of the primers. First strand DNA synthesis was carried 
out in following composition: 
Preparation 1 (RNA with poly-dT) 10.5 µl 
5x First Strand Buffer (Roche) 4 µl 
Dithiothreitol (DTT, 0.1 M; Roche) 2 µl 
dNTPs (10 mM, Roche) 2 µl 
RNAsin (Promega) 0.5 µl 
Reverse Transcriptase (Roche) 1 µl 
 total volume 20 µl 
The reverse transcription was carried out in a water bath at 42°C for one hour. 
Afterwards, 40 µl RNase-free water were added to each reaction and 3 µl were used for 
qRT-PCR. The cDNA was stored at -80°C. 
3.2.3.2.2 Quantitative real-time PCR 
The quantification of a specific sequence from the cDNA transcripts was performed with 
the Lightcycler® Taqman® Master Kit (Roche), including a thermostable Taq DNA 
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polymerase. A qRT-PCR follows the general principle of a PCR reaction, while the 
amplified DNA produced during the reaction is detected in real-time by using a 
fluorescence dye. This fluorescence dye can either be a DNA intercalating molecule or 
– as used in this study – a fluorescence-labeled probe. The detected fluorescence 
signal increases proportionally to the amount of amplified DNA. Quantification is carried 
out during the exponential phase under following conditions: the ratio of template DNA, 
primer, and polymerase is optimal, the other reactants (e.g. dNTPs) are sufficient, and 
the amount of side products is marginal. The end phase of the reaction is indicated with 
a plateau, creating a sigmoid curve during the measurement as typical for an enzymatic 
reaction. The starting point of the exponential phase is named threshold cycle (CT-
value) or crossing point. At this point, the measured fluorescence exceeds significantly 
the background fluorescence. The fluorescence-labeled probes from the Universal 
Probe Library (Roche) are short locked nucleic acids, which are chemically modified 
nucleic acids that bind with a higher affinity as natural nucleic acids. Thereby, these 
short locked nucleic acids hybridize at the same temperature as longer, specific primers 
with a length of 20-25 nucleotides. The probes are coupled with a quencher dye at the 
3’ end. When the Taq polymerase approaches and degrades the hybridized probe due 
to its 5’-3’ exonuclease activity, the reporter fluorophore is released from the quencher 
dye and the fluorescence signal can be detected. 
The Universal Probe Library allows detection of more than 98% of the 37,000 human 
gene transcripts included in the National Center for Biotechnology Information (NCBI) 
Reference Sequence Database with only 90 different probes due to the combination 
with gene-specific primers, which were designed with the Assay Design Center (section 
3.1.12). Primer pairs and respective probes for each gene measured in this study are 
listed in section 3.1.5.1. 
In each quantification reaction a control sample (non-treated 1205Lu) with dilutions 
served as standard curve. With the CT-values in the standard curve the relative value of 
a specific gene expression was determined. To normalize the relative amount of the 
measured target gene, a ubiquitously expressed gene was quantified in the same 
sample. In this study all quantified genes were normalized to the expression of 
hypoxanthin-guanine phosphoribosyltransferase (HPRT), an enzyme that plays a 
central role in the generation of purine nucleotides through the purine salvage pathway. 
Each reaction was carried out in LightCycler capillaries (Roche) in the composition: 
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H2O, PCR grade 4.5 µl 
Probe 0.1 µl 
Forward primer (10 µM) 0.2 µl 
Reverse primer (10 µM) 0.2 µl 
Reaction master mix (including enzyme) 2 µl 
cDNA 3 µl 
Capillaries were spun down at 1,000 rpm, 4°C, for 30 seconds. 
The program for qRT-PCR reaction was: 
Initial denaturation (1 cycle) 94°C 10 minutes 
Amplification/quantification 94°C 10 seconds 
(50 cycles) 60°C 30 seconds 
 72°C 1 second 
Cooling down to 40°C 0.1°C per second  
3.2.3.3 Copy DNA sequencing 
To identify the mutation status of SOX10 and MIA in cell lines WM278, WM1232, and 
1205Lu, cDNA of these cell lines was generated as described in section 3.2.3.2.1. A 
PCR reaction with a proof reading DNA polymerase (Herculase II) was performed as 
described in section 3.2.2.7. Primers for amplification of SOX10 or MIA cDNA are listed 
in section 3.1.5.2. The PCR product was controlled on a 1% agarose gel and purified 
with a NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel). Four-hundred ng of 
the DNA was sequenced with primers according to section 3.1.5.2 by Eurofins 
Genomics. 
3.2.3.4 RNA sequencing 
For RNA sequencing analysis, 1x106 1205Lu melanoma cells were seeded in a T75 
flask. Twenty-four hours later, the cells were transfected with 7.8 µg pCMV-SOX10 or 
pCMV6 according to section 3.2.2.2. Twenty-four hours later, cells were lysed in 1.2 ml 
QIAzol and 0.2 ml was used in order to control SOX10 overexpression by RNA isolation 
and qRT-PCR. The other part was delivered to the group of Dr. Helmut Blum at the 
Gene Center Munich, where the RNA sequencing analysis was performed with a 
GenomeAnalyzer IIx (Illumina, San Diego, USA). 
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RNA was isolated with the trizol method (according to 
https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf). Copy DNA was 
generated with the NuGEN (Leek, Netherlands) RNAseq complete library preparation kit 
by using 100 ng of the total RNA for mixed random-/poly adenosine-primer first-strand 
cDNA synthesis. The cDNA was bead-purified (AmpureXP, Beckman-Coulter) and 
fragmented by sonication (Bioruptor, Diagenode, 25 cycles 30s on/30s off). The 
fragmented cDNA was used for preparation of Illumina-compatible sequencing libraries 
using the NuGEN RNAseq complete library preparation kit according to the 
manufacturer’s protocol. In brief, the cDNA fragments are ligated to adapters with 
known sequences and sample-specific barcodes, which allows pooling of the samples 
and assignment of the SOX10-overexpressing and control samples at the mapping 
step. Adapter ligation was done with sample-specific barcodes and the resulting library 
was amplified (KAPA high fidelity polymerase, eight cycles, 95°C 80 sec, 55°C 30 sec, 
72°C 60 sec) and quantified on a Bioanalyzer 2100 (Agilent) for quality control. 
Barcoded libraries were pooled at 10 nM concentration for multiplexed sequencing. 
Libraries were hybridized to a flow cell, amplified for generation of clusters and 
sequenced with an Illumina Genome Analyzer IIx. Hereby, blocked, fluorescence-
labeled nucleotides are incorporated stepwise by a DNA-polymerase. After each step, 
the fluorescence is measured on the clusters enabling the determination of incorporated 
nucleotide by its fluorescence. After deblocking and read extension the sequence of the 
library can be determined. Sequencing was performed to a mean coverage of 20 x 106 
reads each. Sequencing runs were done in single-read mode with an 80-base read 
length. 
For each sample replicate, raw reads were filtered for adapter sequences. After 
removing the first five bases due to random priming effects, the raw reads were filtered 
from the 3’ and 5’ end with a quality cutoff of 20. Reads below a length of 30 were 
discarded. Filtered reads were mapped with Tophat2 (v.2.0.3) to the human reference 
genome (HG19) supplied by annotated gene models in the GTF formate from the online 
available iGenomes project of Illumina. Only uniquely mapped reads were used to 
calculate the number of reads falling into each gene with the HTSeq-count script 
(v.0.5.3) in the union mode and using no strand information from the HTSeq package. 
Differentially expressed genes were calculated with the DESeq package. Genes were 
regarded as differentially expressed when the adjusted P value was < 0.05. The 
mapped reads from each replicate were merged, and the numbers of reads falling into 
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the exonic regions of the annotated genes were counted. A gene was determined as 
expressed if more than 15 reads could be properly aligned to that gene.  
In the first sequencing experiment, a high rate of reads mapped to the sequence of the 
transfected plasmid and had to be excluded from the analysis. Another sequencing 
experiment was performed with the same isolated mRNA but with DNA digestion 
(Thermo Scientific ds DNase #EN0771) prior to cDNA synthesis and library generation. 
Description of RNA sequencing is based on the material and method section from [90]. 
3.2.3.5 Protein isolation 
3.2.3.5.1 Whole cell extracts 
To isolate whole cell proteins, adherent cells were washed twice with PBS and 
detached with 0.2% EDTA in PBS at 37°C, 5% CO2, for 10 minutes. The pellet was 
centrifuged at 2,600 rpm, 4°C, for 3 min, washed twice with PBS, and resolved in 50 µl 
CSH or RIPA (in case of detection of PMP2) buffer. After incubation for 30 minutes on 
ice, the soluble protein fraction was separated from the cell debris by centrifugation at 
13,200 rpm, 4°C, and 20 minutes. The supernatant was transferred into a new tube. 
The protein concentration in cell extracts was determined with the Pierce™ BCA Protein 
Assay Kit (ThermoFisher Scientific). This assay combines chelation of Cu2+ by the 
peptide backbone and subsequent reduction to Cu1+ in an alkaline environment (biuret 
reaction) with the reaction of bicinchoninic acid (BCA) and the reduced cuprous cation, 
generating an intense purple-colored complex. Reagents A was diluted 1:50 in reagent 
B and 1 ml of the solution were added in a plastic cuvette. Ten µl of the protein lysate 
were added and mixed. A standard curve generated by a dilution row of bovine serum 
albumin (BSA, New England Biolabs, 10 mg/ml) in the lysis buffer with final 
concentrations of 80, 40, 20, 10, and 5 mg/ml in the cuvette was included in each 
measurement. After an incubation step at room temperature for 20 minutes, the optical 
density at 562 nm was determined with a SmartSpec 3000 photometer with reagent A 
plus B and lysis buffer as reference. The protein extract was stored at -80°C. 
3.2.3.5.2 Nucleic extracts 
Fractional cell lysis to isolate nucleic proteins was performed with the Nuclear Extract 
Kit from Active Motif. Cells from a confluent T75 flask were washed with 5 ml ice cold 
PBS/phosphatase inhibitor provided in the kit and cells were detached in 3 ml of this 
solution with a cell scraper followed by centrifugation at 500 rpm, 4°C, for 5 minutes. 
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The pellet was resuspended in 500 µl hypotonic buffer and incubated on ice for 15 
minutes. To release nuclei, cells were lysed with 25 µl detergent and mixed for 15 
seconds. To separate nuclei from the cytoplasmic fraction, the suspension was 
centrifuged at 13,200 rpm, 4°C, for 30 seconds. The supernatant (cytoplasmic fraction) 
was stored at -80°C. The nuclei were resuspended in 50 µl complete lysis buffer, mixed 
for 10 seconds, and centrifuged at 13,200 rpm, 4°C, for 10 minutes. The supernatant, 
containing soluble nucleic proteins, was transferred into a new tube. To determine the 
concentration of a nuclei extract, 5 µl of the lysate were added to 800 µl H2O bidestilled 
in a plastic cuvette followed by addition of 200 µl Bio-Rad Protein Assay reagent (based 
on the Bradford dye-binding method) and mixing. A standard curve as described in 
section 3.2.3.5.1 was included. The optical density of a sample, generated by the 
complex formation of Coomassie brilliant blue G-250 with amino acids, was determined 
in a SmartSpec 3000 photometer at 595 nm without further incubation. The complete 
lysis buffer included in the kit served as reference. The nucleic extract was stored at -
80°C. 
3.2.3.5.3 Proteins from cell supernatants 
To analyze proteins in the supernatant of a 6-well plate, two times 0.5 ml medium from 
on top of the cells were concentrated in an Amicon® Ultra 0.5 ml Centrifugal Unit 3K 
(nominal molecular weight limit 3 kDa, Millipore/Merck) with two times centrifugation at 
13,200 rpm, 4°C, for 20 minutes in a provided 2 ml tube. The insert was positioned 
head first in a new 1.5 ml tube and centrifuged at 2,000 rpm, 4°C, for 2 minutes. In the 
end, the supernatant was concentrated 200 times and stored at -80°C. Protein 
concentration was determined as described in section 3.2.3.5.1. 
3.2.3.6 Immunoblot according to Laemmli 
3.2.3.6.1 Polyacrylamide gel electrophoresis 
Protein separation by polyacrylamide gel electrophoresis was carried out with protein 
extracts prepared according to section 3.2.3.5.1. For protein denaturation, 10 µg protein 
extract were incubated together with 6 µl NuPAGE® LDS Sample Buffer and 2.4 µl 
NuPAGE® Reducing Agent in a total volume of 24 µl at 70°C for 10 minutes. The 
polyacrylamide gel electrophoresis was carried out in a XCell SureLock™ mini-cell 
electrophoresis system (Life Technologies). Denaturated proteins were loaded on a 
NuPAGE® Novex® 4-12% Bis Tris Gel, and 10 µl SeeBlue® Plus2 pre-stained standard 
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served as size marker. The inner chamber was filled with 200 ml running buffer 
including 500 µl NuPAGE® Antioxidant, the outer chamber with running buffer without 
oxidant. The running time was about 45 minutes at 150 Volt. All reagents and gels were 
purchased from Life Technologies. 
3.2.3.6.2 Immunoblotting 
Proteins separated by polyacrylamide gel electrophoresis were transferred on a PVDF 
membrane using the XCell II module. Blotting pads, filter paper and membrane (all from 
Life Technologies) were soaked in transfer buffer with 0.1% antioxidant and 10% 
methanol p.a. (20% for blotting 2 gels). Arrangement in the module was: cathode – 3 
pads – filter paper – membrane – filter paper – 3 pads – anode for one gel and cathode 
– 2 pads – filter paper – membrane – filter paper – 1 pad – filter paper – membrane – 
filter paper – 2 pads – anode for two gels blotting. The module was filled with transfer 
buffer and the outer chamber with water for cooling. Blotting was performed with 30 Volt 
for 70 minutes. Afterwards the membrane was incubated in blocking solution while 
shaking at room temperature for one hour to reduce nonspecific antibody binding. For 
reversible Ponceau S staining, the blot was incubated in 10 ml Ponceau S staining 
solution for 5 minutes while shaking before the blocking step. Ponceau S-stained 
proteins on the membrane were visualized by subsequent washing with H2O bidestilled. 
3.2.3.6.3 Protein detection 
Detection of specific proteins in the whole cell lysates was accomplished by incubating 
the immunoblot membrane in a solution of the primary antibody as listed in section 
3.1.8.1 in blocking solution or 5% BSA/0.1% Tween20 (in case of Cell Signaling 
antibodies) with 0.02% sodium azide at 4°C and shaking overnight. To remove non-
bound antibodies the membrane was washed with PBS/0.1% Tween20 three times. The 
correlating secondary antibody, coupled with horse radish peroxydase (HRP), was 
diluted as described in section 3.1.8.2 in blocking buffer and incubated with shaking at 
room temperature for one hour. The membrane was washed again three times to 
remove excessive secondary antibody. Proteins were analyzed via chemiluminescence 
generated by the reaction of HRP with the Amersham Enhanced Chemiluminescence 
(ECL) Prime Western Blotting Detection Reagent (GE Healthcare; 1.5 ml per 
membrane) for 5 minutes in darkness. The luminescence signal was detected with high 
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performance chemiluminescence films (GE Healthcare) and automatically developed in 
a KODAK RP X-OMAT Developer and Replenisher. 
3.2.3.7 Electrophoretic mobility shift assay 
To hybridize DIG-labeled oligonucleotides, 22.5 µl of the sense (100 µM) and 22.5 µl of 
the antisense strand (100 µM; for sequences see section 3.1.5.3) were mixed with 1 µl 
MgCl2 (0.5 M) and 1.3 µl Tris-HCl pH 8 (1 M) and incubated at 95°C in a heating block 
for 10 minutes. Afterwards, the heating block was turned off and allowed to cool down to 
room temperature for about 3 hours. One-hundred picomol of double-stranded, DIG-
labeled oligonucleotide were incubated with 2 μg protein extract (prepared from 1205Lu 
according to section 3.2.3.5.2) at 37°C for 30 minutes in a 20 μl reaction mixture 
containing 1x EMSA binding buffer (10 mM Hepes pH 8, 50 mM NaCl, 0.1 mM EDTA, 5 
mM MgCl2, 5% glycerol), 2 μg poly(dG:dC) (InvivoGen) to compete non-specific DNA 
binding, 2 mM DTT, and 4 μg BSA. For supershift, 1 μl anti-SOX10 antibody (sc-
17342x, Santa Cruz) or IgG control (Sigma) was added to the nuclear extract and 
incubated for 30 minutes on ice prior to oligonucleotide addition. DNA-protein 
complexes were separated at 4°C on a 6% DNA retardation gel (Invitrogen/Life 
Technologies) with TBE as running buffer for about 45 minutes at 150 Volt. Afterwards 
DNA-protein complexes were transferred to a positively-charged nylon membrane 
(Roche) by electro blotting with 0.5x TBE as transfer buffer at 30 Volt and cooling on ice 
for 70 minutes. After the transfer, the DNA was UV cross-linked to the membrane with 
an ultraviolet crosslinker (Amersham Life Science/GE healthcare) and energy 900,000 
to 700,000 µJ/cm2. DIG-labeled oligonucleotides were visualized using DIG luminescent 
detection kit (Roche) according to the manufacturer’s protocol and SOX10 was detected 
by immunoblotting on the same membrane. 
3.2.3.8 Immunohistochemistry 
Immunohistochemistry (IHC) allows the detection of antigens in cells of a tissue and is 
widely used in the identification of abnormal cells as found in cancers, staining of 
biomarkers, and analysis of differentially protein expression in different parts of a 
biological tissue. There are several options of visualizing the antigen-antibody binding 
on a tissue e.g., with a coupled enzyme that catalyzes a color-producing reaction or a 
fluorophore tag as fluorescein or rhodamine.  
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In this study, SOX10 expression in the tumor cells of the chick embryo invasion assay 
(section 3.2.2.3.3) was detected with the alkaline phosphatase-anti-alkaline-
phosphatase (APAAP) method. Therefore, paraffin-embedded slices were de-
paraffinized by incubation twice in xylene (Merck) at room temperature for 10 minutes 
followed by incubation in 100%, 96%, 80%, 70% 2-propanol p.a. (AppliChem, 
Darmstadt, Germany) and H2O bidestilled for 4 minutes each. Afterwards, the slides 
were boiled twice for 10 minutes in IHC Select® Citrate Buffer pH 6 (Millipore/Merck) in 
a microwave. After cooling down for 20 minutes, the citrate buffer was exchanged with 
tap water followed by washing twice for 5 minutes with Tris buffer. For localizing the 
antibody solution, each slice was circled with a Dako Delimiting Pen (Dako, Glostrup, 
Denmark). Non-specific binding sites were blocked by covering the slides with 20% 
BSA/Tris buffer. After blocking, the primary antibody (anti-SOX10 rabbit polyclonal 
antibody, Medac Diagnostika, dilution 1:25 in Tris buffer) was added and incubated at 
4°C in a wet chamber overnight. The excessive antibody was removed by washing 
twice with Tris buffer for 4 minutes. Antibody detection was carried out with the Dako 
REAL™ Detection System (Dako). First, a mouse-anti-rabbit antibody was added in a 
1:100 dilution in 12.5% BSA/Tris buffer at room temperature for one hour followed by 
washing twice with Tris buffer for 4 minutes. Then a rabbit-anti-mouse antibody was 
added in a 1:20 dilution in 12.5% BSA/Tris buffer at room temperature for 30 minutes 
followed by washing as described before. The APAAP antibody was added in a 1:50 
dilution in 12.5% BSA/Tris buffer for 30 minutes followed by washing. The alkaline 
phosphatase was detected with a SIGMA FAST™ Fast Red TR/Naphthol AS-MX 
Alkaline Phosphatase Substrate Tablets Set (Sigma) by resolving the tablets in 1 ml 
H2O bidestilled. The substrate was added and incubated for 6 to 20 minutes in darkness 
with monitoring the color change. After color change, the substrate was removed by 
washing twice for 4 minutes with Tris buffer. A counterstaining with Mayer’s hemalum 
solution (hemalum solution acid according to Mayer, Roth) followed by a short wash in 
H2O bidestilled, 1 minute incubation in hemalum solution, two times short wash in tap 
water, 5 minutes incubation in tap water and short wash in H2O bidestilled. For 
conservation, a cover glass was fixed on top of the tissue slices with about 150 µl 
Kaiser’s glycerol gelatin (Merck, preheated to 50°C in a water bath) per microscope 
slide. H&E staining and MIB1 IHC were performed as previously described by Busch et 
al. [38]. Pictures were taken with a TissueFAXS (TissueGnostics). 
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3.2.3.9 Chromatin immunoprecipitation 
For analyzing protein-DNA binding in vivo by chromatin immunoprecipitation (ChIP) 
7.5x106 1205Lu cells in 10 ml TU2% medium were fixed with 1% formaldehyde (Merck) 
at room temperature and shaking for 10 minutes. The reaction was stopped by adding 
125 mM glycine (1.25 M stock solution, Fluka/Sigma) and incubating at room 
temperature while shaking for 5 minutes. Cells were washed twice with ice-cold PBS 
and centrifugation (1,000 rpm, 4°C, and 3 minutes) in between. Pellets were 
resuspended in 1 ml cell lysis buffer and incubated on ice for 10 minutes followed by a 
centrifugation at 5,000 rpm at 4°C for 5 minutes. The supernatant was aspirated and the 
pellet deep frozen at -80°C. The next step was to expose the genomic DNA and shatter 
it into fragments of 100 to 1,000 bp size. This was accomplished by resuspending the 
cell pellet in 250 µl nuclear lysis buffer followed by incubation for 10 minutes on ice. 
Nuclei were sonicated twice with the settings 30 seconds on, 30 seconds off for 10 
minutes, and 25% amplitude with an EpiShear™ Probe Sonicator (Active Motif). To 
control DNA shearing, 25 µl of the sheared chromatin were added to 5 µl of a 10% 
chelex (Sigma) suspension in TE buffer and 20 µg Proteinase K (Qiagen). The 
chromatin was digested at 56°C for 15 minutes, heated to 95°C for 15 minutes, and 
controlled on a 1% agarose gel. If shearing was successful, the chromatin was diluted 
1:10 in IP dilution buffer and pre-cleared with salmon sperm DNA/Protein G agarose 
beads (Millipore, washed 3 times with IP dilution buffer prior to usage) at 4 °C for 30 
minutes to get rid of non-specific DNA binding. Beads were removed by spinning down 
at 1000 rpm, 4°C, for 2 minutes and the supernatant (pre-cleared, sheared chromatin) 
was used for further steps. One-tenth of this chromatin was kept as input control. In the 
next step, DNA fragments that were bound by SOX10 were precipitated by adding 2.4 
µg anti-SOX10 antibody to one half of the sheared chromatin and an 2.4 µg control IgG 
(Sigma) to the other half followed by incubation on a wheel at 4°C overnight. For 
immunoprecipitation, 30 µl salmon sperm DNA/Protein G agarose beads were added 
and incubated on the wheel at 4°C for further 2 hours. To remove non-specific bound 
protein-DNA complexes, following washing steps were performed while shaking on ice 
with 600 µl of each buffer and centrifugation at 1,000 rpm, 4°C, for 1 minute in between: 
IP dilution buffer 1 minute 
Low salt wash buffer 1 minute 
High salt wash buffer 5 minutes 
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LiCl wash buffer 5 minutes 
TE buffer 1 minute 
The cross-link between protein-DNA complexes was removed by incubating the beads 
in 120 µl elution buffer with 6 µl 5 M NaCl at 65°C overnight. The input control was 
included in this step analogously. RNA and proteins were removed by adding 30 µg 
RNase and incubating at 37°C for 1-2 hours followed by adding Proteinase K to a final 
concentration of 0.4 mg/ml and further incubation at 56°C for 2 hours. NTB buffer 
(Macherey-Nagel) was added in the range 5:1 followed by a column purification of the 
DNA fragments with the Nucleospin PCR Clean-up Kit (Macherey-Nagel) according to 
manufacturer’s protocol and elution with 50 µl NE buffer. Three µl were subjected to 
qRT-PCR with primers according to section 3.1.5.2. Co-purified DNA in anti-SOX10 and 
control IgG samples was determined relative to the input control. 
3.2.4 Statistical analyses 
Unless otherwise stated, all experiments were performed in at least three independent 
experiments. Data show mean values ± standard deviation (SD). Statistics were 
calculated in Prism v 5.04 (GraphPad Software, San Diego, CA, USA). Two groups 
were compared using an unpaired two-tailed t-test. For multiple comparisons, one-way 
analysis of variance (one-way ANOVA) with Dunnett’s post hoc test was used. The 
(linear) correlation of expression between two genes in human skin and melanoma cell 
lines was evaluated by Pearson’s correlation. Differences were considered significant at 
a P-value of 0.05 or less. 
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4 Results 
4.1 Expression of SOX9 and SOX10 in human skin and melanoma cells 
To characterize the role of selected proteins in a specific tissue type, the expression of 
these proteins has to be analyzed. Concerning the analysis of proteins in tumor cells, it 
is important to determine the relative expression compared to non-transformed cells in 
the first step. The expression of SOX9 and SOX10 in melanocytes, melanocytic naevi, 
primary and metastatic melanoma cell lines and tissues have already been investigated 
[4], [8], [44], [52], [238], [239]. However, expression values varied substantially between 
the different studies.  
In this study expression of SOX9 and SOX10 was analyzed in a panel of human skin 
cells, melanoma cell lines, and short term-cultured melanoma cells. 
4.1.1 Expression in human fibroblasts, melanocytes, and melanoma cell lines 
SOX10 and SOX9 mRNA levels were measured by qRT-PCR in cultivated primary 
human fibroblasts from two different donors (Figure 6 a and Figure 7 a, white bars), 
primary human melanocytes from three different donors (Figure 6 a and Figure 7 a; 
black bars), and 12 melanoma cell lines derived from tumors of different progression 
stages (Figure 6 a and Figure 7 a, grey bars; RGP = radial growth phase, VGP = 
vertical growth phase). The expression on protein level was determined in the same 
samples by immunoblotting (Figure 6 b and Figure 7 b, c).  
SOX10 mRNA levels in fibroblasts were low and no protein was detected by 
immunoblotting (Figure 6 a and b). Although higher amounts of SOX10 mRNA were 
detected in melanocytes compared to melanoma cells on mRNA level, this observation 
was less pronounced on protein level. Among the different melanoma cell lines SOX10 
mRNA levels varied and SOX10 protein was detected in 8 of 12 melanoma cell lines. 
Two of the four negative ones derived from tumors of radial growth phase (SbCl2, 
WM3211) suggesting that SOX10 protein expression is associated with a more invasive 
or metastatic phenotype. Measured protein and mRNA amounts of SOX10 correlated in 
all analyzed melanoma cell lines except for cell line SbCl2.  
Mean levels of SOX10 mRNA and protein in fibroblasts, melanocytes, and melanoma 
cell lines were compared. SOX10 was significantly decreased in fibroblasts and 
melanoma cells compared to melanocytes on mRNA (Figure 6 c) as well as on protein 
level (Figure 6 d). 
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Figure 6: Expression of SOX10 in human skin cells and melanoma cell lines. 
(a) SOX10 mRNA (mean ± SD of three independent experiments) was assessed by qRT-PCR in 
fibroblasts (two donors, white bars), melanocytes (three donors, black bars), and melanoma cell lines of 
different progression stages (RGP = radial growth phase, VGP = vertical growth phase, and metastatic; 
grey bars). (b) SOX10 protein levels were assessed in the same cells as described in (a) using a SOX10-
specific antibody. Detection of β-Actin served as loading control. Numbers above the blots display 
quantification of the SOX10 bands with Fiji ImageJ, normalized to β-Actin. Mean mRNA (c) and protein 
(d) amounts of SOX10 in human fibroblasts (HF), melanocytes (HM), and melanoma cell lines (mel) were 
compared with a scatter blot. Significant decrease of SOX10 in HF and mel compared to HM were found 
on mRNA and protein level (one-way ANOVA versus HM, *P<0.0001 for mRNA and *P<0.01 for protein). 
No significant change between HF mRNA and protein was found compared to mel (t-test). 
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In case of SOX9, moderate mRNA levels were measured in fibroblasts and 
melanocytes, while varying amounts were detected in the different melanoma cell lines 
(Figure 7 a). 
Antibodies against SOX9 from the companies Chemicon, Zytomed Systems, and 
Millipore were used in this study. In addition to SOX9 (predicted molecular weight 56 
kDa, detected about 65 kDa), a protein in the molecular weight range of SOX10 
(predicted molecular weight 50 kDa, detected 58 kDa) was detected with these 
antibodies. As example, the Millipore antibody was used in Figure 7 b. Thus, the tested 
SOX9 antibodies fail to discriminate between SOX9 and SOX10 epitopes and so 
deteriorate the discrimination, a problem that was also described by Shakhova et al. 
[238]. An antibody against SOX9 phosphorylated at serine 181 (Anaspec Inc.) was 
included in the studies, which specifically detected the SOX9 epitope without non-
specific SOX10 binding (Figure 7 c). Serine 181 (S181) in the SOX9 amino acid 
sequence represents a consensus phosphorylation site for the protein kinase A (PKA). 
Phosphorylation at this site leads to nuclear localization of SOX9 by enhancing its 
binding to the nucleocytoplasmic transport protein importin β [172]. Therefore, SOX9 
phosphorylated at S181 represents transcriptionally active, nuclear SOX9. Using SOX9- 
and phospho-SOX9 specific antibodies for detection, SOX9 protein levels were found to 
be weak in fibroblasts and melanocytes, while melanoma cells displayed varying 
expression levels (Figure 7 b and c). 
Phospho-SOX9 (pSOX9) protein correlated with mRNA levels in the analyzed 
melanoma cell lines except for WM1366, WM239A, and WM9.  
Mean levels of SOX9 mRNA and protein in fibroblasts, melanocytes, and melanoma cell 
lines were compared. No significant change was found on mRNA for the three cell types 
(Figure 7 d). Also on protein level no significant change was found, although a tendency 
of higher expression in melanoma cell lines compared to fibroblasts and melanocytes 
was observed (Figure 7 e). 
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Figure 7: Expression of SOX9 in human skin cells and melanoma cell lines. 
SOX9 expression was assessed in the same cell lines as described in Figure 6 on mRNA (a) and on 
protein (b, c) level. SOX9 expression on protein level was detected with a SOX9-specific antibody 
(Millipore, b) or a phospho-SOX9 specific antibody (c). An asterisk marks the non-specific SOX10 signal 
detected with the SOX9 antibody (Millipore). Detection of β-Actin served as loading control. Numbers 
above the blots display quantification of the bands with Fiji ImageJ, normalized to β-Actin. Mean mRNA 
(d) and protein (e) amounts of SOX9 in human fibroblasts (HF), melanocytes (HM), and melanoma cell 
lines (mel) were compared with a scatter blot. No significant change of SOX9 in HF and mel compared to 
HM were found on mRNA and protein level (one-way ANOVA versus HM, n.s. = not significant). No 
significant change between HF mRNA and protein was found compared to mel (t-test).  
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Inverse mRNA expression of SOX9 and SOX10 was observed in 8 of 12 analyzed 
melanoma cell lines (WM3211, WM278, WM1366, WM793, WM9, WM1158, WM1232, 
451Lu). A significant negative linear correlation was found in these cell lines (Figure 8, 
Pearson coefficient ρ = -0.8343, *P = 0.01). 
 
4.1.2 Expression in short term-cultured melanoma cells 
Cancer cell lines proliferate indefinitely in cell culture. However, long term cultivation of 
cells can cause genotypic and phenotypic alterations. Therefore, melanoma cells were 
freshly isolated from patient tumor samples (pm = primary melanoma, km = cutaneous 
metastasis, gm = brain metastasis). MITF and human melanoma black 45 (HMB45) 
detected by immunoblotting were used as markers for melanoma cells (Figure 9) [89], 
[129]. SOX10, pSOX9, and SOX9 protein levels were detected by immunoblotting in 
these cells (Figure 9). Compared to primary melanoma and most cutaneous melanoma 
samples SOX10 was little expressed in cell line LMU-KM04 and highly expressed in 
brain metastasis cell line LMU-GM01. SOX9 and pSOX9 protein was detected in 
variable amounts in all analyzed short term-cultured melanoma cell lines. 
 
Figure 8: Inverse correlation of SOX9 and 
SOX10 mRNA expression. 
Negative linear correlation between SOX10 and 
SOX9 mean mRNA values (according to 
Figures 6 and 7) was found in melanoma cell 
lines WM3211, WM278, WM1366, WM793, 
WM9, WM1158, WM1232, and 451Lu (Pearson 
correlation, ρ = -0.8343, *P = 0.01). rel. u. = 
relative units. 
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Analyses of SOX9 and SOX10 expression in melanoma cell lines as well as in short 
term-cultured melanoma cells indicate an inverse expression pattern of SOX9 and 
SOX10 and an association of SOX10 with tumor metastasis. 
4.2 Inhibition of SOX9 and SOX10 via RNA interference 
RNA interference is a frequently used method to manipulate gene expression and 
thereby gaining insight into its cellular functions. Generally, RNA interference prevents 
the cell from virus infections via small interfering RNAs (siRNAs), regulates gene 
expression via microRNAs (miRNAs), or controls transposons via P-element induced 
wimpy testis (PIWI) interacting RNAs (piRNAs). The potential of double-stranded RNA 
(dsRNA) to effectively silence selected genes was first described 1998 in the nematode 
worm Caenorhabditis elegans by Andrew Fire and Craig Mello [71], who shared the 
Nobel Prize in Physiology and Medicine 2006. The dsRNA is recognized by the Dicer 
enzyme that processes it into 21-23 nucleotide siRNAs. These siRNAs are incorporated 
into a multicomponent nuclease complex, the RNA-induced silencing complex (RISC), 
and is unwound into single strands [97]. After degradation of the sense strand, the 
antisense strand serves as a matrix for sequence-specific RNA degradation. 
Small interfering RNAs for silencing SOX9 (siSOX9b) and SOX10 (siSOX10a) have 
been described previously [72]. All siRNAs have been designed according to the 
algorithms of Reynolds [214] and Ui-Tei [271]. To minimize the risk of non-specific 
effects of the RNA interference, two different siRNAs were included in the analyses. 
Figure 9: Expression of SOX9 and SOX10 in 
short term-cultured human melanoma cells. 
SOX10, pSOX9, and SOX9 protein expression 
was assessed by immunoblotting in short term-
cultured human melanoma cells from primary 
tumors (LMU-PM01, LMU-PM02, and LMU-
PM03), cutaneous metastases (LMU-KM03, 
LMU-KM04, and LMU-KM05), a brain 
metastasis (LMU-GM1), and 1205Lu as 
reference. Detection of MITF and HMB45 
served as markers for melanoma cells, β-Actin 
served as loading control. An asterisk marks 
the non-specific SOX10 signal detected with 
the SOX9 antibody. 
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The effectiveness of the gene knockdown was tested in metastatic melanoma cell line 
1205Lu by transfection of the two different siRNAs and a control siRNA, which was 
designed not to interfere with the human transcriptome.  
Inhibition of SOX9 by both SOX9-targeting siRNAs led to a decrease of SOX9 mRNA 
down to 40% (Figure 10 a), while siSOX10a reduced SOX10 mRNA expression down to 
approximately 50%, and siSOX10b down to approximately 60% (Figure 10 b).  
 
 
 
 
 
 
To analyze a potential cross-regulation, SOX10 mRNA was assessed after SOX9 
inhibition and vice versa. Transfection of siSOX9a and siSOX9b reduced SOX10 mRNA 
Figure 10: Inhibition of SOX9 and 
SOX10 via RNA interference.  
(a) SOX9 mRNA (mean ± SD of three 
independent experiments) was measured 
in 1205Lu cells 48 hours after transfection 
of SOX9-targeting siRNAs (siSOX9a and 
siSOX9b) in comparison to a control 
siRNA (siControl). (b) SOX10 mRNA 
expression was analyzed according to (a) 
after transfection of SOX10-targeting 
siRNAs (siSOX10a and siSOX10b) in 
comparison to siControl. (c) SOX10 
mRNA expression was analyzed in the 
SOX9-inhibited 1205Lu cells described in 
(a). (d) SOX9 expression was analyzed in 
the SOX10-inhibited cells described in 
(b). (e) SOX9, pSOX9, and SOX10 were 
detected 72 hours after transfection of 
both SOX9- and SOX10-targeting and 
control siRNAs. An asterisk marks the 
non-specific SOX10 signal detected with 
the SOX9 antibody (Millipore). Detection 
of β-Actin served as loading control. 
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Figure 11: SOX10 inhibition in cell lines 
WM278, WM1232, and 1205Lu. 
SOX10 protein expression was detected by 
immunoblotting in cell lines WM278, 
WM1232, and 1205Lu 24 hours after 
transfection of two SOX10-targeting siRNAs 
(siSOX10a and siSOX10b) and a control 
siRNA (siControl). Detection of β-Actin 
served as loading control. 
expression down to approximately 30% and 70%, respectively (Figure 10 c), while both 
SOX10-targeting siRNAs did not decrease but slightly increase SOX9 mRNA 
expression (Figure 10 d). 
On protein level, SOX9 and SOX10 were effectively reduced using both specific siRNAs 
(Figure 10 e). The reduction on protein level was more pronounced for SOX10 than for 
SOX9. Similar to the observation on mRNA level, transfection of SOX9-targeting 
siRNAs also reduced SOX10 protein levels, especially when using siSOX9a. In contrast 
to the findings on mRNA level, SOX10 inhibition reduced SOX9 protein expression. 
These data indicate that the effect of SOX9 on SOX10 is on a transcriptional level, while 
the effect of SOX10 on SOX9 is on a post-transcriptional level. 
Further analyses focused on the functional characterization of SOX10 in melanoma. 
Three different cell lines (VGP cell line WM278 and metastatic cell lines WM1232 and 
1205Lu) were examined in this study to find out whether effects were cell line 
dependent. Effective inhibition of SOX10 on protein level is shown in Figure 11. 
Transfection of SOX10-targeting siRNA led to strong decrease (in WM1232) up to 
complete abolishment (in WM278 and 1205Lu) of detectable SOX10 protein already 
after 24 hours. 
 
4.3 Phenotypic effects of SOX10 inhibition in melanoma cells 
4.3.1 Effects of SOX10 inhibition on melanoma cell proliferation 
Effects of SOX10 inhibition were analyzed in time course experiments with melanoma 
cell lines WM278, WM1232, and 1205Lu every 24 hours up to 120 hours post 
transfection. Microscopically imaging revealed changes in cell number and morphology 
starting from 72 hours post transfection of both SOX10-targeting siRNAs compared to 
control cells. 
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Figure 12: Alteration of cell morphology and reduction of number after SOX10 inhibition. 
Cell morphology after SOX10 inhibition was monitored by bright field and fluorescence imaging every 24 
hours up to 120 hours post transfection of siSOX10a, siSOX10b, siControl or without siRNA in cell lines 
1205Lu, WM278, and WM1232. (a) Representative pictures after 24, 72, and 120 hours are shown for 
1205Lu and after 120 hours for WM278 and WM1232. Scale bar = 200 µm. (b) 1205Lu cells were stained 
with a calcein AM and EthD-1 120 hours post transfection with siSOX10a, siSOX10b or siControl and 
fluorescence pictures were taken about 45 minutes after adding the dye. Scale bar = 50 µm. 
Some cells started to round up and die, while others had increased protrusions and 
showed a change towards a more dendritic phenotype, which was most prominent after 
120 hours and observed in all analyzed cell lines (Figure 12 a).  
To discriminate between living and dead cells, 1205Lu melanoma cell were stained with 
a LIVE/DEAD® viability/cytotoxicity kit (Life Technologies) according to the 
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manufacturer’s protocol. Living cells possess ubiquitous intracellular esterase activity 
that converts the non-fluorescent membrane-permeant calcein AM to a strong 
fluorescent polyanionic calcein. This non-membrane-permeant calcein has an extinction 
maximum of 495 nm and an emission maximum of 515 nm. The other dye in this assay, 
ethidium homodimer (EthD-1), cannot permeate the intact cellular membrane. However, 
it enters damaged membranes and binds nucleic acids. Thereby, its fluorescence is 
enhanced around 40-fold, with an extinction maximum of 495 nm and an emission 
maximum of 635 nm. In conclusion, living cells appear green under a fluorescence 
microscope while dead cells appear with red colored nuclei. 
Compared to the cells transfected with control siRNA, the confluence of SOX10-
inhibited cells was reduced to around 50% (Figure 12 b). They showed altered cell 
morphology although their cell membrane stayed intact. Red staining from EthD-1 
incorporation increased upon SOX10 inhibition with both siRNAs, with siSOX10a more 
than with siSOX10b. 
Because SOX10 inhibition reduced the number of adherent cells it possibly affects 
melanoma cell proliferation. To test this hypothesis the viability of SOX10-inhibited 
melanoma cells compared to cells transfected with control siRNA or without siRNA was 
determined with a CellTiter-Blue® Cell Viability Assay (Promega). This method is based 
on the metabolic capacity of cells, as viable cells reduce the provided indicator dye 
resazurin into the highly fluorescent resorufin. As nonviable cells lose their metabolic 
capacity, they cannot generate the pink resofurin leading to a lack of signal in the 
corresponding probing channel.  
Cell viability analysis demonstrated that both SOX10-targeting siRNAs significantly 
reduced cell viability after 72 hours in all three cell lines (Figure 13 a-c). After 120 hours, 
cell viability was reduced down to around 50% in cell line WM278 for both siRNAs 
(Figure 13 a), down to 30.2% in cell line WM1232 for siSOX10a and 43.7% for 
siSOX10b (Figure 13 b), and down to 41.8% in cell line 1205Lu for siSOX10a and 
59.2% for siSOX10b, respectively (Figure 13 c). Thus, the effect on cell viability was in a 
similar range for both SOX10-targeting siRNAs in all three analyzed melanoma cell 
lines. 
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SOX10 might also affect cell proliferation by influencing cell cycle progression. Cell 
cycle progression can be directly measured by flow cytometry. Generally, the cell cycle 
can be divided into three stages: the interphase, the mitotic phase, and cytokinesis. 
Interphase is the prerequisite for every cell division and requires about 90% of the total 
time of a cell cycle. It is subdivided into Gap1- (G1-), synthesis- (S-), and Gap2- (G2-) 
phases. Every passage between these phases is strictly controlled by checkpoints. 
They ensure that the cell is ready for the next step in the cycle and that damaged or 
incomplete DNA is not passed on to daughter cells. During G1-phase the cell harbors a 
single chromosome set (2N) and it increases its supply of proteins, the number of 
organelles, as well as its size. The G1 checkpoint control makes sure that all 
preparations for DNA replication have been completed. From this phase, cells can enter 
a non-dividing quiescent G0-phase, which is common for fully differentiated cells as e.g. 
neurons and which can last permanently. When cell cycle continues, the DNA 
replication commences during S-phase were all chromosomes gain two sister 
chromatids. 
Figure 13: Investigation of cell viability 
after SOX10 inhibition. 
Cell viability 24, 48, 72, 96, and 120 hours 
after siRNA transfection with siSOX10a, 
siSOX10b, siControl, or without siRNA was 
determined in cell lines WM278 (a), WM1232 
(b), and 1205Lu (c) in three independent 
experiments (mean ± SD). A significant 
difference compared to siControl with 
*P<0.05 is marked by an asterisk (one-way 
ANOVA). 
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In G2-phase the cell harbors a double chromosome set (4N) and continues to grow. The 
G2 checkpoint control makes sure that the cell is ready to enter mitosis and thereby cell 
division. The change in the amount of DNA during cell cycle progression can be 
quantified after staining of proliferating cells with the DNA intercalating agent propidium 
iodide (PI). One molecule PI incorporates every 4 to 5 DNA bases while the excitation 
maximum shifts about 30-40 nm to the red, the emission maximum about 15 nm to the 
blue, and the fluorescence is about 10-fold enhanced [6]. The proportional binding of PI 
to DNA allows direct conclusion to the amount of DNA present in a cell as the cell 
doubles its DNA amount in S phase. Thus, a cell in G2- and early M-phase will have 
twice the DNA amount of a cell in G1-phase and thereby intercalates twice the amount 
of PI. The change in fluorescence can be directly detected by flow cytometry. PI is 
impermeable for the membrane of a living cell and therefore cell membranes have to be 
permeabilized with 70% ethanol. Removal of RNA is also required for this assay as PI 
can also bind RNA. Figure 14 shows a typical histogram of actively proliferating 1205Lu 
melanoma cells.  
Figure 14: Schematic profile of cell cycle 
progression in 1205Lu cells. 
The scheme represents a typical histogram of 
non-treated 1205Lu cells after staining with PI 
and analysis by FACS. This method allows the 
differentiation of cell cycle phases due to their 
different amounts of DNA. As displayed in the 
histogram, a strong signal is detected for cells in 
G0- and G1-phase (left peak, black), that carry 
a single chromosome set (2N) and a weaker 
signal for cells in G2- or mitosis (M)-phase (right 
peak, light grey), that possess a double 
chromosome set (4N). The signal for cells in S-
phase, which are replicating their DNA, is 
located in between (medium grey). For non-
treated 1205Lu cell a distribution of 50-60% in G1-, 20-25% in S-, and 20-25% in G2/M-phase was 
measured. 
The distribution of cells in G1-, S-, and G2/M-phase differed between SOX10-inhibited 
and control 1205Lu cells from 24 to 48 hours after siRNA transfection (Figure 15 a). 
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Figure 15: Influence of SOX10 inhibition on cell cycle progression. 
(a) Representative histograms after staining with PI and flow cytometry of 1205Lu melanoma cells 24 and 
48 hours after transfection with siSOX10a or siControl are depicted. (b) Bar charts represent the 
percentage distribution of 1205Lu cells in G1- (black), S- (medium grey), and G2/M-(light gray) phases 24 
and 48 hours after transfection with siSOX10a, siSOX10b, siControl, or without siRNA and cell cycle 
analysis. Error bars represent mean ± SD of cells in G1-phase from three independent experiments. (c) 
Bar charts of WM278 and WM1232 cells treated as described in (b) 48 hours after siRNA transfection. (d) 
SOX10, p21, and pRB were detected by immunoblotting 48 hours after transfection of siSOX10a, 
siSOX10b, and siControl in cell lines WM278, WM1232, and 1205Lu. Detection of β-Actin served as 
loading control. 
The amount of SOX10-inhibited 1205Lu cells in S- and G2/M-phase were reduced 
compared to control cells and the number in G1-phase was increased 48 hours after 
siRNA transfection. Quantification revealed an increase of cells in G1-phase for SOX10 
inhibition with both SOX10-targeting siRNAs compared to control cells after 48 hours 
(Figure 15 b). This effect was more pronounced for siSOX10b compared to siSOX10a. 
Similar effects were found in the cell lines WM278 and WM1232 after 48 hours (Figure 
15 c).  
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As mentioned before, cell cycle progression is regulated at so-called checkpoints. 
These checkpoints are controlled by cyclins and cyclin-dependent kinases (CDKs) 
[185]. CDKs are constitutively expressed in cells but they are inactive without cyclins. 
Cyclins themselves have no catalytic subunit and they are synthesized at specific 
stages of the cell cycle in response to growth signals. Together they form active 
complexes. These complexes themselves can be blocked by several inhibitors that stop 
cell cycle progression e.g. upon DNA damage. P21 belongs to the CDK interacting 
protein/kinase inhibitory protein gene family and it can arrest cell cycle in G1 by direct 
binding to cyclin/CDK-complexes [100]. It can be activated by p53 as response to DNA 
damage [281]. P21 was found upregulated upon SOX10 inhibition in all three 
investigated cell lines 48 hours after siRNA transfection (Figure 15 d). Another protein 
that regulates G1- to S-phase transition is retinoblastoma protein (RB). RB physically 
associates with E2F transcription factors and blocks their transactivation domain in G0- 
and early G1-phase [83]. In late G1, phosphorylated RB (pRB) releases E2F 
transcription 1 to transcribe genes, which are necessary for S-phase progression. A 
decrease in pRB was found in all cell lines upon SOX10 inhibition with a higher effect 
for siSOX10a in cell line WM278 and for siSOX10b in cell lines WM1232 and 1205Lu 
(Figure 15 d). Increased p21 levels and decreased RB phosphorylation are a sign of cell 
cycle arrest in G1. 
Furthermore, the DNA damage marker γH2A.X was upregulated upon SOX10 inhibition 
as detected by immunoblotting (Figure 16 upper panel). 
 
Figure 16: Increase in DNA damage markers after 
SOX10 inhibition. 
The DNA-damage marker γH2A.X and the 
transcription factor p53 were detected by 
immunoblotting in cell lines WM278, WM1232, and 
1205Lu 72 hours after transfection of siSOX10a, 
siSOX10b, and siControl. Detection of β-Actin served 
as loading control. 
 
H2A.X is phosphorylated at Ser139 (named γH2A.X) by PI3K-like kinases, which 
attracts DNA damage response proteins [305]. Thus, it is required for checkpoint-
mediated cell cycle arrest and DNA repair following DNA double-strand breaks.  
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Furthermore, p53 was found accumulated especially after transfection of siSOX10b 
(Figure 16 lower panel). P53 is a transcription factor that acts as “guardian of the 
genome” [144]. Usually it is inactive and continuously degraded upon ubiquitinylation. 
As a response to DNA damage, p53 is stabilized through phosphorylation, accumulates, 
and triggers responses such as cell cycle arrest, DNA repair, apoptosis, and 
senescence. 
In conclusion, these data suggest that SOX10 inhibition reduces melanoma cell 
proliferation, leads to cell cycle arrest in G1, and causes DNA damage. 
4.3.2 Effects of SOX10 inhibition on melanoma cell death 
To further investigate the influence of SOX10 inhibition on melanoma cell survival, 
SOX10-inhibited compared to control cells were analyzed by flow cytometry quantifying 
cell death. 
Phosphatidylserine (PS) is a phospholipid membrane component, which is actively 
being held towards the cytosolic side of the membrane by the enzyme flippase. When a 
cell undergoes apoptosis, PS is no longer restricted by flippase and flips to the 
extracellular surface. It is a well known mechanism to signal macrophages to engulf a 
dying cell [276]. This mechanism serves as marker to analyze apoptosis. The protein 
Annexin V (AN) specifically binds to PS and therefore enables its detection. In this 
study, AN labeled with the fluorescent dye fluorescein (Annexin V-Fluos) was used for 
detection with excitation at 488 nm and emission at 518 nm by flow cytometry. During 
cell death the membrane integrity is lost and allows AN to bind the intracellular facing 
PS. This status is discriminated from apoptosis by simultaneously staining with PI, 
which is only permeable for disordered membranes.  
FACS analyses demonstrated an increase in cell death, i.e., AN- and PI-positive cells, 
about 72 hours after siSOX10 transfection (Figure 17 a-c). Cell death increased 
significantly with both SOX10-targeting siRNAs in all three cell lines after 96 hours. After 
120 hours, the population of AN- and PI-positive cells was raised up to 41.6% 
(siSOX10a) and 28.2% (siSOX10b) in cell line WM278 (Figure 17 a), to around 60% 
with both SOX10-targeting siRNAs in cell line WM1232 (Figure 17 b), and to 55.9% 
(siSOX10a) and 33% (siSOX10b) in cell line 1205Lu (Figure 17 c). Thus, the effect of 
siSOX10a on cell death is stronger than siSOX10b in cell lines WM278 and 1205Lu. 
Minor differences in onset of cell death were found for both SOX10-targeting siRNAs in 
cell line WM1232. 
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No increase in AN- and PI-positive cells could be detected 96 hours after transfection of 
SOX10-targeting siRNAs compared to controls in the SOX10-negative cell line WM3211 
(Figure S1). Therefore, SOX10 inhibition leads to an increase in cell death in SOX10-
positive but not in SOX10-negative melanoma cells.  
 
 
FACS analysis of Annexin V-Fluos- and PI-stained SOX10-inhibited or control 1205Lu 
cells demonstrated an increase in the AN- and PI-positive but also in the AN-positive 
and PI-negative cell fraction (apoptotic cell fraction) in SOX10-inhibited cells after 72 
hours (Figure 18 a). This observation was also made during time course analysis: 
SOX10 inhibition increased the amount of AN-positive and PI-negative cells, which was 
significant for siSOX10 after 72 hours and for siSOX10b after 120 hours (Figure 18 b). 
These data indicate that SOX10 inhibition induces apoptosis in melanoma cells. 
Figure 17: Cell death analysis after SOX10 
inhibition in melanoma cells. 
Cell death was quantified by staining with 
Annexin V-Fluos and PI and subsequent 
FACS analysis in cell lines WM278 (a), 
WM1232 (b), and 1205Lu (c) every 24 hours 
up to 120 hours post siRNA (siSOX10a, 
siSOX10b, and siControl) or no siRNA 
transfection. Percentages of the AN- and PI-
positive (AN+/PI+) cells as mean ± SD of three 
independent experiments are shown. A 
significant difference to siControl with *P<0.05 
is marked by an asterisk (one-way ANOVA). 
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Figure 18: Increase in the apoptotic cell fraction and activation of caspase 8, caspase 9, and 
caspase 3 after SOX10 inhibition. 
(a) Representative dot blots of 1205Lu cells after staining with Annexin V-Fluos and PI are shown 24 and 
72 hours after transfection of siSOX10a and siControl. An increase of the AN-positive and the AN+/PI+ 
cell fractions were detected in the SOX10-inhibited cells after 72h. (b) Time course analysis of AN-
positive and PI-negative cells showed a significant increase in apoptotic cells 72 and 96 hours after 
transfection with siSOX10a (*P = 0.0028 after 72 hours and *P = 0.001 after 96 hours, one-way ANOVA 
versus siControl), while it was significantly increased in siSOX10a and siSOX10b-transfected cells after 
120 hours (*P < 0.0001, one-way ANOVA versus siControl). (c) Pro- and cleaved (arrows) isoforms of 
caspase 8 and caspase 9 were analyzed 72 hours after transfection of siSOX10a, siSOX10b, and 
siControl in cell lines WM278, WM1232, and 1205Lu. (d) Caspase 3 activation (arrows) was detected in 
siSOX10a-transfected WM278 and 1205Lu cells and in both SOX10-targeting siRNAs-transfected 
WM1232 cells 72 hours after siRNA transfection. After 120 hours, caspase 3 activation in SOX10-
inhibited cells was found in all analyzed melanoma cell lines with a stronger effect for siSOX10a than 
siSOX10b. 
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Apoptosis is one of three forms of programmed cell death (PCD) together with 
autophagy and necroptosis. The term PCD defines the death of a cell, mediated by 
intracellular signaling that is executed via a programmed mechanisms [191]. It is an 
essential process, e.g., during the development of fingers and toes in the human 
embryo, to preserve tissue homeostasis, and to remove damaged cells. 
However, it is also a common feature in the development of cancer. In contrast, 
necrosis is initiated by external factors as injury or infection. While autophagy can lead 
either to survival or to death, apoptosis and necroptosis only end up in cell death. PCD 
by necroptosis is mediated by receptor interacting protein (RIP) kinases, poly 
(adenosine phosphate ribose) polymerase-1 (PARP1), nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases, and calpains. During necroptosis, the 
integrity of the cell membrane is disrupted and intracellular material is released into the 
extracellular milieu leading to inflammatory responses. 
Apoptosis, which is activated through irreparable DNA damage, has been described for 
the first time by Kerr et al. [127]. It is characterized by morphological changes like cell 
shrinkage, nuclear condensation and fragmentation, constriction of cell content in 
membrane-sealed vesicles, and loss of adhesion to either adjacent cells or the 
extracellular matrix (ECM). On cellular level, apoptosis is characterized by chromosomal 
DNA cleavage, PS externalization due to loss of flippase activity, and a number of 
specific proteolytical processes. Apoptosis can be induced by two different pathways: 
the extrinsic death receptor pathway and the intrinsic mitochondrial pathway. The 
extrinsic pathway is triggered by binding of death ligands (e.g. Fas ligand, tumor 
necrosis factor [TNF], and TNF-related apoptosis-inducing ligand [TRAIL]) to death 
receptors (e.g. FAS, TNF-receptor 1, TRAIL-receptor 1, and TRAIL-receptor 2) upon 
death stimuli. These complexes recruit Fas-associated protein with death domain 
(FADD) and initiator pro-caspases 8 and 10 to become the death-inducing signaling 
complex (DISC). Through proteolytical cleavage, caspase 8 becomes activated and 
further activates the effector caspase 3, which promotes the apoptotic phenotype by 
destroying structural proteins, e.g., microfilament actin and intermediate filament lamin 
and by activating nucleases. The intrinsic pathway controls cell death through 
mitochondrial pro-enzymes. Upon initiation, the mitochondrial membrane becomes 
permeable and releases cytochrome c into the cytosol. Cytochrome c recruits apoptotic 
protease activating factor 1 (APAF-1) and pro-caspase 9 forming the apoptosome that 
activates the caspase 9/3 signaling cascade eventually leading to apoptosis. 
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The mitochondrial membrane integrity is regulated by Bcl-2 proteins. The Bcl-2 family is 
composed of key regulators of apoptosis and they play a central role in regulating the 
survival of tumor cells. This family includes a number of pro- and anti-apoptotic 
members, which are subdivided into three different classes according to their Bcl-2 
homology domains (BH-domains) and functions. Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and A1 are 
anti-apoptotic Bcl-2 proteins, Bak, Bax, and Bok are pro-apoptotic Bcl-2 effector 
proteins, and Bid, Bim, Bad, Bmf, Hrk, Bik, Noxa, and Puma are pro-apoptotic BH3-only 
proteins [304]. Melanoma cells require the presence of specific anti-apoptotic Bcl-2 
proteins [234]. Bax and Bak are essential for induction of intrinsic apoptosis [291]. It is 
suggested that they form pores at the outer mitochondrial membrane to release pro-
apoptotic factors to the intermembrane. 
Caspase 8 and 9 activation was analyzed by immunobloting 72 hours after siRNA 
transfection in cell lines WM278, WM1232, and 1205Lu. Cleaved caspase 8 fragments 
were detected for both SOX10-targeting siRNAs in case of WM1232 and for siSOX10a 
in case of 1205Lu cells (Figure 18 c upper panel). Caspase 9 activation was detected 
for both SOX10-targeting siRNAs in cell lines WM1232 and 1205Lu (Figure 18 c lower 
panel). Neither caspase 8 nor caspase 9 activation was found for WM278 cells. 
Activation of effector caspase 3 was found in all cell lines for siSOX10a and in cell line 
WM1232 for siSOX10b after 72 hours (Figure 18 d upper panel). After 120 hours, 
activation of effector caspase 3 was detectable in all three cell lines with both SOX10-
targeting siRNAs (Figure 18 d lower panel). Time point and extent of detectable 
caspase 3 activation is comparable with the onset of cell death as determined by FACS 
(Figure 17). 
To further analyze the mechanism of induced cell death through SOX10 inhibition the 
expression of Bcl-2 family member Bax and Bak, which are essential for induction of 
intrinsic apoptosis as mentioned before, and the anti-apoptotic Bcl-2 were investigated. 
Immunoblot detection 72 hours after siRNA transfection revealed an increase of Bax in 
all three cell lines transfected with siSOX10a and siSOX10b compared to siControl 
(Figure 19 a). Bak was only increased in SOX10-inhibited 1205Lu.  
Intrinsic apoptosis can also be induced by caspase 8 activation through procession of 
the 22 kDa protein Bid to the 15 kDa fragment t-Bid [157], [165]. Since not only 
activation of caspase 9 but also of caspase 8 was found upon SOX10-inhibition, Bid 
expression was examined (Figure 19 a). However, no procession of Bid to t-Bid was 
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found. Bcl-2 was found downregulated in SOX10-inhibited cells from all three cell lines 
(Figure 19 b). These data indicate that SOX10 inhibition can trigger intrinsic apoptosis. 
 
4.3.3 Effects of SOX10 inhibition on melanoma cell invasion 
During embryogenesis, SOX10 expression can be found in early migrating NCCs and 
melanoblasts [126], [179]. Migration and invasion are also important attributes of the 
malignant potential of melanoma cells. Therefore, it was investigated if SOX10 also 
contributes to the migratory capacity of melanoma cells.  
As SOX10 inhibition also affected melanoma cell proliferation and survival (sections 
4.3.1 and 4.3.2), an in vitro Matrigel invasion assay was selected to analyze the 
migratory capacity of SOX10-inhibited melanoma cells. This assay allows examination 
of cell invasion within 5 hours. The Matrigel matrix is a soluble basement membrane 
preparation extracted from an Engelbreth-Holm-Swarm mouse sarcoma and contains 
extracellular matrix proteins like laminin, collagen IV, heparin sulfate proteoglycans, and 
entactin/nidogen. It also contains several growth factors that naturally occur in tumors 
and thereby mimicking the in vivo environment of tumor cells. To pass the Matrigel layer 
cells need to migrate, actively degrade, and proteolyse the ECM-related Matrigel.  
Figure 19: Increase of the pro-
apoptotic factors Bax and Bak 
and decrease of the anti-
apoptotic Bcl-2 after SOX10 
inhibition. 
Expression of the Bcl-2 family 
members Bax, Bak, and Bid (arrow 
points to estimated size of tBid) as 
well as SOX10 (a) and Bcl-2 (b) 
was detected in cell lines WM278, 
WM1232, and 1205Lu 72 hours 
after transfection of siSOX10a, 
siSOX10b, and siControl. Detection 
of β-Actin served as loading control. 
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To conduct this assay, melanoma cells were seeded in nutrition-free medium on top of a 
pored Matrigel-coated membrane. To stimulate melanoma cells to pass the Matrigel 
layer, the well below was filled with fibroblast-conditioned medium. This medium 
contains secreted factors that attract melanoma cells. Invaded melanoma cells at the 
bottom of the pored membrane can be stained and quantified. A schematic overview 
over this assay is presented in Figure 20. 
Figure 20: Schematic overview of the Matrigel 
invasion assay. 
To test invasion through an extracellular matrix- 
mimicking Matrigel layer, melanoma cells are 
seeded in nutrition-free medium on top of a 
Matrigel-coated transwell insert. The Matrigel layer 
is covering a pored membrane. Bellow the insert, 
the well contains fibroblast-conditioned medium, 
which attracts melanoma cells. Through migration 
and proteolysis, melanoma cells can reach the lower part of the insert. To quantify the invaded cells, the 
remaining cells and the Matrigel on the upper part of the insert are removed with cotton swabs and cells 
on the lower part are fixed and stained with a Diff-Quik staining set (Medion Diagnostics). Invaded cells 
can be counted by microscopic magnification. 
As transfection of SOX10-targeting siRNAs reduced SOX10 expression already 24 
hours after siRNA transfection (section 4.2, Figure 11), it was possible to determine the 
effect of SOX10 on invasion at a time point when cell death has not been induced yet. 
Matrigel invasion assays with SOX10-inhibited and control WM278, WM1232, and 
1205Lu cells revealed a significant reduction of melanoma cell invasion at an early time 
point after SOX10 inhibition (Figure 21 a-c). As expected due to their tumor’s origin, 
control cells of metastatic melanoma cell line 1205Lu showed the highest invasion 
capacity in this assay (Figure 21 c), while cells from the VGP cell line WM278 migrated 
slower, leading to a reduced cell yield under the membrane (Figure 21 a). Against 
expectations, control WM1232 invaded less than WM278 and 1205Lu (Figure 21 b). 
Figure 21 d shows representative pictures of membranes with fixed and stained invaded 
melanoma cells. 
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Figure 21: Matrigel invasion assay with SOX10-inhibited melanoma cells. 
Invasion through a Matrigel layer was assessed with cell lines WM278 (a), WM1232 (b), and 1205Lu (c) 
24 hours after transfection of siSOX10a, siSOX10b, siControl, or without siRNA in three independent 
experiments. Compared to the control siRNA-transfected cells, SOX10 inhibition significantly reduced the 
number of invaded cells in three independent experiments. A significant difference compared to siControl 
with *P<0.05 is marked by an asterisk (one-way ANOVA). (d) Representative pictures of membranes after 
Matrigel invasion assay and cell staining with 1205Lu melanoma cells are shown. 
Another in vitro model system for investigating melanoma cell invasion is the three-
dimensional spheroid assay. In the first step, tumor cell aggregates are formed by 
cultivating melanoma cells on top of an agar-coated well. The agar prevents cell 
adhesion to the well’s bottom. These so-called spheroids are more representative for 
tumors in vivo in terms of morphology, cell-cell contacts, decreased proliferation rates, 
and a hypoxic core. It is a well accepted tumor model, which is broadly used for, e.g., 
screening of small molecule inhibitors [140].  
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As a second part of this assay, spheroids can be embedded in an ECM-mimicking 
collagen matrix that requires active migration and invasion for tumor cell spreading. 
Nutrition for the cells is provided in the collagen matrix.  
To perform this assay with SOX10-inhibited cells, siRNAs were transfected 24 hours 
before seeding the melanoma cells on top of the agar-coated wells. However, in 
contrast to control treatment, SOX10 inhibition impaired the formation of compact cell 
aggregates as tested in cell lines 1205Lu (Figure 22 a) and WM278 (Figure 22 b) at 
early time points (24 and 48 hours after seeding on the agar-coated wells). 
Figure 22: Analysis of spheroid formation after SOX10 inhibition. 
1205Lu (a) and WM278 (b) melanoma cells were subjected to spheroid formation by cultivation on agar-
coated wells 24 hours post transfection with siSOX10a, siSOX10b, siControl, or no siRNA. 
Representative pictures were taken 24 and 48 hours after seeding. Compared to the control cells, 
SOX10-inhibited cells did not form compact spheroids. Scale bar = 200 µm. 
To analyze the molecular background of impaired spheroid formation, integrin 
expression was examined after SOX10 inhibition. Integrins mediate cell-matrix- as well 
as cell-cell-contacts. Downregulation of ITGA(integrin α)4 and ITGB(integrin β)3 was 
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found in the cell line WM278 upon SOX10 inhibition while ITGA3 and ITGB1 were 
upregulated in all three analyzed cell lines (WM278, WM1232, 1205Lu) upon SOX10 
inhibition (chapter 7, Figure S2). No tendency was found for ITGAV. Thus, impaired 
spheroid formation might be related to a change in cell adhesion proteins. 
Furthermore, LIVE/DEAD staining of the forming spheroids demonstrated that no 
change in the amount of EthD-1-positive cells could be found in SOX10-inhibited 
compared to control cells (chapter 7, Figure S3 a). Even calcein-positive SOX10-
inhibited cells did not form compact spheroids. Thus, impaired spheroid formation in 
SOX10-inhibited melanoma cells seems not to be related to increased cell death. 
To further investigate the role of cell death in SOX10-mediated cell invasion cell death 
after SOX10-inhibition was blocked by treatment with Z-VAD and Nec-1 (chapter 7, 
Figure S3 b). Z-VAD is a caspase inhibitor and Nec-1 blocks necroptosis, which could 
be also activated by SOX10 inhibition due to an early increase of the AN- and PI-
positive cell fraction (section 4.3.2, Figure 18 a). Due to this treatment, SOX10 inhibition 
did not induce cell death after 96 hours anymore but the invasion capacity of SOX10-
inhibited melanoma cells remained significantly reduced (chapter 7, Figure S3 b). These 
data also indicate that reduced invasion after SOX10 inhibition is not only related to 
onset of cell death. 
In the end, another assay was selected to further examine the effect of SOX10 on 
melanoma cell invasion. With the chick embryo invasion assay invasion capacity can be 
analyzed and quantified in vivo, located in an embryonic microenvironment [38]. This 
assay was performed in collaboration with Dr. Christian Busch at the Section Dermato-
Oncology, University of Tübingen, Tübingen, Germany. In short, 1205Lu cells 
transfected with siSOX10a, siControl, or no siRNA were injected into brain vesicles at 
the hindbrain (rhombencephalon) of chick embryos at an early stage of their 
development (stages 12-13 according to Hamburger and Hamilton [94]). Melanoma 
cells form tumors in the dorsal neuroepithelium with single cells invading in the 
surrounding brain tissue. Histological analysis 96 hours after injection revealed the 
formation melanoma nodules in all embryos, also when SOX10-inhibited melanoma 
cells had been injected (Figure 23 a). Sections were stained for the proliferation marker 
MIB (Figure 23 b). More than 90% of tumor cells stained positive for MIB1, also tumor 
cells in nodules of SOX10-inhibited tumors, except for the central necrotic area. 
Strikingly, the invasion of tumor cells in the surrounding host tissue was impaired upon 
SOX10 inhibition (Figure 23 a and b). 
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Figure 23: Chick embryo invasion assay with SOX10-inhibited and control 1205Lu cells. 
1205Lu melanoma cells were injected into the rhombencephalic brain vesicle of chick embryos 24 hours 
after transfection with siSOX10a, siControl, or without siRNA. Tumor formation and invasion were 
analyzed 96 hours later. Representative chick embryo sections were stained with H&E (a), MIB1 (b), or 
anti-SOX10 antibodies (e), (f), (g). Scale bar sizes are depicted in the pictures. Arrows point to invading 
melanoma cells. (c) The maximum diameter of each tumor was measured microscopically in two 
directions. Tumor sizes did not change significantly when comparing siSOX10a- and siControl-tumors (P 
= 0.1702 for diameter 1 and P = 0.5034 for diameter 2; t-test). (d) Quantification of invading cells was 
performed by counting three sections of the largest tumor diameter of each embryo (siSOX10a n = 6, 
siControl n = 4, no siRNA n = 7; one-way ANOVA versus siControl, *P < 0.001). 
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Regarding the control cells, invasion in single cells and clusters was evident (Figure 23 
a and b, arrows). Nodules of the three experimental groups were measured in two 
directions and no significant difference was found indicating that the tumor formation 
and size was not affected by SOX10 inhibition (Figure 23 c). Quantification of invaded 
tumor cells in all embryos demonstrated a significant decrease of tumor cell invasion by 
SOX10 inhibition (Figure 23 d). SOX10 staining revealed strong nuclear signals in the 
tumor nodules and invading tumor cells in the control group (Figure 23 e and f) whereas 
SOX10 staining was reduced or absent in the tumors formed by SOX10-inhibited 
melanoma cells (Figure 23 g) demonstrating that the siRNA had still been preventing 
SOX10 expression. Thus, SOX10 inhibition seems to directly influence the invasion 
capacity of melanomas but not their proliferative potential at least in this model system. 
Taken together, these data suggest that SOX10 has a critical influence on melanoma 
cell invasion independent of cell proliferation or survival. 
4.4 Identification of MIA as a target gene of SOX10 
4.4.1 Expression of MIA and regulation by different transcription factors 
As a transcription factor, SOX10 can influence a large variety of cellular processes 
either by directly or indirectly controlling the transcription of specific genes that mediate 
these processes. As the reduction of melanoma cell invasion upon SOX10 inhibition in 
vitro was observed at an early time point, even before onset of cell death, SOX10 might 
directly affect the transcription of a factor that is actively promoting cell migration. 
Literature research revealed that not SOX10 but the closely related SOX9 regulates 
melanoma inhibitory activity (MIA) in chondrocytes [299]. MIA was first identified during 
the search for autocrine growth factors in melanoma as part of a fraction of the 
supernatant of a melanoma cell line derived from a central nervous system metastasis 
[18]. It was shown that the fraction containing MIA could effectively inhibit tumor cell 
proliferation and colony formation. MIA was found to be specifically expressed in 
melanoma while it was absent in melanocytes and normal skin biopsies [27], [198]. But 
rather than functioning as a tumor inhibitor, it was shown that MIA is actively promoting 
melanoma cell migration [205]. Secreted at the rear part of a migrating melanoma cell it 
binds to and thereby inhibits the attachment of integrins to fibronectins causing cell 
detachment from the ECM [10], [28], [254]. Further studies revealed that MIA 
contributes to melanoma cellular invasion and formation of metastases [24], [28]. MIA 
was also described as a serum marker for melanoma progression [27], [252]. Figure 24 
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a shows an immunoblot analysis of MIA expression after SOX9 and SOX10 inhibition in 
1205Lu cells.  
Figure 24: MIA 
expression after SOX9 
and SOX10 inhibition 
and correlation of MIA 
with SOX10 expression 
in melanoma cells. 
MIA, SOX9, pSOX9, and 
SOX10 expression was 
assessed by 
immunoblotting 72 hours 
after SOX9 and SOX10 
inhibition in cell lines 
1205Lu (a) and WM278 
(b). Detection of β-Actin 
served as loading control. 
(c) MIA expression was 
assessed by 
immunoblotting in 
fibroblasts (two donors), 
melanocytes (three 
donors), and 12 
melanoma cell lines. 
Phospho-SOX9 and 
SOX10 immunoblots from 
Figures 6 and 7 are shown 
for better comparison. (d) 
Positive linear correlation 
between  SOX10 and MIA 
mean mRNA values of 
three independent experiments was found in melanoma cell lines SbCl2, WM3211, WM35, WM278, 
WM1366, WM793, WM239A, WM9, WM1158, WM1232, 451Lu, and 1205Lu (Pearson correlation, ρ = 
0.6293, *P = 0.0283). (e) No significant correlation between SOX9 and MIA mRNA was found in these 
cell lines (Pearson correlation, ρ = -0.1594, P = 0.6207). 
MIA expression was strongly downregulated by SOX9 but also by SOX10 inhibition. A 
combination of siRNAs targeting both transcription factors did not completely abolish 
MIA expression. However, in cell line WM278, where merely siSOX9a effectively 
downregulated SOX9 expression, MIA protein levels were only slightly decreased 
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(Figure 24 b). On the other hand, SOX10 inhibition in this cell line strongly reduced MIA 
expression. MIA expression was then investigated in the same cells as described in 
section 4.1.1. Confirming previously published data [25], [198], MIA was expressed in 
the majority (8 of 12) of melanoma cell lines while it was absent in fibroblasts and 
melanocytes (Figure 24 c). In contrast to SOX9, a striking correlation was observed for 
SOX10 and MIA protein expression in all melanoma cell lines. This correlation was 
significant on mRNA level for SOX10 (Figure 24 d) but not for SOX9 (Figure 24 e). 
These data suggest that SOX10 rather than SOX9 is relevant for MIA expression in 
melanoma cells. 
Previously, it has been shown that the transcription factors HMG1 and the p65 subunit 
of nuclear factor kappa B (NFκB) bind to a highly conserved region within the MIA 
promoter and thereby function as regulators of MIA [203]. Expression of HMG1 and p65 
as well as p65 phosphorylation (p-p65) was investigated in fibroblasts, melanocytes and 
melanoma cell lines (Figure 25 a). 
Figure 25 : Expression of 
HMG1 and p65 in human skin 
cells and melanoma cell lines 
and their expression after 
SOX10 inhibition. 
(a) HMG1, p65, and MIA 
protein expression as well as 
p65 phosphorylation (p-p65) 
was assessed by 
immunoblotting in fibroblasts 
(two donors), melanocytes 
(three donors), and 12 
melanoma cell lines. No 
correlation could be observed. 
β-Actin served as a loading 
control. (b) HMG1 and p65 
expression levels were 
detected by immunoblotting in 
cell lines WM278, WM1232, 
and 1205Lu 48 hours after transfection with siSOX10a and siSOX10b or control siRNA. No reduction in 
protein expression was found for p65, while HMG1 was reduced only by siSOX10a in WM1232 cells. β-
Actin served as a loading control. 
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However, expression of HMG1 and p65 or p65 phosphorylation did not correlate with 
MIA expression in skin cells or melanoma cell lines. Furthermore, SOX10 inhibition did 
only reduce the expression of HMG1 using siSOX10a in one cell line (WM1232) but not 
using siSOX10b and not in other cell lines (Figure 25 b). Moreover, p65 expression was 
not affected by SOX10 inhibition. 
These data strengthen the important regulatory role of SOX10 in MIA expression. 
4.4.2 Analysis of SOX10 binding to the MIA promoter 
Immunoblot analysis of MIA expression in cell lines WM278, WM1232, and 1205Lu 
early after SOX10 inhibition demonstrated that MIA protein levels were decreased 
already 24 hours after transfection of SOX10-targeting siRNAs and almost abolished 
after 72 hours (Figure 26 a).  
 
Figure 26: Regulation of MIA expression and promoter activity by SOX10 as well as MIA promoter 
binding studies. 
(a) SOX10 and MIA expression was assessed by immunoblotting 24 and 72 hours after transfection with 
siSOX10a, siSOX10b, or siControl in melanoma cell lines WM278, WM1232, and 1205Lu. Detection of β-
Actin served as a loading control. (b) MIA full-length promoter activity in a pGL3-reporter construct was 
determined by luciferase assay 48 hours after transfection of 1205Lu cells with siSOX10a, siSOX10b, or 
siControl and 24 hours after transfection of pGL3-MIA and a renilla vector. Mean ± SD of three 
independent replicates are shown. A significant reduction of MIA reporter activity compared to siControl is 
marked by an asterisk (*P = 0.0003, one-way ANOVA). Norm. = normalized to renilla activity. (c) 
Percentages of precipitated DNA in relation to the input DNA after ChIP assay with anti-SOX10 antibody 
(black bars) or IgG control (grey bars) are shown. Recovered DNA (mean ± SD) with primers hybridizing 
in the MIA promoter region or a control locus (hAct Int 2) was determined by qRT-PCR in four 
independent experiments. Significant increase of recovered MIA promoter DNA was found using the 
SOX10-specific antibody compared to IgG control and the recovered DNA of hAct Int 2 (t-test, *P<0.05). 
No significant change was found comparing recovered DNA of hAct Int 2 using the SOX10-specific 
antibody compared to IgG control. 
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Of note, the intensity of MIA reduction correlated with that of siRNA-mediated 
downregulation of SOX10 since SOX10 inhibition has been less effective in WM1232 
and so was MIA reduction. 
A luciferase reporter assay was used to analyze MIA promoter activation. This assay is 
based on a firefly luciferase vector that contains the promoter sequence or promoter 
fragments of the gene of interest in front of the expression sequence for the enzyme 
firefly luciferase. An activation of the promoter leads to transcription and translation of 
luciferase while the amount of produced enzyme is proportional to the strength of 
promoter activation. The enzyme in turn is detected by adding its substrate luciferin, 
which is converted to oxyluciferin in the presence of O2 and ATP. This reaction forms 
oxyluciferin in an electronically excited state and thereby generating bioluminescence 
when the excited oxyluciferin returns to the ground state by releasing a photon. The 
light emission was directly measured with a luminometer (Luminometer GloMax 96, 
Promega). To emend difference in cell number or transfection efficiency, a control 
vector leading to constitutive expression of a renilla luciferase was co-transfected. The 
renilla luciferase converts its substrate coelenterazine to coelenteramid, which can be 
detected independently from the oxyluciferin production and is therefore used for 
normalization of the reaction. 
MIA promoter activity was assessed after SOX10 inhibition. Figure 26 b shows that both 
SOX10-targeting siRNAs significantly reduced the MIA promoter activity compared to 
control treatment (Figure 26 b). 
A ChIP assay was performed in order to investigate direct binding of SOX10 to the MIA 
promoter. This assay allows the analysis of protein-DNA interactions in living cells. At 
the beginning of this assay, the specific binding of a protein - in this study the 
transcription factor SOX10 - to a promoter site was fixed with formaldehyde, which 
cross-links proteins to the genomic DNA. The genomic DNA was then fragmented and 
DNA fragments bound by SOX10 were purified by precipitation with a SOX10-specific 
antibody. A control antibody (IgG) was included to examine non-specific binding. After 
several washing steps and de-crosslinking, the precipitated DNA was purified and 
further analyzed by qRT-PCR. 
Thereby, the MIA promoter region but not a control DNA region - human actin intron 2 
(hAct Int2) - was found to be significantly enriched around 4-fold using a SOX10-specific 
antibody (Figure 26 c). Thus, direct binding of SOX10 to the MIA promoter was verified. 
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To further determine SOX10-responsive elements within the MIA promoter region, 
deletion constructs of the MIA promoter were analyzed after SOX10 inhibition or control 
transfection (Figure 27 a). The residues between -493 and -1, with respect to the 
translation start site, have been described to be necessary and sufficient to mediate 
high levels of cell type-specific MIA gene expression [25]. Truncated promoter 
fragments -200- and -212 bp displayed reduced activation upon SOX10 inhibition while 
this effect was increased in longer constructs (-275 and -493 bp) and lost in the -160 bp 
fragment. Therefore, SOX10 seems to affect the activity of proximal MIA promoter 
regions.  
 
Figure 27: MIA promoter constructs and mutation studies. 
(a) Reporter constructs containing truncated MIA promoter fragments were subjected to luciferase 
reporter assays in 1205Lu cells after transfection with siSOX10b or siControl. Promoter activity as mean ± 
SD of three independent experiments is displayed. Baseline expression levels of constructs were similar 
(data not shown) and siControl activities were set to 1. (b) Luciferase assays with the full-length MIA 
promoter including mutations in five predicted SOX binding sites in 1205Lu cells are shown as mean ± 
SD from three independent experiments. (c) The proximal element of the MIA promoter is depicted. 
Sequences including the predicted binding sites as mentioned in the text are shown. Underlined 
nucleotides were mutated (A to C, T to G, and vice versa) in the full-length MIA reporter construct. 
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To identify the specific binding site of SOX10 within the MIA proximal promoter region, 
in silico analysis were performed with the MatInspector from Genomatix Software 
GmbH and JASPAR version 5.0_alpha and the MIA promoter sequence according to 
>gi|224589810|ref|NC_000019.9|:41279500-41280875 Homo sapiens chromosome19, 
GRCh37.p5 from the NCBI data base. 
The MatInspector uses general SOX binding site alignment matrices (V$SORY based 
on SOX/SRY-sex/testis determining and related HMG box factors) for binding site 
prediction as no specific SOX10 alignment matrix is available for this software. 
Predicted binding sites are listed in Table 13. Nine potential SOX binding sites were 
found within the MIA promoter region with five binding sites within the first 493 bp. 
Binding sites G1 and G2 comprise the same core binding position. 
Bin-
ding 
site 
Matrix Matrix 
sequence 
according to 
IUPAC 
Start 
posi-
tion 
End 
posi-
tion 
Anchor 
posi-
tion 
Strand Sequence 
G1 V$HM
GIY.01 
RNRAATTTNC
SNN 
-213 
 
-189 -201 + tctgggAATTtcctt
gggcttacag 
G2 V$HM
GIY.01 
RNRAATTTNC
SNN 
-222 -198 -210 - caaggaAATTccc
agataaggtcca 
G3 V$SO
X5.01 
NNAACAATN
N 
-281 -257 -269 - cctcaaCAATcac
agaggcctagat 
G4 V$SO
X9.03 
NNACAADGG
MRSBCTTTB
MDMV 
-442 
 
-418 -430 - ggagaACAAggc
agccctttgatta 
G5 V$SO
X5.01 
NNAACAATN
N 
-487 -463 -475 + agcataCAATattc
agtcagtactc 
G6 V$SO
X5.02 
NNGAACAAT
WNN 
-633 -609 -621 - tgggaACAAtaaa
aaagccaatagt 
G7 V$SO
X9.03 
NNACAADGG
MRSBCTTTB
MDMV 
-730 -706 -718 + gaaaaAAAAggg
aggggttataatc 
G8 V$HM
GA.01 
NDKCSNNRT
NAATKANK 
-897 -873 -885 - tatgcccaattAAT
Ccattttttta 
G9 V$HM
GA.01 
NDKCSNNRT
NAATKANK 
-1070 -1046 -1058 - tatgcccagttAAT
Tttttgtattt 
Table 13: General SOX binding sites as evaluated with the MatInspector from Genomatix.  
Matrices that define the binding site prediction are presented according to the International Union of pure 
and Applied Chemistry (IUPAC): R = G or A; Y = T or C; K = G or T; M = A or C; S = G or C; W = A or T; 
B = G or T or C; D = G or A or T; H = A or C or T; V = G or C or A; N = any. Positions of binding sites are 
given in relation to the protein start ATG. Binding site prediction is related to the sense, anti-coding (+) 
strand or the antisense, coding (-) strand of the DNA. Capital letters in the predicted sequence mark the 
core binding nucleotides. 
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With the JASPAR database, binding site prediction with a specific SOX10 alignment 
matrix was possible (Model-ID MA0442.1; Figure 28).  
Figure 28: Model-
ID MA0442.1 for 
SOX10 binding 
site prediction. 
The model-ID for 
SOX10 binding 
site prediction 
MA0442.1 from 
the JASPAR 
database is shown 
as graphical 
design and mathematical matrix. The illustration was obtained from http://jaspar.binf.ku.dk/cgi-
bin/jaspar_db.pl?ID=MA0442.1&rm=present&collection=CORE. 
Thirty-one potential binding sites were found with this software and are listed in Table 
14. J1 to J10 lie within the first 493 bp.  
Binding 
site 
Score Relative 
score 
Start End Strand Predicted site 
sequence 
J1 7.094 0.919 -81 -76 + CCTTGT 
J2 4.824 0.819 -90 -85 - TTGTGT 
J3 4.605 0.809 -98 -93 - CTTGG 
J4 4.820 0.818 -102 -97 - TCTTGT 
J5 5.559 0.851 -225 -220 + CTTTGG 
J6 4.521 0.805 -267 -262 + GATTGT 
J7 5.846 0.864 -273 -268 + CTCTGT 
J8 7.094 0.919 -428 -423 + CCTTGT 
J9 4.669 0.812 -439 -434 - CTTTGA 
J10 6.352 0.886 -482 -477 - TATTGT 
J11 4.669 0.812 -507 -502 + CTTTGC 
J12 8.910 1.000 -585 -580 + CTTTGT 
J13 4.521 0.805 -610 -605 + CATTTT 
J14 6.352 0.886 -619 -614 + TATTGT 
J15 4.805 0.818 -625 -620 + CTTTTT 
J16 5.846 0.864 -640 -636 + CTCTGT 
J17 4.605 0.809 -651 -646 + CTTGGT 
J18 5.846 0.864 -688 -683 - CTCTGT 
J19 4.805 0.818 -726 -721 - CTTTTT 
J20 4.805 0.818 -735 -730 - CTTTTT 
J21 4.824 0.819 -743 -738 + CTGTCT 
J22 4.521 0.805 -893 -888 - CATTTT 
J23 5.846 0.864 -929 -924 - CTCTGT 
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J24 5.561 0.851 -970 -965 - CACTGT 
J25 4.521 0.805 -1048 -1043 - CATTAT 
J26 6.636 0.899 -1066 -1061 - TTTTGT 
J27 5.559 0.851 -1157 -1152 + CTTTGG 
J28 4.605 0.809 -1186 -1181 + CTTGGT 
J29 4.824 0.819 -1214 -1209 + CTGTCT 
J30 5.561 0.851 -1246 -1241 + CACTGT 
J31 6.352 0.886 -1341 -1336 - CATTCT 
Ten binding sites within the MIA promoter as predicted with JASPAR (J6 – J10, J14, 
J15, J19, J22, and J26) were also predicted with the MatInspector. Five of these ten 
sites even included the same core nucleotides (J6, J8, J10, J14, and J19). Thus, 
binding site G3 equals J6 and J7, G4 equals J8 and J9, G5 equals J10, G6 equals J14 
and J15, G7 equals J19, G8 equals J22, and G6 equals J26.  
Predicted binding sites between -493 and -160 bp of the full-length MIA reporter 
construct were mutated consecutively with a QuikChange Lightning Site-Directed 
mutagenesis kit (Agilent Technologies) by exchanging A to C or T to G and vice versa 
(Figure 27 c) followed by luciferase assay analyses. Although promoter activity of the 
truncated fragments -200 and -212 were reduced by SOX10 inhibition (Figure 27 a), 
mutations in G1/G2 (Mut#1) had almost no effect on the whole MIA promoter activity 
(Figure 27 b). Also mutation of J5 (-220 to -225 bp; Mut#2) did not affect the MIA 
promoter activity and same is true for mutation of G3 (J6; Mut#3). Strikingly, with the 
reporter constructs Mut#4 (G4/J8) and Mut#5 (J9), the MIA promoter activity was almost 
abrogated.  
Binding sites G4/J8 and J9 lie in close proximity. Monomeric as well as dimeric binding 
of SOX10 to DNA was demonstrated before [228]. Thus, J8 and J9 display potential 
SOX10 homodimeric binding sites. Further predicted binding sites were not analyzed 
but binding to these sites cannot be excluded. 
Direct binding of SOX10 to the binding sites G4/J8 and J9 was assessed by EMSA. 
This assay was performed with a nuclear extract from 1205Lu cells and DIG-labeled 
oligonucleotides. The nuclear extract was incubated with the oligonucleotides at 37°C 
before separation on a 6% DNA retardation gel. In case of supershift experiments using 
Table 14: SOX10 binding sites as evaluated with the JASPAR database and model-ID MA0442.1. 
Score and relative score evaluate the sequence alignment of input profile and model-ID using a modified 
Needleman-Wunsch algorithm. Positions of binding sites are given in relation to the protein start ATG. 
Binding site prediction is related to the sense, anti-coding (+) strand or the antisense, coding (-) strand of 
the DNA. Bold letters mark the binding sequences, which were also predicted with the MatInspector from 
Genomatix. Identical core binding sites are underlined. 
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a SOX10-specific or a control IgG antibody, nuclear extract and antibodies were 
incubated on ice prior to oligonucleotide addition. After electrophoretic separation, 
protein-bound oligonucleotides were transferred on a positively charged nylon 
membrane before fixation by UV crosslink. This method allows the detection of the 
oligonucleotides through their DIG-label and specific protein detection via 
immunoblotting.  
The oligonucleotide cons (DIG-AGACTGAGAACAAAGCGCTCTCACAC) contains a 
published SOX binding consensus sequence (bold letters), which was shown to be 
bound by SOX10 [52] and was defined as a consensus SOX binding sequence (5’-
A/TA/TCAAT/A-3’ and complementary sequence 5’-T/ATTGT/AT/A-3’) according to 
Mollaaghababa and Pavan [179]. The oligonucleotide MIA_B (DIG-5’-
TGGTAATCAAAGGGCTGCCTTGTTCTCCTGC)-3’ contains the binding sites G4/J8 
and J9 (bold letters). 
 
Results of EMSA analyses are shown in Figure 29. Both oligonucleotides were bound 
by SOX10 as shown by supershift of the DNA fragments when pre-incubated with the 
SOX10 antibody but not with a control IgG. However, different shift patterns were 
observed when using either the cons or the MIA_B oligonucleotide by detecting DIG or 
SOX10 on the EMSA membrane. Restricted protein-DNA complexes that resemble 
monomeric SOX10 to the control oligonucleotide were observed. With the MIA_B 
oligonucleotide, protein-DNA complexes were detected that had a different restriction 
Figure 29: EMSA with DIG-labeled oligonucleotides 
containing a SOX consensus binding sequence 
and the predicted SOX10 binding sites in the MIA 
promoter. 
EMSA was performed with a DIG-labeled SOX 
consensus binding sequence (cons) or a DIG-labeled 
MIA promoter oligonucleotide (MIA_B) containing both 
predicted SOX10 binding sites (G4/J8 and J9). 
Supershifts were performed with an anti-SOX10 
antibody or IgG control. DIG (upper) and SOX10 
(lower) signals were detected on the EMSA membrane. 
An asterisk marks SOX10 monomeric, an arrow 
SOX10 dimeric binding.  
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pattern than the monomer-bound oligonucleotide. These differences in shift patterns 
point to dimeric binding of SOX10 to the MIA_B oligonucleotide and thus to the G4/J8 
and J9 binding sites. 
In conclusion, the secreted protein MIA, which was described to be directly involved in 
melanoma cell migration, was identified as a direct target gene of SOX10. 
4.4.3 Investigation of potential coregulators of SOX10 
In contrast to SOX10, MIA is not expressed in melanocytes. Previously, it was 
suggested that COOH-terminal binding protein 1 (CtBP1) affects cell type-specific MIA 
promoter activation. It has been shown that CtBP1 binds to the MIA promoter and 
functions as transcriptional repressor of MIA [204]. Furthermore, CtBP1 has been 
shown to be expressed in human melanocytes and normal skin biopsies. Analysis of 
CtBP1 expression in the cell lines investigated in this study revealed higher expression 
levels of CtBP1 in fibroblasts and melanocytes compared to melanoma cell lines (Figure 
30 a). The expression of CtBP1 was significantly decreased in melanoma cell lines 
compared to melanocytes (Figure 30 b). Therefore, it is possible that the presence of 
repressors in melanocytes override the activity of transcription factors such as SOX10. 
Figure 30: Expression of the transcriptional repressor CtBP1 in fibroblasts, melanocytes, and 
melanoma cell lines. 
(a) CtBP1 expression on mRNA level (mean ± SD) was assessed by qRT-PCR in fibroblasts (two donors, 
white bars), melanocytes (three donors, black bars), and 12 different melanoma cell lines (grey bars) in 
three independent experiments. (b) Analysis of median CtBP1 expression levels with a scatter blot 
demonstrates a significant decrease in expression of melanoma cells (mel) compared to human 
melanocytes (HM; t-test, *P<0.0001). 
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Furthermore, it is possible that coregulators of SOX10 are present in melanoma cell 
lines but not in melanocytes. Potential coregulators of SOX transcription factors were 
analyzed in silico with the ModelInspector from the Genomatix software by 
determination of published interaction motifs. Three such motifs were identified within, 
upstream, and downstream of the MIA promoter region (Figure 31 a). 
The motif identified downstream of the promoter region (+358 to +448; V$SORY, 
V$SORY, V$EGFR) includes binding of early growth response 2 (EGR2) and SOX10. 
EGR2 and SOX10 have been shown to activate the MPZ first intron element individually 
as well as synergistically and that EGR2 facilitates binding of SOX10 [148], [149]. EGR2 
was inhibited via siRNA (Figure 31 b). Despite effective downregulation of EGR2 with 
the siRNA, EGR2 inhibition did not affect MIA expression and was therefore excluded 
as part of a coregulatory model. 
The motif within the promoter region (-225 to -191; V$NFKB, V$SORY) includes binding 
of NFκB and HMG1. This cooperative binding was described by Poser et al. [203] and 
others [155], [266], [295], [302]. However, no effective reduction of MIA expression 
could be achieved by p65 inhibition (Figure 31 c) and p65 and MIA expression did not 
correlate in melanocytes or melanoma cells as demonstrated before (section 4.4.1, 
Figure 25). 
The third motif lies upstream of the MIA promoter region and includes SOX and paired 
box 6 (PAX6) alignment matrices (-2148 to -2102; V$SORY, V$PAX6). A cooperative 
binding of PAX6 and SOX2 was demonstrated in the chicken delta-crystallin enhancer 
region [124], [134]. Inhibition of PAX6 by siRNA reduced MIA expression on mRNA and 
protein level but did not affect SOX10 expression (Figure 31 d and e). SOX10 inhibition 
also had no effect on PAX6 expression (data not shown). As a control, MIA promoter 
activation was analyzed after PAX6 inhibition (Figure 31 f). Interestingly, PAX6 inhibition 
decreased MIA promoter activity indicating further PAX6 binding sites within the MIA 
promoter region. The effect of PAX6 and SOX10 overexpression on the MIA promoter 
region is shown in Figure 31 g. MIA promoter activity was increased by SOX10 but not 
by PAX6 overexpression. Also overexpression of both factors did not further enhance 
the promoter activity. Therefore, it is not suggested that PAX6 and SOX10 function as 
coregulators of MIA at least not within the MIA promoter region. 
Considering these experiments, the absence of MIA expression in melanocytes might 
be rather due to the presence of transcriptional repressors than absence of coregulators 
of SOX10. 
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Figure 31: SOX10 transcriptional coregulator motifs upstream, within, and downstream of the MIA 
promoter region and impact of these factors on MIA regulation. 
(a) Binding motifs of PAX6/SOX before (-2148 to -2102), NFκB/SOX within (-225 to -191), and 
EGR2/SOX behind (+358 to +448) the MIA promoter region were identified with the ModelInspector from 
Genomatix. (b) Expression of EGR2 and MIA (mean ± SD) was assessed in 1205Lu cells in three 
independent experiments 72 hours after transfection of an EGR2-targeting and a control siRNA. (c) 
Expression of SOX10, p65 (encoded by the gene RELA), and MIA was assessed by immunoblotting in 
1205Lu cells 6 days after transfection of siRELA or siControl (with repeated siRNA transfection after 3 
days). Detection of β-Actin served as loading control. (d) Messenger RNA expression (mean ± SD) of 
PAX6 and MIA was assessed in 1205Lu cells in three independent experiments 72 hours after 
transfection of siPAX6 or siControl. MIA expression on protein level was assessed in the same cells by 
immunoblotting. Detection of β-Actin served as loading control. (e) SOX10 expression was assessed in 
the same cells as described in (d). (f) Activity of the MIA full-length promoter was determined by 
luciferase reporter assay 48 hours after transfection of siPAX6 or siControl in 1205Lu cells (three 
independent experiments, mean ± SD). (g) Luciferase reporter assay of the MIA full-length promoter 48 
hours after transfection of vectors for SOX10 (pCMV-SOX10) or PAX6 (pCMV-PAX6) ectopic 
overexpression or a control plasmid (pControl). Mean ± SD of three independent experiments are shown. 
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4.4.4 Analysis of MIA-mediated invasion after SOX10 inhibition 
The role of MIA in the decrease of melanoma cell invasion after SOX10 inhibition was 
tested in a so-called rescue experiment. SOX10-inhibited or control 1205Lu cells were 
transfected with a vector for ectopic MIA overexpression (pCMX-MIA). Thereby, MIA 
expression levels were increased in the SOX10-inhibited cells (Figure 32 a). 
As MIA is a secreted protein, MIA levels in the supernatant of SOX10-inhibited and 
control cells transfected with the MIA vector or a control vector were determined by 
immunoblotting (Figure 32 b). In contrast to cells transfected with the control plasmid 
and siRNA, the secretion of MIA in MIA-overexpressing cells transfected with siControl 
was less pronounced than expected from the intracellular expression level (Figure 32 a 
and b). Secretion of MIA in the SOX10-inhibited cells transfected with the MIA 
expression vector was at a comparable level as with the control cells transfected with 
the control plasmid.  
Cells were applied to Matrigel invasion assays (Figure 32 c). As seen before (section 
4.3.3), invasion of SOX10-inhibited 1205Lu cells was significantly reduced compared to 
control cells, which was not affected by co-transfection of a control vector. 
However, ectopic MIA expression in the SOX10-inhibited cells significantly increased 
their invasion capacity compared to SOX10-inhibited cells transfected with the control 
vector, although it did not significantly alter the invasion of control cells.  
Figure 32 d shows representative membranes with invaded and stained melanoma 
cells. 
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Figure 32: Ectopic MIA expression in SOX10-inhibited melanoma cells and Matrigel invasion 
analysis. 
(a) 1205Lu cells were transfected with siSOX10a, siSOX10b, or siControl. Twenty-four hours later a 
vector for ectopic MIA overexpression (pCMX-MIA) or a control vector (pControl) was transfected. 
Immunoblot analyses of MIA, SOX10, or β-Actin (loading control) were performed 48 hours after siRNA 
and 24 hours after plasmid transfection. (b) MIA expression in supernatants of cells described in (a) was 
analyzed by immunoblotting. Ponceau S staining served as loading control. (c) 1205Lu cells treated as 
described before were subjected to Matrigel invasion assays. Quantification of five independent 
experiments is shown. SOX10 inhibition without MIA overexpression significantly decreased melanoma 
cell invasion (one-way ANOVA versus siControl, *P<0.05). Ectopic MIA expression significantly increased 
the invasion capacity of SOX10-inhibited but not of control cells (t-test, *P<0.05). (d) Representative 
pictures of membranes after Matrigel invasion assays are shown. 
Viability of these cells was determined 4 days after siRNA and 3 days after plasmid 
transfection (Figure 33). Thereby, it was shown that ectopic MIA expression did not 
increase melanoma cell viability in SOX10-inhibited or control cells but rather led to a 
slight decrease at prolonged time points. Thus, the increased invasion capacity through 
MIA overexpression is not related to enhanced cell viability. 
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Figure 33: Analysis of cell viability after 
ectopic MIA expression in SOX10-inhibited 
melanoma cells. 
Cell viability was examined 96 hours after 
transfection of siSOX10a, siSOX10b, or 
siControl and 72 hours after plasmid 
transfection of pCMX-MIA or pControl in 1205Lu 
cells. Mean ± SD of three independent 
experiments are shown. MIA overexpression did 
not increase cell viability of SOX10-inhibited 
cells. 
In summary, MIA seems to be critical for SOX10-mediated melanoma cell invasion. Still, 
other factors regulated by SOX10 might also contribute to the reduction of invasion 
upon SOX10 inhibition. 
4.5 Analysis of known target genes of SOX10 
One of the best characterized SOX10 target genes is the basic helix-loop-helix leucine 
zipper transcription factor MITF. MITF is a key factor for melanocyte specification as it 
regulates proliferation and survival of melanoblasts and activates enzymes for 
melanogenesis [273]. Loss of MITF is manifested in the Waardenburg syndrome type 
2A [265], a dominantly inherited syndrome of hearing loss and pigmentary disturbances. 
Regarding melanoma, MITF gene amplification was found in 10-20% of cases and MITF 
has been shown to be a dominant oncogene by driving melanoma cell proliferation or 
invasion, depending on its expression levels [39], [80]. Furthermore, MITF has been 
described as a highly sensitive immunohistochemical marker for melanoma and as a 
molecular marker for tumor cells in the peripheral blood of melanoma patients [130], 
[136]. 
It has been shown that SOX10 binds to the proximal melanocyte-specific M-MITF 
promoter and an upstream enhancer [22], [152], [200], [206], [275], [285] and both 
factors cooperate in activating the DCT promoter [164], [207]. 
Analysis of MITF expression in melanoma cell lines WM278, WM1232, and 1205Lu 
demonstrated that SOX10 inhibition specifically reduced expression of the M-MITF 
isoform, which is present in cell line WM1232 but not in WM278 and 1205Lu (Figure 34 
a upper panel). The same observation was made in the cell lines LMU-GM1 and WM9 
(Figure 34 b and c). Both SOX10 and M-MITF were absent in fibroblasts and present in 
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melanocytes, while their expression correlated in almost all investigated melanoma cell 
lines (except for WM278 and 1205Lu, Figure 34 d). 
Another previously suggested target gene of SOX10 is erb-b2 receptor tyrosine kinase 
3 (ERBB3). The epidermal growth factor receptor ERBB3 has been shown to be 
required for embryonic development of NCCs and their derivatives as Schwann cells 
and melanocytes [33], [37]. It has also been suggested that ERBB3 contributes to the 
progression of benign nevi to melanoma as well as to the metastatic progression of 
melanoma [37]. Antibody-mediated internalization and degradation of ERBB3 inhibits 
melanoma cell growth and migration [11]. Therefore several functions of ERBB3 
resemble SOX10 functions in embryonic development and melanoma progression. 
Furthermore, it was shown that SOX10 controls expression of ERBB3 in NCCs and 
binds to an enhancer region of the ERBB3 gene locus [31], [36], [208]. 
Inhibition of SOX10 in cell lines WM278, WM1232, 1205Lu, LMU-GM1, and WM9 
reduced ERBB3 expression (Figure 34 a lower panel, b, and c). 
Similarly to SOX10, ERBB3 protein was absent in fibroblasts and present in 
melanocytes (Figure 34 e). SOX10 and ERBB3 protein levels correlated in all 
melanoma cell lines (Figure 34 e). Figure 34 b and c demonstrates that MIA was also 
downregulated in SOX10-inhibited WM9 while MIA expression was absent in LMU-
GM1. 
Thus, previously described target genes of SOX10, which were shown to execute 
similar functions in the development of melanocytes and melanoma, were also 
regulated by SOX10 in melanoma cell lines examined in this study and might contribute 
to observed phenotypes. 
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Figure 34: Expression of M-MITF and ERBB3 after SOX10 inhibition and their expression in human 
skin cells and melanoma cell lines. 
(a) Expression of SOX10, MITF (upper panel) and ERBB3 (lower panel) was detected by immunoblotting 
in cell lines WM278, WM1232, and 1205Lu 72 hours after transfection of SOX10-targeting or control 
siRNAs. For MITF, a specific decrease in the M-isoform (asterisk) was found in SOX10-inhibited WM1232 
cells. SOX10, ERBB3, MITF, and MIA expression was analyzed in cell lines LMU-GM1 (b) and WM9 (c) 
by immunoblotting 72 hours after transfection of siSOX10a, siSOX10b, or siControl. SOX10, MITF (d), 
and ERBB3 (e) protein expression was analyzed in fibroblasts (two donors), melanocytes (three donors), 
and 12 melanoma cell lines according to section 4.1.1. While SOX10 and M-MITF expression correlated 
in fibroblasts, melanocytes, and 10 of 12 melanoma cell lines (except for WM278 and 1205Lu), SOX10 
and ERBB3 expression correlated in all investigated cell lines (e). Detection of β-Actin served as loading 
control. 
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4.6 Effects of SOX10 overexpression on melanoma cell invasion 
Next to loss-of-function experiments via siRNA-mediated SOX10 inhibition, gain-of-
function experiments were performed by SOX10 overexpression. Stable SOX10 
overexpression by lentiviral transduction or selection after lenti-plasmid transfection 
failed (data not shown). Therefore, a transient overexpression approach with a SOX10 
vector (pCMV-SOX10) with the recombinant SOX10 coding sequence under control of a 
cytomegalovirus (CMV) promoter was selected. 
SOX10 overexpression was performed in SOX10 negative cell lines WM3211 and 
WM1366 as well as in cell line 1205Lu, which displayed a medium level of SOX10 
expression compared to other melanoma cell lines (section 4.1.1). 
A SOX9 vector with the recombinant SOX9 coding sequence under control of a CMV 
promoter (pCMV-SOX9) and a CMV promoter-containing vector without coding 
sequence (pControl) were included as controls.  
Effects of SOX9 and SOX10 overexpression on melanoma cell invasion were examined 
by Matrigel invasion assays three days after plasmid transfection (Figure 35 a). SOX10 
overexpression significantly increased cell invasion in all investigated cell lines. In 
contrast, SOX9 overexpression significantly increased invasion only in cell line 1205Lu. 
Overexpression of both transcription factors slightly increased cell viability only in cell 
line WM1366 (Figure 35 b). These data further strengthen the hypothesis that the 
positive influence of SOX10 on melanoma cell invasion is not related to its effect on 
melanoma cell viability. 
Effects of SOX9 and SOX10 transient overexpression were also investigated in a three-
dimensional spheroid model as described in section 4.3.3 with the cell line WM3211. 
SOX10 but not SOX9 overexpression significantly increased the invasion area of 
WM3211 cells in this assay (Figure 35 c). Also, expression of SOX9 and SOX10 could 
be detected in these spheroids by immunoblotting (Figure 35 d) and thereby showing 
that the transient overexpression had still been lasting in the spheroids, even 6 days 
after transient transfection. Figure 35 e shows representative pictures of the three-
dimensional spheroid assay. Thus, SOX10 rather than SOX9 promotes melanoma cell 
invasion. 
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Figure 35: Two- and three-dimensional invasion assays with SOX9- and SOX10-overexpressing 
melanoma cells. 
(a) WM3211, WM1366, and 1205Lu cells were subjected to Matrigel invasion assay 72 hours after 
transient transfection of vectors for SOX9 and SOX10 overexpression or a control vector (pControl). 
Mean ± SD of four independent experiments are shown. An asterisk marks a significant, n.s. a non-
significant increase in invasion compared to pControl (one-way ANOVA, *P<0.05). Representative 
stained membranes after Matrigel invasion assay are shown. (b) Cell viability (mean ± SD) was 
determined in cells mentioned in (a) in three independent experiments. (c) WM3211 transfected with 
pCMV-SOX9, pCMV-SOX10, and pControl were subjected to spheroid assays 72 hours days after 
transfection. Quantification of invasion areas with the Fiji ImageJ software were performed 48 hours after 
embedding in collagen with cultivation on agar for 24 hours in between. Mean ± SD of four independent 
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Figure 36: Investigation of MIA, ERBB3, and 
MITF expression after overexpression of SOX9 
and SOX10. 
Expression of pSOX9, SOX9, SOX10, MIA, ERBB3, 
and MITF was assessed by immunoblotting in 
WM3211, WM1366, and 1205Lu cells 72 hours 
after transfection of vectors for SOX9 and SOX10 
overexpression or a control vector (pControl). MIA 
expression was increased after SOX10 
overexpression in 1205Lu cells but not in the other 
cell lines. No increase in ERBB3 or M-MITF 
(asterisk) was found. LMU-GM1 served as positive 
control for M-MITF. Detection of β-Actin served as 
loading control. 
 
 
 
experiments (with 2 to 4 technical replicates each) are shown. An asterisk marks a significant, n.s. a non-
significant increase in invasion compared to pControl (one-way ANOVA, *P<0.05). (d) Immunoblot with 
cell lysates from WM3211 spheroids 6 days after transfection demonstrates lasting expression of SOX9 
and SOX10 by transient plasmid transfection. Detection of β-Actin served as loading control. (e) 
Representative pictures of spheroid assays are shown. Scale bar = 100 µm. 
To analyze the cellular background of this increased invasion upon SOX10 
overexpression, the previously described target genes of SOX10, i.e., MIA, ERBB3, and 
MITF, were examined by immunoblotting (Figure 36). 
 
MIA expression was elevated in cell line 1205Lu by SOX10 but not by SOX9 
overexpression. However, neither increase nor expression of MIA was found for cell 
lines WM3211 and WM1366. Furthermore, no increase in ERBB3 and M-MITF levels 
was found in all tested cell lines.  
These data indicate that SOX10 overexpression may regulate further target genes that 
can directly affect melanoma cell invasion. 
4.7 Identification of further SOX10 target genes by RNA sequencing 
RNA sequencing studies were performed in order to identify further genes regulated by 
SOX10 overexpression. For these studies, 1205Lu - a melanoma cell line with a median 
expression level of SOX10 according to section 4.1.1 - was selected. The increase of 
SOX10 expression after pCMV-SOX10 transfection was tested in a time course 
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experiment. The CMV6 vector without the SOX10 recombinant coding sequence 
(pCMV6) was included as control vector. SOX10 levels were highly elevated 16 hours 
after plasmid transfection (Figure 37 a).  
 
Figure 37: Significantly regulated genes after SOX10 overexpression identified by RNA 
sequencing. 
(a) Time course analysis 4, 8, 16, and 24 hours after transfection of pCMV-SOX10 or pCMV6 control 
showed a strong increase of SOX10 protein expression after 16 and 24 hours. Detection of β-Actin 
served as loading control. (b) Three replicates of 1205Lu cells transfected with pCMV-SOX10 (s1-s3) or 
pCMV6 (c1-c3) for 24 hours were subjected to RNA sequencing. The heat map displays six genes that 
were significantly regulated by SOX10 overexpression. (c) Heat map of significantly regulated genes of 
cells mentioned above after DNase digestion of isolated RNA and subsequent RNA sequencing. (d) Heat 
map of significantly regulated genes of cells as mentioned in (c) in two (s3, s2) versus two (c3, c1) 
biological replicates. Dark blue indicates a high, light blue or white a low number of reads. 
To ensure an effect on target gene transcription, samples for RNA sequencing were 
collected in QIAzol 24 hours after plasmid transfection in three biological replicates of 
SOX10 overexpressing and control cells. RNA sequencing was performed in 
collaboration with Dr. Stefan Krebs and Dr. Helmut Blum at the Gene Center of the LMU 
Munich with an Illumina Genome Analyzer IIx. In the first sequencing experiment, a high 
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rate of reads mapped to sequences of the transfected vectors and had to be excluded 
from the analysis. In the end, six genes were significantly regulated by SOX10 
overexpression (Figure 37 b, Table 15). 
Gene Base 
mean 
Base 
mean A 
Base 
mean B 
Fold 
change 
Log2-fold 
change 
P-
value 
P-value 
adjusted 
NR1D1 173.925 75.597 272.252 0.278 -1.849 3.81E
-06 
0.016 
H1FX-
AS1 
40.985 17.922 64.049 0.280 -1.837 1.26E
-05 
0.043 
KLF10 168.812 106.808 230.817 0.463 -1.112 2.14E
-06 
0.011 
PPP1R
15A 
254.715 163.241 346.189 0.472 -1.085 2.00E
-08 
0.0002 
TIPAR
P 
928.433 615.458 1241.40
8 
0.496 -1.012 2.57E
-11 
5.29E-07 
PMP2 21.9877 41.930 2.044 20.518 4.359 3.19E
-08 
0.0002 
Table 15: Results from RNA sequencing experiment without DNase digestion.  
“Base mean” equals the mean of reads, “base mean A” the reads from the cells transfected pCMV-
SOX10 and “base mean B” the cells transfected with the control vector pCMV6. Log2 = binary logarithm. 
Krueppel-like factor 10 (KLF10) is a zinc finger transcription factor implicated in cell 
differentiation and in serving as a potential marker for diseases as breast cancer, 
cardiac hypertrophy, and osteoporosis [260]. It is known to be involved in repressing cell 
proliferation and inflammation as well as inducing apoptosis. Nuclear receptor subfamily 
1, group D, member 1 (NR1D1) is a ligand sensitive transcription factor that negatively 
regulates the expression of core clock proteins in the circadian rhythm [63]. It is also 
involved in the regulation of metabolism, inflammation, and cardiovascular processes. 
Furthermore, activation of NR1D1 has anti-proliferative effects on breast cancer cells 
[284]. Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) recruits the 
serine/threonine-protein phosphatase 1 (PP1) to dephosphorylate the eukaryotic 
translation initiation factor 2 alpha (eIF-2α) and thereby attenuating translational 
elongation [35]. It mediates growth arrest and apoptosis in response to DNA damage, 
negative growth signals, and protein malfolding. Staining of nevi and melanoma tissue 
samples showed high expression of PPP1R15A in nevi while it was decreased with 
melanoma thickness indicating that it might play a role in the malignant transformation 
of nevus to melanoma [135]. H1FX antisense RNA 1 (H1FX-AS1) is a non-coding RNA. 
H1FX is a member of the histone H1 family. Peripheral myelin protein 2 (PMP2) is a 
small basic protein that binds fatty acids and is one of the major proteins in 
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development and maintenance of the myelin sheath predominantly in the peripheral 
nervous system [96]. It can stack lipid biolayers, affect membrane dynamics, and is 
suggested to be important for lipid transport to and from the myelin membrane. It has 
not been related to melanoma or any other malignancies yet. Two, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly (ADP-ribose) polymerase (TIPARP) 
is a mono-ADP-ribosyltransferase that ribosylates core histones and functions as a 
repressor of aryl hydrocarbon receptor (AHR) [167]. AHR mediates toxic effects of 
environmental contaminants e.g. TCDD via its targets such as cytochrome p450. Single 
nucleotide polymorphisms in the TIPARP gene were were found in ovarian cancer [87]. 
Another sequencing experiment was performed with the same isolated mRNA but with 
DNA digestion prior to cDNA synthesis and library generation. In this experiment, only 
SOX10 and PPP1R15A were significantly regulated among the three replicates (Figure 
37 c, Table 16). 
Gene Base 
mean 
Base 
mean A 
Base 
mean B 
Fold 
change 
Log2-fold 
change 
P-value P-value 
adjusted 
SOX10 26584.
363 
52595.49
2 
573.234 91.752 6.520 6.74E-
98 
1.04E-93 
PPP1
R15A 
1029.1
13 
607.423 1450.803 0.419 1.256 6.36E-
09 
4.88E-05 
Table 16: Results from RNA sequencing experiment including DNase digestion. 
Significant regulation by SOX10 overexpression was found in five genes when two of 
the three biological replicates were compared. These genes were ferritin light 
polypeptide 1 (FTL), ribosomal protein 27 a (RPL27a), and growth hormone 1 (GH1) 
next to PPP1R15A and SOX10 (Figure 37 d, Table 17). 
Gene Base 
mean 
Base 
mean A 
Base 
mean B 
Fold 
change 
Log2-fold 
change 
P-
value 
P-value 
adjusted 
SOX10 32141.
329 
63670.6
39 
612.019 104.034 6.701 0 0 
PPP1R
15A 
1009.0
57 
668.175 1349.94
0 
0.495 -1.015 2.38E
-05 
0.071 
FTL 32026.
134 
36846.3
97 
27205.8
71 
1.354 0.438 4.74E
-07 
0.002 
RPL27
A 
7646.4
65 
8923.88
7 
6369.04
3 
1.401 0.487 8.40E
-06 
0.031 
GH1 1508.3
62 
747.237 2269.48
7 
0.329 1.603 4.03E
-11 
3.02E-07 
Table 17: Results from RNA sequencing experiment with DNase digestion comparing replicates c1 
and c2 with s2 and s3.  
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In order to identify general and not cell line-specific target genes of SOX10, the genes 
mentioned above were examined for mRNA expression in cell lines WM3211, WM1366, 
and 1205Lu 24 hours after transfection of the SOX10 and the control vector. A heat 
map of the binary logarithms of the mean mRNA values is displayed in Figure 38. 
 
GH1 mRNA was only detectable in 1205Lu (data not shown) and therefore excluded 
from further analyses.  
 
Figure 39: Log2-fold mRNA expression of 
genes identified by RNA sequencing. 
Mean mRNA values of significantly regulated 
genes by SOX10 overexpression described in 
Figure 38 were analyzed by normalization of 
SOX10 overexpression- to pCMV6-values and 
converted into log2 values. These values were 
related to an according color scale, in which red 
means high and blue means low expression. 
SOX10 overexpression increased SOX10 and 
PMP2 mRNA values in all three investigated cell 
lines. 
 
 
Strikingly, when calculating the binary logarithm of the mRNA values normalized to the 
control vector (pCMV-SOX10/pCMV6) in all three analyzed cell lines, a clear 
Figure 38: Expression of SOX10-regulated 
genes identified by RNA sequencing. 
Expression of SOX10, KLF10, NR1D1, H1FX-
AS1, PPP1R15A, PMP2, TIPARP, FTL, and 
RPL27A were analyzed in cell lines WM3211, 
WM1366, and 1205Lu 24 hours after transfection 
of pCMV-SOX10 or pCMV6 control vector. 
Binary logarithms of mean mRNA values from 
three independent experiments are displayed in 
a heat map generated with the HeatMapper from 
Broad Institute. Red indicates a relatively high, 
blue a relatively low expression. 
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upregulation of SOX10 and of PMP2 mRNA was found (Figure 39), indicating that 
SOX10 transactivates PMP2. 
4.8 Identification of PMP2 as a target gene of SOX10 
4.8.1 Analysis of the regulation of PMP2 by SOX10 
Considering the results of the RNA sequencing and the expression patterns in Figures 
38 and 39, it stands to reason that PMP2 is a potential target gene of SOX10. Figure 40 
displays the results of mRNA expression of SOX10 and PMP2 24 hours after 
transfection of the SOX10 or the control vector. SOX10 overexpression increased 
PMP2 mRNA expression around 10-fold in cells lines WM3211 and 1205Lu and around 
100-fold in cell line WM1366. 
 
Figure 40: Analysis of PMP2 expression after SOX10 overexpression. 
SOX10 (a) and PMP2 (b) mRNA expression (mean ± SD of three independent experiments) were 
assessed in cell lines WM3211 (light grey bars), WM1366 (medium grey bars), and 1205Lu (black bars) 
24 hours after plasmid transfection of pCMV-SOX10 or pCMV6. 
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Furthermore, PMP2 expression was investigated after SOX10 inhibition in cell lines 
WM278, WM1232, and 1205Lu. Reduction of PMP2 mRNA by SOX10 inhibition was 
found in all three cell lines (Figure 41 a). Apparently, WM278 cells displayed up to 150-
fold increased mRNA levels in the control samples compared to cell lines WM1232 and 
1205Lu. On protein level, distinct PMP2 signals were only detected in cell line WM278 
(Figure 41 b). Here, SOX10 inhibition also strongly reduced PMP2 protein expression. A 
time course analysis demonstrated that SOX10 inhibition was capable of effectively 
reducing PMP2 protein expression already after 24 hours (Figure 41 c). This early 
regulatory event points to a direct transactivation of PMP2 by SOX10.  
 
Figure 41: Analysis of PMP2 expression after SOX10 inhibition. 
(a) PMP2 mRNA expression (mean ± SD) was assessed after SOX10 inhibition in cell lines WM278 (light 
grey bars), WM1232 (medium grey bars), and 1205Lu (black bars) 48 hours after transfection of 
siSOX10a, siSOX10b, or siControl in three independent experiments. (b) PMP2 protein expression was 
assessed in the same cells described in (a) 48 hours after siRNA transfection. Detection of β-Actin served 
as loading control. (c) Time course analysis of SOX10, PMP2, and β-Actin expression by immunoblotting 
24, 30, and 48 hours after transfection with SOX10-targeting or control (Ctrl) siRNAs revealed reduced 
PMP2 protein expression already after 24 hours.  
Analysis of PMP2 protein expression after SOX10 or SOX9 overexpression is shown in 
Figure 42. In cell line WM278, SOX10 rather than SOX9 overexpression was sufficient 
to slightly increase PMP2 expression as determined by PMP2 quantification in relation 
to -Actin with the FIJI ImageJ software (Figure 42 a). However, no PMP2 protein at all 
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was found in cell lines WM3211, WM1366, and 1205Lu (Figure 42 b) although an 
increase in PMP2 mRNA has been detected before (Figure 40). 
To sum up these data, it was shown that SOX10 inhibition reduced PMP2 mRNA and 
protein expression. An increase of PMP2 by SOX10 overexpression was found on 
mRNA level in all investigated cell lines while increased protein expression was only 
observed in a PMP2-positive melanoma cell line. 
Figure 42: Investigation of PMP2 expression 
after SOX10 overexpression. 
(a) PMP2, pSOX9, SOX9, SOX10 and β-
Actin protein expression was assessed by 
immunoblotting in cell line WM278 48 and 72 
hours after transfection of pCMV-SOX9, pCMV-
SOX10 or pControl. The non-specific SOX10 
signal of the SOX9 antibody is marked by an 
asterisk. Numbers above the blot display 
quantification of the PMP2 bands (upper bands) 
with Fiji ImageJ, normalized to β-Actin. (b) 
PMP2 protein expression was assessed by 
immunoblotting in cell lines WM3211, WM1366, 
and 1205Lu 72 hours after transfection of 
vectors for SOX9 and SOX10 overexpression 
or a control vector. Detection of β-Actin served 
as loading control. WM278 cells transfected 
with a PMP2 expression vector (pCMV-PMP2) 
were included as PMP2-positive control.  
 
4.8.2 Analysis of SOX10 binding to the PMP2 promoter 
A direct transactivation of PMP2 by SOX10 was assessed by in silico analyses for 
potential SOX10 binding sites within the PMP2 promoter as well as by ChIP (according 
to section 4.4.2). The first 1075 bp before the PMP2 protein start site 
(>gi|568815590:c81449371-81448296 Homo sapiens chromosome 8, GRCh38 Primary 
Assembly; NCBI database), comprising the PMP2 promoter region, were analyzed with 
the MatInspector from Genomatix software and with the JASPAR database. With the 
MatInspector, 19 binding sites for the SOX/SRY-sex/testis determining and related 
HMG box factors matrix family were predicted (Table 18). G1/G2, G4/G5, G6/G7/G8, 
G16/G17, and G18/G19 were overlapping identified binding sites. 
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Binding 
site 
Matrix Start 
position 
End 
position 
Anchor 
position 
Stra
nd 
Sequence 
G1 V$HBP1
.02 
-166 -142 -154 - actaagcAATGaatgg
ctcttcaat 
G2 V$HBP1
.01 
-169 -145 -157 - aagcaatgAATGgctc
ttcaatggc 
G3 V$SOX3
.01 
-227 -203 .-215 + tggagaCAAAgggaa
gtattatgtg 
G4 V$HBP1
.01 
-261 -237 -249 - ataaaatgAATGagatt
actatttg 
G5 V$HMGI
Y.01 
-281 -257 -269 + tcaaaaAATTtttgaag
attcaaat 
G6 V$HMG
A.01 
-367 -343 -355 - ctgtgatcatgAATGaa
tgtgtgtg 
G7 V$HBP1
.02 
-371 -347 -359 - gatcatgAATGaatgtg
tgtgtgtt 
G8 V$HBP1
.01 
-374 -350 -362 - catgaatgAATGtgtgt
gtgtttag 
G9 V$SOX1
5.01 
-425 -401 -413 - tctgcACAAttaagaatt
cttattg 
G10 V$SRY.
02 
-478 -454 -466 - taagtATTAtgataaca
gtctcaaa 
G11 V$SOX6
.01 
-598 -574 -586 - ggcagACAAagaagt
cagtctattg 
G12 V$SOX6
.01 
-688 -664 -676 - gcacaACAAagattttc
agctagaa 
G13 V$HBP1
.02 
-756 -732 -744 + cattttaAATGacttaaa
cacaaat 
G14 V$HMG
A.01 
-760 -736 -748 + gattcattttaAATGactt
aaacac 
G15 V$HMG
A.01 
-814 -790 -802 + ttgtcaatataAATTagt
actcttt 
G16 V$HBP1
.01 
-873 -849 -861 + tataattaAATGagatc
acccgtat 
G17 V$HMG
A.01 
-880 -856 -868 - tgatctcatttAATTatat
cactaa 
G18 V$SRY.
02 
-911 -887 -899 + tggatATAAtaatagttc
ctaactc 
G19 V$SRY.
02 
-918 -894 -906 - gaactATTAttatatcca
ttttacc 
Table 18: General SOX binding sites in the PMP2 promoter as evaluated with the MatInspector 
from Genomatix.  
Matrices that define the binding site prediction are named. Positions of binding sites are related to the 
protein start ATG. Binding site prediction is related to the sense, anti-coding (+) strand or the antisense, 
coding (-) strand of the DNA. Capital letters in the predicted sequence mark the core binding nucleotides. 
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With JASPAR seven binding sites were predicted. J3, J5, and J6 were identical to the 
MatInspector predicted sites G3, G11, and G12 and their binding core sequence, 
respectively (Table 19). 
Binding 
site 
Score Relative 
score 
Start End Strand predicted 
site 
sequence 
J1 7.097 0.920 -25 -20 + CTGTGT 
J2 6.812 0.907 -137 -132 - CAGTGT 
J3 8.910 1.000 -222 -217 - CTTTGT 
J4 6.812 0.907 -512 -507 - CAGTGT 
J5 8.910 1.000 -584 -579 + CTTTGT 
J6 8.910 1.000 -674 -669 + CTTTGT 
J7 6.812 0.907 -835 -830 + CAGTGT 
Table 19 SOX10 binding sites in the PMP2 promoter as evaluated with the JASPAR database and 
model-ID MA0442.1. 
Score and relative score evaluate the sequence alignment of input profile and model-ID using a modified 
Needleman-Wunsch algorithm. Positions of binding sites are related to the protein start ATG. Binding site 
prediction is related to the sense, anti-coding (+) strand or the antisense, coding (-) strand of the DNA. 
Bold letters mark the binding sequences, which were also predicted with the MatInspector from 
Genomatix. Identical core binding sites are underlined.Genomatix software. Identical core binding sites 
are underlined. 
For ChIP analyses, primers hybridizing within the PMP2 promoter region were designed 
in the Roche Assay Design Center but only two sets of primer pairs (set 1 = -608 to -
532, set 2 = -1040 to -1019) were suitable for the Lightcycler Taqman Master qPCR 
system (Figure 43 a). Only with primer set 1 a significant enrichment of recovered DNA 
through SOX10 ChIP could be detected indicating that SOX10 can bind in the proximal 
but not further distal PMP2 promoter region (Figure 43 b). 
The three potential SOX10 binding sites that were recognized by the MatInspector and 
JASPAR (p1 = J3/G3, p2 = J5/G11, and p3 = J6/G12) were integrated in DIG-labeled 
oligonucleotides for EMSA analysis. A control DIG-labeled oligonucleotide containing a 
published SOX binding consensus sequence binding site [52] was included in the 
analysis. EMSA was performed with nuclear extracts from 1205Lu cells with ectopic 
SOX10 overexpression. 
DIG detection on the EMSA membrane showed a strong shift signal with the control 
fragment that vanished through supershift with the SOX10 but not with the control 
antibody (Figure 43 c upper panel). Only for the p1-containing oligonucleotide, a distinct 
DIG-related signal could be detected, which was shifted up with the SOX10 antibody.  
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Figure 43: SOX10 binding studies in the 
PMP2 promoter region. 
(a) The schematic overview of the PMP2 
promoter illustrates predicted SOX10 binding 
sites (p1, p2, and p3) and primer pairs for ChIP 
assay. (b) Percentages of precipitated DNA in 
relation to the input DNA after ChIP assay with 
1205Lu cells and with anti-SOX10 antibody 
(black bars) or IgG control (grey bars) are 
shown. Recovered DNA (mean ± SD) with 
primer pairs hybridizing in the PMP2 promoter 
region or a control locus (hAct Int 2) was 
determined by qRT-PCR in four independent 
experiments. Significant increase of around two-
fold was found for recovered PMP2 promoter 
DNA with the SOX10-specific antibody and 
primer set 1 but not primer set 2 in comparison 
to the IgG control and the recovered DNA of 
hAct Int 2 (t-test, *P<0.05). (c) EMSA with 
1205Lu cells ectopically overexpressing SOX10 
was performed with DIG-labeled 
oligonucleotides containing a consensus SOX10 
binding sequence (cons) or the predicted SOX10 
binding sites within the PMP2 promoter (p1-3). 
DIG-detection (upper panel) revealed a strong 
shift of the cons oligonucleotide while a weak 
shift signal was found for p1, which was up-
shifted with the SOX10 antibody (signals marked by asterisks). SOX10 detection of the EMSA membrane 
revealed strong binding of SOX10 to the cons oligonucleotide and weak binding to p1, p2, and p3.  
Detection of SOX10 on the EMSA membrane revealed a different pattern (Figure 43 c 
lower panel). SOX10-DNA-complexes that were specifically restricted with the SOX10 
antibody were found with all DNA fragments. The signal was most prominent with the 
control fragment. However, signals obtained with p2 and p3 were less distinct compared 
to p1. Furthermore, shift patterns for p1 suggested a multiple binding of SOX10 to this 
oligonucleotide although no more binding sites were predicted for this sequence. 
Considering the results from the ChIP and EMSA experiments, it is possible that SOX10 
binds to the proximal promoter region of the PMP2 gene. 
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4.8.3 Investigating EGR2 as a transcriptional coregulator of SOX10 
EGR2 (also known as Krox20) has been described as a common coregulator of SOX10 
in myelin gene regulation [258]. Clustering of EGR2/SOX10 binding sites in myelin gene 
regulatory elements appears to be common [118], [122]. EGR2 itself controls 
myelination in the peripheral nervous system [267] and was found to be regulated by 
SOX10 in vitro and in vivo in Schwann cells [211]. Furthermore, in vivo ChIP-
sequencing and microarray analyses identified PMP2 expression to be positively 
regulated by both, SOX10 and EGR2, in myelinating peripheral nerves from rat pups 
[251].  
Potential coregulation of PMP2 by SOX10 and EGR2 has been investigated (Figure 44). 
SOX10 inhibition was capable of reducing PMP2 but also EGR2 expression in cell line 
WM278 (Figure 44 b-d).  
Accordingly, EGR2 inhibition reduced PMP2 expression as shown in Figure 44 c and d, 
but not as strong as SOX10 inhibition. However, co-inhibition of SOX10 and EGR2 
significantly stronger decreased PMP2 mRNA expression than SOX10 inhibition alone, 
indicating cooperative regulation of PMP2 by SOX10 and EGR2 also in melanoma cells 
(Figure 44 c). 
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Figure 44: PMP2 expression after SOX10 and/or EGR2 inhibition. 
SOX10 (a), EGR2 (b), and PMP2 (c) expression was analyzed by qRT-PCR (mean ± SD of three 
independent experiments) in cell line WM278 48 hours after siRNA transfection. SOX10 was significantly 
downregulated by siSOX10a/siControl and siSOX10a/siEGR2 but not by siEGR2/siControl (one-way 
ANOVA versus 2xsiControl, *P<0.01). EGR2 and PMP2 were significantly downregulated by all siRNA 
combinations in comparison to 2xsiControl (one-way ANOVA, *P<0.01). Moreover, the combination of 
siEGR2 and siSOX10a led to a significantly higher downregulation of PMP2 than siSOX10a/siControl (t-
test, *P=0.0107). (d) Immunoblot analysis of samples mentioned above 48 hours after siRNA 
transfection. Detection of β-Actin served as loading control. An asterisk marks the specific PMP2 band as 
determined in section 4.9.2.1.  
4.9 Expression and functional characterization of PMP2 in melanoma 
4.9.1 PMP2 expression in human skin cells and melanoma cell lines 
Expression of PMP2 mRNA was assessed in fibroblasts (2 donors), melanocytes (3 
donors), and 12 melanoma cell lines as described in section 4.1.1 (Figure 45 a).  
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Figure 45: Expression of PMP2 in human skin cells and melanoma cell lines. 
(a) PMP2 mRNA expression (mean ± SD) was investigated in fibroblasts (2 donors), melanocytes (three 
donors, black bars), and 12 different melanoma cell lines (grey bars) by qRT-PCR in three independent 
experiments. (b) PMP2 protein expression was detected by immunoblotting with a PMP2 antibody from 
mouse (PMP2 m, used in previous immunoblots) and a PMP2 antibody derived from rabbit (PMP2 r) in 
cell lines described in (a). Detection of β-Actin served as loading control. PMP2 is expressed in cell lines 
WM278 and WM239A according to the positive control (WM278 transfected with pCMV-PMP2). 
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Figure 46: Analysis of PMP2 expression after SOX10 inhibition in 
WM239A. 
PMP2, SOX10, and β-Actin (loading control) protein expression was 
assessed by immunoblotting 48 hours after transfection of SOX10-
targeting or control siRNAs. 
Little or no PMP2 mRNA expression was found in fibroblasts and in 6 of 12 melanoma 
cell lines (SbCl2, WM3211, WM1366, WM793, WM1158, 1205Lu). Moderate PMP2 
mRNA levels were found in melanocytes. Strikingly, 2 of 12 melanoma cell lines 
(WM278 and WM239A) showed very high expression levels. PMP2 expression was 
further assessed on protein level (Figure 45 b). Due to the relatively poor quality of the 
PMP2 antibodies tested, a positive control, i. e., WM278 cell line ectopically 
overexpressing PMP2, was loaded. The PMP2 antibody derived from mouse (PMP2 m) 
was used in the previous experiments and displayed a high background. Therefore 
another PMP2 antibody derived from rabbit (PMP2 r) was included for expression 
analyses. This antibody also displayed background bands. Nevertheless, according to 
the positive control, a clear signal for PMP2 protein expression was detected in cell 
lines WM278 and WM239A while no expression was found in fibroblasts and 
melanocytes. Only faint or non-specific bands were detected in the other melanoma cell 
lines.  
Downregulation of PMP2 in SOX10-inhibited cells was also detected in cell line 
WM239A (Figure 46).  
 
In the end, PMP2 seems to be only expressed in a small subset of melanoma cell lines. 
Nevertheless, it is interesting that a protein, which is crucial for myelination of Schwann 
cells, is expressed in melanoma cells at all. The expression of other known SOX10-
regulated myelin proteins myelin protein zero (MPZ) [196] and proteolipid protein 1 
(PLP1) [256] was investigated in a subset of fibroblasts, melanocytes, and melanoma 
cell lines (Figure 47 a and b, respectively). Moderate and high mRNA levels of MPZ and 
PLP1 were found in melanocytes, respectively. Moderate mRNA expression of PLP1 
was detected in WM239A. Strikingly, both factors were found highly expressed in 
melanoma cell line WM278. These data indicate that SOX10-regulated myelin proteins 
seem to be expressed in a subset of melanoma cell lines. 
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Figure 47: Expression of MPZ and PLP1 in human skin cells and melanoma cell lines. 
MPZ (a) and PLP1 (b) mRNA expression was assessed by qRT-PCR (mean ± SD of three independent 
experiments) in human fibroblasts (one donor), melanocytes (one donor, black bars), and in 8 melanoma 
cell lines (grey bars). MPZ and PLP1 are considerably higher expressed in WM278 compared to other 
melanoma cell lines. 
4.9.2 Phenotypic effects of PMP2 inhibition and overexpression in melanoma 
cells 
4.9.2.1 Inhibition of PMP2 via RNA interference 
Loss- and gain-of-function experiments were carried out to further investigate potential 
functions of PMP2 in melanoma cells. PMP2 was inhibited by RNA interference with two 
different PMP2-targeting siRNAs (siPMP2a and b). Both siRNAs effectively inhibited 
PMP2 expression as shown for WM278 cells (Figure 48). Inhibition on protein level 
demonstrated that the specific PMP2 band detected with the PMP2 antibody (source 
mouse) is the upper one of the detected signals around 15 kDa, which corresponds to 
the theoretical molecular weight of 14.9 kDa (132 amino acids). 
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Figure 48: Inhibition of PMP2 via RNA interference. 
PMP2 mRNA expression (mean ± SD of three 
independent experiments) was assessed 24 hours and 
protein expression 48 hours after transfection of 
PMP2-targeting siRNAs (siPMP2a and siPMP2b) and 
control siRNA (siControl). Detection of β-Actin served 
as loading control. According to these data both 
PMP2-targeting siRNAs effectively reduced PMP2 
expression. Of the two signals around 15 kDa detected 
with the PMP2 antibody (source mouse), the upper 
one represents the specific PMP2 signal, marked by 
an asterisk. 
 
 
4.9.2.2 Effects of PMP2 inhibition on melanoma cell proliferation 
Phenotypic effects of PMP2 inhibition were analyzed in melanoma cell lines WM278, 
WM239A, and LMU-GM1. LMU-GM1 was established from a melanoma brain 
metastasis (section 4.1.2). Although PMP2 was also found expressed in the central 
nervous system (according to the Human Protein Atlas, section 3.1.12), it was not 
expressed in this metastasis originated from the brain (Figure 49), which therefore 
served as control cell line for further experiments. 
 
Figure 49: PMP2 is not expressed in cell line LMU-GM1. 
Expression of PMP2 and SOX10 was analyzed in cell line LMU-GM1. No signal 
for PMP2 protein could be detected. Cell line WM278 served as positive, β-Actin 
as loading control. An asterisk marks the specific PMP2 signal. 
 
Microscopically imaging revealed a change in cell number and morphology. After 96 
hours, cell number of PMP2-inhibited WM278 and WM239A cells was strongly 
decreased compared to control cells (Figure 50). Due to a slower proliferation rate, 
confluence of LMU-GM1 cells was less than in cell lines WM278 and WM239A. 
However, the overall cell number of LMU-GM1 was not affected by PMP2 inhibition. 
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Furthermore, PMP2-inhibited WM278 and WM239A cells tended to display prolonged 
protrusions. This change in morphology was not found for PMP2-negative LMU-GM1 
cells after PMP2-targeting siRNA transfection. 
 
Figure 50: Analysis of cell number and morphology after PMP2 inhibition. 
PMP2-positive WM278 and WM239A cells as well as PMP2-negative LMU-GM1 cells were transfected 
with siPMP2a, siPMP2b, siControl, or no siRNA. 96 hours later, cells were stained with the Diff-Quik 
staining solution and microscopical images were taken. Representative pictures of two independent 
experiments are shown. Scale bar = 200 µm. PMP2 inhibition reduced the cell number and caused 
prolonged cell protrusions in cell lines WM278 and WM239A, but not in cell line LMU-GM1.  
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Analysis of cell viability 24 to 120 hours after siRNA transfection demonstrated a 
considerably enhanced reduction in cell viability by PMP2 inhibition in cell lines WM278 
(Figure 51 a) and WM239A (Figure 51 b) in comparison to control cells. Ninety-six hours 
after siRNA transfection, cell viability of PMP2-inhibited WM278 cells was reduced down 
to 48.9% with siPMP2a and 72.5% with siPMP2b and in WM239A cells down to around 
63% by both PMP2-targeting siRNAs. In contrast, cell viability of LMU-GM1 cells was 
hardly affected by PMP2 inhibition (Figure 51 c). 
 
Figure 51: Analysis of cell viability, p21 expression, and caspase3 activation after PMP2 inhibition. 
Small interfering RNAs siPMP2a, siPMP2b, siControl, or no siRNA were transfected in PMP2-positive 
WM278 (a), WM239A (b), and PMP2-negative LMU-GM1 cells (c) and cell viability was determined every 
24 hours up to 120 hours after transfection. Mean ± SD of four independent experiments are shown. (d) 
P21 and caspase 3 were detected by immunoblotting 120 hours after siRNA transfection. While p21 level 
were increased in both cell lines with both PMP2-targeting siRNAs, caspase 3 activation (arrows) was 
only found for siPMP2b in cell line WM278. Detection of β-Actin served as loading control. 
Immunoblot analyses demonstrated an increase in p21 by siPMP2a and siPMP2b 
transfection compared to the control siRNA in both WM278 and WM239A, while 
caspase 3 was only activated by siPMP2b in cell line WM278 (Figure 51 d). A slight 
activation of caspase 3 was detected for siPMP2b- and siControl-transfected WM239A 
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cells. Thus, PMP2 inhibition seems to affect cell viability in PMP2-positive melanoma 
cells potentially by blocking cell cycle progression. 
4.9.2.3 Analysis of PMP2-mediated invasion after SOX10 inhibition 
Matrigel invasion assays with PMP2-inhibited compared to control WM278 cells showed 
a slight decrease in invasion that was only significant for siPMP2b (Figure 52). 
Figure 52: Matrigel invasion assay after 
PMP2 inhibition. 
WM278 cells were subjected to Matrigel 
invasion assays 72 hours after transfection with 
siPMP2a, siPMP2b, or siControl. Quantification 
of invaded cells is shown as mean ± SD of 7 
independent experiments. Invasion was 
significantly decreased after inhibition with 
siPMP2b (one-way ANOVA versus siControl; 
*P<0.05). Representative stained membranes 
after Matrigel invasion assay are shown. 
  
To analyze a contribution of PMP2 in SOX10-mediated cell invasion, WM278 were 
stably transfected with a vector for PMP2 overexpression (pLenti-PMP2) and a control 
vector (pLenti-Control), both containing a puromycin resistance gene as selection 
marker. SOX10 was inhibited in these cells by siRNA transfection (Figure 53 a). While 
SOX10 inhibition reduced PMP2 expression in control cells, it did not affect PMP2 
expression in the stably overexpressing cells. These cells were subjected to Matrigel 
invasion assays 24 hours after siRNA transfection (Figure 53 b). SOX10 inhibition 
significantly reduced invasion of the cells through the Matrigel layer as shown before 
(section 4.3.3, Figure 21) and this effect was observed in the control as well as in the 
PMP2-overexpressing cells.  
Furthermore, the invasion capacity of PMP2-overexpressing cells was significantly 
increased compared to control cells. However, overexpression of PMP2 in SOX10-
inhibited cells could not significantly increase the invasion compared to SOX10-inhibited 
control cells, although no significant change in invasion was found compared to cells 
transfected with the control siRNA and control vector. PMP2 overexpression had no 
impact on cell viability in this assay (Figure 53 c).  
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Thus, although PMP2 overexpression seems to enhance cell invasion, a direct effect of 
PMP2 on SOX10-mediated melanoma cell invasion could not be demonstrated.  
 
Figure 53: Invasion and cell viability of PMP2-overexpressing melanoma cells after SOX10 
inhibition. 
WM278 cells were transfected with vectors for stable overexpression of PMP (pLenti-PMP2) and a control 
vector (pLenti-control), selected with puromycin, and grown till complete confluence. (a) Twenty-four 
hours after transfection of siSOX10a or siControl (siCtrl), SOX10, PMP2, and β-Actin (loading control) 
were detected by immunoblotting. (b) Cells described in (a) were subjected to Matrigel invasion assays. 
Invaded cells per well are depicted as mean ± SD of five independent experiments. SOX10 inhibition 
significantly decreased cell invasion in pLenti-PMP2 and pLenti-Control cells, while PMP2 overexpression 
significantly increased invasion compared to control cells (*P<0.05, t-test). However, PMP2 
overexpression could not significantly increase melanoma cell invasion in SOX10-inhibited cells 
compared to control cells transfected with siSOX10a or siControl (P>0.05, t-test). Representative stained 
membranes after Matrigel invasion assay are shown below. (c) Cell viability of cells described in (a) is 
depicted. 
4.9.2.4 Effects of PMP2 overexpression on melanoma cell invasion 
To further investigate the influence of PMP2 on melanoma cell migration and invasion, 
experiments with PMP2 stable overexpression in a PMP2-negative melanoma cell line 
(WM3211) was carried out with vectors containing a puromycin resistance gene for 
selection. 
In order to specify the PMP2 functions in melanoma cells, mutated variants of PMP2 
were generated. A mutation of PMP2 at position 27 (L27D) prevents its binding to the 
cell membrane as demonstrated by Ruskamo et al. [219]. Furthermore, the three protein 
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residues that were shown to bind fatty acids [168] were mutated to R106E, R126E, 
Y128F and this mutant has been further on called Mut3. 
Analysis of mRNA expression after stable transfection of pLenti-PMP2, pLenti-PMP2 
L27D, and pLenti-PMP2 Mut3 in WM3211 cells demonstrated high expression levels of 
all PMP2 variants compared to cells stably transfected with a control plasmid (pLenti-
Control) or non-transfected cells (Figure 54). However, on protein level only the PMP2 
wild type- and the L27D mutant-variants could be detected. Apparently, the Mut3 
mutation resulted missing PMP2 protein translation or protein degradation. 
 
 
Stably overexpressing PMP2 wild type, L27D, Mut3, control and untreated WM3211 
cells were subjected to spheroid assays. Quantification of the invasion areas of the 
different cells showed significantly increased invasion of PMP2- and PMP2 L27D 
mutant-overexpressing cells compared to the PMP2 Mut3 mutant-overexpressing and 
control cells up to 4- or 2.5-fold, respectively (Figure 55 a). Representative pictures of 
spheroid assays with staining of calcein AM and EthD-1 are shown in Figure 55 b. No 
differences in staining of living and dead cells in the different groups were found.  
In conclusion, PMP2 overexpression promotes melanoma cell invasion. 
Figure 54: Stable expression of PMP2 wild type 
and mutants in cell line WM3211. 
The PMP2-negative cell line WM3211 was 
transfected with vectors for stable overexpression 
of PMP2 (pLenti-PMP2), the L27D mutant (pLenti-
PMP2 L27D), and the Mut3 mutant (pLenti-PMP2 
Mut3) as well as a control vector (pLenti-Control). 
Cells were selected with puromycin and grown till 
complete confluence. PMP2 expression was 
assessed in these cells as well as in untreated 
WM3211 cells on mRNA (mean ± SD of three 
independent experiments) and protein level. 
Expression of mRNA compared to protein shows 
that PMP2 or the L27D mutant of PMP2 were 
highly expressed while only mRNA expression 
could be detected for the Mut3 mutant. Numbers 
above the bars display mean mRNA values. 
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Figure 55: A three-dimensional invasion assay with PMP2 wild type- and mutant-overexpressing 
WM3211 melanoma cells. 
WM3211 cells were stably transfected with vectors for overexpression of PMP2 (pLenti-PMP2) or the 
mutated forms L27D (pLenti-PMP2 L27D) and Mut3 (pLenti-PMP2 Mut3) as well a control vector (pLenti-
Control). Together with untreated WM3211 cells, these cells were subjected to a three-dimensional 
spheroid assay. (a) The invasion area was determined 96 hours after cultivation on agar-coated wells and 
48 hours after embedding in collagen. The invasion area of untreated WM3211 cells was set to 1. Bars 
show mean ± SD of five independent experiments with 2 to 4 technical replicates each. Invasion area of 
PMP2 wild type- and PMP2 L27D-expressing cells was significantly increased compared to pLenti-
Control transfected cells (one-way ANOVA versus siControl, *P<0.0001). Invasion of PMP2 wild type-
expressing cells was significantly increased compared to PMP2 L27D-expressing cells (*P=0.0027; t-
test). (b) Representative pictures after LIVE/DEAD staining and fluorescence microscopy are shown. 
Scale bar = 100 µm. 
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4.10 Analysis of further SOX10 target genes 
SOX10 is essential at multiple stages of Schwann cell development as for their 
differentiation from NCCs and for the entry into promyelinating and myelinating stages 
[31], [69]. The transcriptional regulation of myelination includes several genes that are 
not only the major myelin genes, but also genes for lipid biosynthesis and genes that 
control cell cycle exit [263]. It is possible that these genes also display analogous 
functions in other cell types. Therefore, genes that are regulated by SOX10 in Schwann 
cells might be also involved in melanoma cell physiology.  
The regulation of the epidermal growth factor receptor ERBB3, which is essential for 
Schwann cell development and maintenance [33], by SOX10 in melanoma cells has 
already been shown in section 4.5. 
EGR2 has already been described as a common coregulator and also as a target gene 
of SOX10 in Schwann cells [82], [122], [211], [251], [258]. Cooperative regulation of 
PMP2 by EGR2 and SOX10 in melanoma cells has been verified in this study (section 
4.8.3). Results shown in Figure 44 indicated that SOX10 inhibition influences EGR2 
expression in cell line WM278. Considerably reduced mRNA expression of EGR2 after 
SOX10 inhibition was found in cell lines WM278 and WM1232 (Figure 56 b) and to a 
lesser extend in 1205Lu (Figure 56 c). 
A coordinated and balanced interaction between SOX10 and EDNRB is required for 
enterous nervous system and melanocyte development [253], [306]. Furthermore, it has 
been shown that SOX10 regulates EDNRB in human melanocytes [303]. A complex 
relationship between EDNRB and neurofibromin, which is mutated in neurofibromatosis 
type 1, has been suggested [58]. Neurofibromatosis type 1 is characterized by the 
development of Schwann cell-based tumors and skin hyper-pigmentation. Moreover, 
altered expression of EDNRB is related to brain metastases in patients and increases 
melanoma cell proliferation and spontaneous metastasis in the central nervous system 
[55]. It further seems to be specifically required for the final differentiation step of 
melanocytes but also for de-differentiation of mature melanocytes as well as for 
melanoma progression, survival and metastasis [220]. Downregulation of EDNRB was 
found in all three investigated melanoma cell lines after SOX10 inhibition (Figure 56 a-c, 
right panel). In conclusion, SOX10 regulation of genes that are critical in Schwann cell 
development and homeostasis as well as in other cell types of the nervous system can 
be found in melanoma cells and seems to be critical for melanoma cell physiology. 
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Figure 56: Expression of EGR2 and EDNRB after SOX10 inhibition in melanoma cells. 
SOX10, EGR2, and EDNRB expression was assessed on mRNA level 48 hours after transfection of 
siSOX10a, siSOX10b, or siControl in WM278 (a), WM1232 (b), and 1205Lu (c) in three independent 
experiments (mean ± SD). Downregulation of EDNRB mRNA was found in all SOX10-inhibited melanoma 
cells while strong downregulation of EGR2 was found in cell lines WM278 and WM1232 and to a lesser 
extent in cell line 1205Lu.  
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5 Discussion 
Within recent years, the transcription factor SOX10 has been increasingly regarded to 
be an important player in melanoma and got into the focus of melanoma research by 
different groups. In this study SOX10 expression, functional, and binding studies have 
been performed to more deeply characterize the role of SOX10 in melanoma and led to 
the discovery of yet undescribed target genes.  
5.1 Expression of SOX9 and SOX10 in human cell lines, tissues, and 
cancer 
Expression of SOX10 as well as the closely related SoxE factor SOX9 were analyzed in 
fibroblasts, melanocytes and melanoma cells both from established and short term 
cultures. SOX10 expression was absent in fibroblasts while it was found expressed in 
melanocytes from three different donors, in 8 of 12 established melanoma cell lines, and 
in 2 of 7 short term-cultured melanoma cells (sections 4.1.1 and 0). SOX10 expression 
levels in melanocytes were considerably higher compared to melanoma cells and 
differed in melanoma cell lines. Moreover, SOX10 expression was more common in 
metastatic cell lines than in lines from primary tumors.  
Notwithstanding, SOX9 expression varied throughout the different melanoma cell lines 
and was also detected in fibroblasts and melanocytes although in smaller amounts. In a 
subset of melanoma cell lines (8/12) SOX9 and SOX10 mRNA expression levels 
correlated inversely (section 4.1.1). 
Cook et al. demonstrated that SOX10 is highly expressed in unpigmented melanocyte 
precursors (melanoblasts) and melanoma cells but downregulated in differentiated 
melanocytes in vitro although it seems to be transcriptionally active in all these cell 
types [52]. SOX10-positive IHC staining in melanocytes, benign nevi, giant congenital 
nevi as well as in primary and metastatic melanoma tissues was found in previous 
studies [4], [8], [49], [72], [176], [178], [188], [239], [243]. Broad SOX10 expression with 
varying protein levels in melanoma cell lines has been described before [52], [72], [173], 
[238]. 
Some studies showed that the intensity of SOX10 expression inversely correlates with 
the malignant potential of nevi, primary, invasive, and metastatic melanoma [4], [243]. In 
contrast, other groups found an increase of SOX10 expression from benign nevi to 
metastatic melanoma [8], [173], [238]. Moreover, strong SOX10 expression in 
melanoma tissues correlated with poor patient’s prognosis [4], [49]. 
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The inconsistent SOX10 expression data in melanocytes and melanoma cells may be 
caused by different culture conditions in vitro and usage of different antibodies in situ. 
Nevertheless, all data confirm that SOX10 is a marker of the melanocytic lineage and 
commonly expressed in melanoma. 
According to the Human Protein Atlas (section 3.1.12), SOX10 protein is little expressed 
in the heart muscle, moderately expressed in the cerebral cortex, cerebellum, and soft 
tissue, while it is highly expressed in the salivary gland, hippocampus, lateral ventricle, 
and skin. In cancer tissues, distinct SOX10 nuclear immunoreactivity was observed in 
melanomas and gliomas. Elevated SOX10 expression was also found in frequently 
metastatic and aggressive breast cancers [62]. 
In general, SOX10 has been described as a sensitive and specific marker for 
Schwannian and melanocytic neoplasms as well as for peripheral nerve sheath tumors 
[176], [178], [188], [296]. Due to its widespread expression, SOX10 is not useful to 
differentiate between benign and malignant lesions in these tumors [178]. 
SOX9 has been detected in melanocytes in vitro and in vivo as well as in melanoma cell 
lines and melanoma tissues [8], [44], [52], [137], [194]. Shakhova et al. suggested that 
SOX9 acts as a repressor of SOX10 and its expression was absent in nevi and 
melanocytes as well as in SOX10-positive melanoma cells [238]. Cheng et al. found 
significantly elevated SOX9 expression levels in melanoma cell lines with an invasive 
phenotype and reduced levels in cell lines with a proliferative phenotype [44]. 
Furthermore, they described that strong SOX9 expression correlated with poor patient’s 
prognosis in vivo. In contrast, Passeron et al. demonstrated that SOX9 is down-
regulated in more aggressive melanomas and that SOX9 overexpression in melanoma 
cell lines inhibited tumorigenicity both in mice and in human ex vivo melanoma models 
[195]. Again, these differences might be caused by different model systems or antibody 
discrepancies. Problems with the specificity of SOX9 antibodies were described by 
Shakhova et al. [238] and in this study. 
According to the Human Protein Atlas (section 3.1.12), nuclear SOX9 protein 
expression can be found in several tissues with the highest staining patterns in tissues 
of liver, pancreas, and the digestive tract, in prostate, seminal vesicle, uterine cervix, 
endometrium, fallopian tube, tonsil, thyroid gland, nasopharynx, bronchus, and skin. 
Cancer tissues displayed moderate to strong nuclear SOX9 staining with highest 
positive rates in breast, cervical, colorectal, head and neck, pancreatic, stomach cancer, 
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and glioma. A negative prognostic role of SOX9 was suggested in these cancer types 
as well as in urothelial and ovarian cancers [41], [158], [171], [182], [282], [283]. 
In IHC stainings, co-expression of SOX9 and SOX10 was found in nevi, primary 
melanomas, and metastases [8], [72]. Also some melanoma cell lines do express both 
SoxE transcription factors [52], [72]. In this study, co-expression of SOX9 and SOX10 
was found in a subset of melanoma cell lines although the majority showed an inverse 
expression pattern for SOX9 and SOX10 (section 4.1.1). A mutual exclusive expression 
pattern for SOX9 and SOX10 in melanoma cell lines has also been shown in previous 
studies [44], [238] suggesting a negative cross-regulatory feedback loop between SOX9 
and SOX10. 
5.2 SOX9 and SOX10 inhibition in melanoma cells and mutual regulation 
In this study SOX9 and SOX10 were inhibited via RNA interference. To control for 
possible off-target effects, two different siRNAs specifically targeting SOX9 or SOX10 
were used. A control siRNA that does not interfere with the human transcriptome was 
included in the experiments. All SOX9- and SOX10-targeting siRNAs effectively 
inhibited SOX9 or SOX10, respectively (section 4.2). Furthermore, SOX10 mRNA levels 
were found down-regulated by SOX9 inhibition, while SOX9 mRNA levels slightly 
increased upon SOX10 inhibition. On protein level, both SOX9 and SOX10 were found 
downregulated by SOX10 or SOX9 inhibition, and vice versa. These data indicate that 
SOX9 might influence SOX10 on a transcriptional level and SOX10 might influence 
SOX9 on a post-transcriptional level. 
Previous studies in chick, xenopus, and zebrafish suggested that the most important 
contribution of SOX9 during embryonic development is its ability to induce SOX10 
expression in the neural crest in general and specifically in melanocytes and ocular 
glands [5], [45]–[47], [301].  
However, a recent study by Shakhova et al. has shown that SOX9 and SOX10 are 
functional antagonistic regulators of melanoma development [238]. Next to opposing 
expression of these two factors, Shakhova et al. found downregulation of SOX10 by 
SOX9 overexpression and increase of SOX9 by SOX10 knockdown in melanoma cells. 
Furthermore, SOX9 overexpression led to cell cycle arrest, apoptosis, and a gene 
expression profile shared by melanoma cells with reduced SOX10 expression [238]. In 
addition, it has been shown that in SOX10-deficient mice, deletion of SOX9 rescued the 
hypopigmentation phenotype. On molecular level, they found SOX9 binding at the 
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SOX10 promoter, generating a negative feedback loop. Thus, Shakhova et al. 
hypothesize that SOX9 is not required for normal melanocyte stem cell function, the 
formation of hyperplastic lesions, and melanoma initiation but rather plays an anti-
tumorigenic role in melanocytes. These data are consistent with a previous study [195]. 
However, SOX9 was reduced by SOX10 inhibition in the present study (section 4.2). 
Moreover, SOX10 was not downregulated by SOX9 overexpression and SOX10 
overexpression did not affect SOX9 levels (section 4.6, Figure 36). These differences 
may be attributed to the heterogeneity of melanoma cell lines or different expression 
levels investigated in these specific settings. 
In contrast to the hypothesis that SOX9 and SOX10 may function oppositionally, 
redundant functions in gene regulation of both factors have been described in 
melanoma cells and oligodendrocyte precursors [70], [72]. Furthermore, SOX9 - just as 
SOX10 - is able to regulate MITF, DCT, and tyrosinase expression in neonatal and adult 
melanocytes [194]. The analysis of several enhancers regulating SOX10 expression in 
neural crest derivatives indicated that spatial and temporal control of SOX10 is induced 
and maintained by SOX9 and SOX10 in a regulatory loop [292]. 
In conclusion, the impact of SOX9 on SOX10 expression in melanoma and vice versa is 
not clear. Previous and current data point to a mutual regulation of both transcription 
factors. Probably, both factors can act together or have distinct roles in gene regulation, 
depending on the cellular context.  
In general, oncogenic functions in melanoma have been more related to SOX10 than to 
SOX9 as SOX10 has been suggested to be required for melanoma initiation, formation, 
and progression as well as for melanoma cell survival [53], [239]. 
5.3 Influence of SOX10 on melanoma cell survival and cell death 
Results of this study demonstrate that SOX10 inhibition in different melanoma cell lines 
leads to G1 cell cycle arrest, considerably decreases cell viability, and induces cell 
death (sections 4.3.1 and 4.3.2). Enhanced activation of effector caspase 3 as well as 
decrease of anti-apoptotic Bcl-2 and increase of pro-apoptotic Bak and Bax in SOX10-
inhibited cells indicated an onset of intrinsic apoptosis after SOX10 inhibition. Moreover, 
SOX10 inhibition caused DNA damage. 
An essential role of SOX10 in melanoma cell proliferation and survival has been 
described before [53], [239]. Both studies observed a cell cycle arrest in G1 by SOX10 
inhibition in different melanoma cell lines with similar kinetics compared to the present 
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study. Cronin et al. suggested that the G1 arrest upon SOX10 inhibition seems not to be 
related to p53 but rather mediated through RB-E2F transcription factor 1 signaling [53]. 
Like in the present study, Cronin et al. detected a decrease in phospho-RB and an 
increase in p21 after SOX10 inhibition, though in that study cell cycle arrest after 
SOX10 inhibition resulted in cell senescence but not apoptosis.  
Comparable to the present study, Shakhova et al. observed apoptosis and increased 
caspase 3 activation upon SOX10 inhibition in melanoma cells as well as an 
upregulation of apoptotic and mesectodermal differentiation gene clusters [239]. 
Furthermore, studies that analyzed mutations in the SOX10 gene in primary and 
metastatic melanoma samples found only low mutation frequencies suggesting that 
melanoma cells favor the retention of SOX10 wild type functions [53], [54], [110]. 
Sequencing of cDNA from the three cell lines (WM278, WM1232, and 1205Lu) used for 
SOX10 functional investigations in this study has been performed. Only one silent 
mutation (position 927 according to translation start site, T -> C, both encoding 
histidine) was found in cell line 1205Lu. 
All these data highlight a pivotal role of SOX10 in melanoma cell survival and 
proliferation. Likewise, SOX10 mutations cause apoptosis in NCCs leading to severe 
developmental defects as hypopigmentation, hearing deficits, aganglionosis, 
myelinopathies, and block generation of non-neuronal glial cells [64], [116], [125], [246]–
[248]. Therefore, SOX10 seems to be a general pro-survival factor for NCC derivatives 
and melanoma cells. 
5.4 Influence of SOX10 on melanoma cell invasion 
Expression of SOX10 during embryonic development, which is initiated after emigration 
of NCCs from the neural tube, lasts during their migration along the dorsolateral 
pathway. This indicates a specific role of SOX10 in migration and invasion. Previous 
studies with mouse and zebrafish models indicated that SOX10 mediates enteric NCC 
adhesion and migration as well as the migration of oligodendrocyte and melanocyte 
precursors [64], [65], [70], [125], [248], [253], [286]. 
As the inhibition of SOX10 impaired the proper formation of melanoma spheroids 
(section 4.3.3, Figure 22 and chapter 7, Figure S3), the influence of SOX10 on integrin 
expression of various α- and β-subunits has been examined. Integrins of the α- and β-
subunits form heterodimers and the different subsets are responsible for establishing 
cell-cell- and cell-matrix-contacts.  
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A synergistic interaction of SOX10 with ITGB1, which controls enteric NCC migration, 
has been shown before [286]. A considerable decrease of ITGA4 and ITGB3 was found 
in cell line WM278 after SOX10 inhibition, while ITGA3 and ITGB1 were upregulated in 
all three analyzed cell lines (chapter 7, Figure S2). Dysregulation of single integrin 
subunits in comparison between melanoma cells and melanocytes was found in 
different studies and, e.g., the alpha V beta 3 variant was shown to strongly support 
melanoma metastasis [67], [141]. Therefore, it is possible that altered integrin 
expression contributes to the reduced cell-cell adhesion and migratory phenotype after 
SOX10 inhibition. 
Furthermore, SOX10 was shown to directly regulate the gap junction proteins connexin 
32 [21] and connexin 47 [229] in oligodendrocytes. Therefore, it seems that SOX10 is 
able to regulate gap junction proteins, which might be also relevant for the melanoma 
spheroid formation. However, expression of connexin 32 and connexin 47 in melanoma 
cells has not been found in this study (data not shown). 
According to LIVE/DEAD staining, the early impaired spheroid formation of SOX10-
inhibited melanoma cells seems not to be caused by increased cell death (chapter 7, 
Figure S3). 
An influence of SOX10 on melanoma cell migration has been suggested previously [4], 
[235]. Migration-examining experiments have been performed in transwell assays 
against a nutrition gradient or conditioned medium. Agnarsdóttir et al. found both an 
increased (WM793) and a decreased (WM115) melanoma cell migration capacity upon 
SOX10 inhibition via siRNA [4] while Seong et al. demonstrated a 75% decrease in 
migration in murine B16 melanoma cells [235]. In the present study, reduced invasion 
capacity upon SOX10 inhibition was found in all investigated human melanoma cell 
lines in a Matrigel invasion assay (section 4.3.3, Figure 21). The range was similar as 
described by Seong et al., with up to 75% non-invading melanoma cells [235]. The 
onset of impaired cell invasion occurred at an earlier time point than the onset of cell 
death after SOX10 inhibition in vitro. Moreover, blocking cell death did not affect the 
reduced invasion capacity upon SOX10 inhibition (chapter 7, Figure S3).  
Reduced invasiveness into the surrounding host tissue was also observed in a chick 
embryo model in this study (section 4.3.3, Figure 23). Tumor sizes and proliferative 
activity did not differ between SOX10-inhibited and control melanoma nodules. This 
sustained survival as opposed to the in vitro data may be caused by the chick 
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microenvironment, with embryonic growth factors counteracting cell cycle arrest and 
apoptosis. 
Moreover, Matrigel invasion and cell viability experiments with transient transfection of  
vectors for SOX9 and SOX10 overexpression in cell lines WM3211, WM1366 (SOX10 
negative), and 1205Lu (moderate SOX10 expression) indicated that significantly 
increased melanoma cell invasion was specifically related to SOX10 but not SOX9 
overexpression (section 4.6). These findings were also supported by a three-
dimensional invasion model. Cell viability has not been considerably influenced by 
SOX9 or SOX10 overexpression. In the end, results mentioned above provide evidence 
for a pivotal role of SOX10 in melanoma cell invasion. 
Hoek et al. found SOX10 to be highly expressed in proliferative and weakly in 
metastatic melanoma cells [112]. They described three cohorts of melanoma cell lines: 
cohort A characterized by highly proliferative and weakly metastatic potential, cohort B 
by moderate proliferative and metastatic potential, and cohort C by weakly proliferative 
and highly metastatic potential. SOX10 was found to be highly expressed in cohort A 
while it was downregulated in cohort C. The cell lines WM239A (cohort A), WM35 
(cohort B), WM278, WM3211, WM1366, WM793, and 1205Lu (cohort C), respectively, 
have also been investigated in this study. Moderate and high SOX10 expression levels 
were found in WM239A and WM35, respectively (section 4.1.1). In contrast, SOX10 
was highly expressed in WM278 and WM793, moderately in 1205Lu, and not at all 
expressed in WM3211 and WM1366. Also other studies associated SOX10 expression 
with a proliferative but non-invasive melanoma cell phenotype [44], [238]. 
Notwithstanding, the correlation of high SOX10 expression with a highly proliferative 
and weak metastatic potential as well as low SOX10 expression with a low proliferative 
and highly metastatic potential could not be reproduced in this study. 
5.5 Target genes of SOX10 
5.5.1 Previously identified SOX10 target genes 
Several known target genes of SOX10 have been described that are related to survival 
and migration of NCCs and melanoma cells. Regulation of the key transcription factor 
for melanocyte specification MITF by SOX10 has been intensively studied before, 
demonstrating direct binding of SOX10 to the M-MITF promoter and an enhancer 
element [22], [152], [200], [206], [275], [285]. Together, SOX10 and MITF cooperate in 
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activating genes for melanogenesis [164], [207] and the MET promoter in melanoma 
[173], which drives migration, invasion, resistance to apoptosis, and tumor cell growth. 
The role of MITF in the melanocyte lineage extends well beyond promoting melanoblast 
survival. It controls expression of differentiation-associated genes required for 
melanosome biogenesis and intracellular transport [43], as well as metabolism [99], and 
also suppresses melanoma senescence [84]. Importantly, MITF plays both a positive 
and negative role in cell proliferation, with the pro-proliferative activity of MITF causing it 
to be termed a lineage-survival oncogene [80]. This paradox may be explained by the 
rheostat model [39]. On the one hand, low levels of functional MITF promote G1 arrest 
in melanocyte stem cells or invasiveness in melanoma stem-like cells. On the other 
hand, high MITF expression promotes proliferation, or at elevated levels, a G1 arrest 
associated with differentiation. Therefore, proliferation is blocked when MITF activity is 
too high or too low, and cell division is stimulated at a specific MITF expression level. 
The rheostat model for MITF functions is useful for the prediction that up- or 
downregulation of MITF expression could promote switching between phenotypic states 
that are important for melanocyte development and melanoma: invasive and stem-like, 
proliferative, and differentiated [111]. Similarly, it is possible that the effect of SOX10 on 
melanocyte survival and differentiation as well as on melanoma initiation and 
progression is dependent on its cellular level. In this study, levels of SOX10 expression 
were found to be significantly increased in melanocytes compared to melanoma cell 
lines (section 4.1.1, Figure 6). 
The epidermal growth factor receptor ERBB3 has been shown to be required for the 
development of NCCs and derivatives such as Schwann cells [33]. Furthermore, it has 
been demonstrated that ERBB3 is also relevant for Schwann cell and melanoma 
proliferation and migration [11], [37], [166]. SOX10 is a key regulator in differentiation of 
peripheral glia cells. It regulates ERBB3 and binds to an ERBB3 enhancer element [31], 
[36], [208]. Both SOX10 and ERBB3 were found to be highly expressed in pilocytic 
astrocytomas and radiation-induced glioblastomas, suggesting that SOX10-mediated 
overexpression of ERBB3 may drive growth in these tumors [3], [60]. 
Downregulation of M-MITF and ERBB3 upon SOX10 inhibition and co-expression of 
SOX10 and MITF as well as SOX10 and ERBB3 were found in most investigated 
human melanoma cell lines and in all investigated human melanocytes in this study 
(section 4.5). 
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Therefore, several known target genes of SOX10 might be critical for SOX10 functions 
in melanoma survival and invasion. However, in SOX10 transiently overexpressing 
melanoma cell lines, no increase of M-MITF or ERBB3 expression could be detected 
(section 4.6, Figure 36).  
5.5.2 Melanoma inhibitory activity (MIA) 
SOX10 executes ERBB3- and MITF-independent functions, for instance in the 
melanocyte lineage and in melanoma cells [31], [53]. To examine potential target genes 
that might mediate the effect of SOX10 on melanoma cell invasion, genes that are 
migration-related and expressed in melanoma cells but not in melanocytes got into 
focus of this study. Literature research pointed to the secreted protein MIA, which is 
relevant for melanoma cell migration [205]. On a cellular level, MIA is secreted at the 
rear pole of migrating melanoma cells and directly interacts with cell adhesion receptors 
(integrins) and extracellular matrix molecules (fibronectins) promoting cell migration and 
invasion [10], [28], [254]. According to the Human Protein Atlas (section 3.1.12), MIA 
expression on protein level was found in a variety of tissues while high expression in 
cancers was only found in melanoma. MIA is an established melanoma marker and 
correlates with melanoma progression in vivo, although it is absent in melanocytes [26], 
[198]. MIA, also known as cartilage-derived retinoic acid–sensitive protein, is not only 
crucial for melanoma cell migration but also for chondrogenesis and it has been shown 
to be regulated by SOX9 in chondrocytes [299]. Data of this study revealed that SOX9 
but also SOX10 inhibition can reduce MIA expression in melanoma cell lines (section 
4.4.1, Figure 24). However, expression data clearly demonstrate a co-expression of 
SOX10 and MIA but not with SOX9 in melanoma cells on mRNA and protein level. 
Confirming previous publications MIA was not expressed in melanocytes from different 
donors in this study. Together, these data indicate a relevant function of SOX10 but not 
of SOX9 for MIA expression in melanoma cells. 
As SOX10 but not MIA is abundantly expressed in melanocytes, binding of 
transcriptional repressors at the MIA promoter in melanocytes or the presence of 
specific coregulators of SOX10 in melanoma cells might contribute to lineage-specific 
MIA expression. In silico binding motive analyses suggested combinatory binding of 
SOX10 and PAX6, NFκB, or EGR2 at the MIA promoter or upstream and downstream 
regions (section 4.4.3, Figure 31). While no MIA regulation was found for the NFκB 
subunit p65 or EGR2, PAX6 inhibition was able to reduce MIA expression and promoter 
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activity. However, no increase in promoter activity was found upon PAX6 
overexpression and combined overexpression of PAX6 and SOX10 could not further 
enhance MIA promoter activity compared to SOX10 overexpression alone, excluding 
PAX6 as a coactivator of SOX10 in MIA promoter regulation. 
The transcription factors NFκB and HMG1 were described as activators of MIA in a 
previous study [203]. However, no correlation of the NFκB subunit p65 or HMG1 and 
MIA expression were found in melanoma cells (section 4.4.1, Figure 25). 
The transcriptional repressor CtBP1 was suggested to be critical for MIA repression in 
melanocytes [204]. Indeed, significantly higher expression of CtBP1 was found in 
melanocytes compared to melanoma cells in this study, suggesting that absent 
expression of MIA in melanocytes might be mediated by enhanced expression and 
promoter binding of CtBP1 (section 4.4.3). 
Moreover, it is possible that epigenetic changes in melanocytes and melanoma cells 
may have an impact on lineage-specific MIA expression. Altered SOX10 binding to 
melanocyte promoter regions has already been related to epigenetic differences [75]. 
No CpG islands were identified when analyzing the MIA promoter region as well as 
1105 bp before the promoter start site and 530 bp after the start ATG using different 
algorithms (EMBOSS Cpgplot and CpG Island searcher, section 3.1.12; parameters: 
observed GpC/expected GpC > 0.65, percentage GC > 55%, length > 200, and 
distance to next island > 100 bp), excluding DNA methylation but not histone 
acetylation/deacetylation from epigenetically MIA promoter regulation. 
Taken together, these data suggest that absence of MIA in melanocytes, even though 
SOX10 is highly expressed, might be related to the presence of transcriptional 
repressors. 
Early downregulation of MIA expression by SOX10 inhibition suggested a direct 
regulation of MIA by SOX10. Direct binding of SOX10 to a specific MIA promoter region 
was shown by reporter and ChIP assays (section 4.4.2). Moreover, two adjacent SOX 
binding sequences were identified that were crucial for MIA full-length promoter activity 
and seemed to be bound by SOX10 in a multimeric pattern. SoxE proteins are 
monomers in solution but they can form dimers by binding to sites on DNA in close 
proximity [289]. In case of SOX10, dimeric binding to such adjacent sites in the MPZ 
promoter has been shown to be important for the transcriptional function of SOX10 
[228]. 
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Interestingly, SOX9 seems to activate the same SOX consensus site in the cartilage-
derived retinoic acid–sensitive protein promoter, which is equivalent to the SOX10 
binding site in the MIA promoter (binding site J9) [299]. Therefore, this might represent 
a common binding site for SOX9 and SOX10. 
When comparing results of the MIA promoter deletion constructs with the mutational 
analyses (section 4.4.2, Figure 27), it is obvious that deletion constructs shorter than 
275 bp retained SOX10 responsiveness, although potential SOX binding sites within 
this area (sites G1/G2, J5, G3/J6) turned out to be not relevant for MIA promoter 
activity. Previous studies revealed a most active cis-regulatory element between -210 
and -181 bp that activates transcription specifically in malignant but not in benign 
melanocytes [86]. This element contains a highly conserved region in comparison of the 
human and the murine promoter. Thus, it is possible that other, still unknown, 
transcription factors regulated by SOX10 alter MIA expression by binding to this area. 
As a consequence, SOX10 may regulate MIA directly as well as indirectly by regulation 
of factors that bind to the proximal MIA promoter region. 
SOX10-dependent upregulation of MIA was only found in the MIA-positive melanoma 
cell line 1205Lu but not in the MIA-negative cell lines WM3211 and WM1366 (section 
4.6, Figure 36). As no increased expression of CtBP1 was found in WM3211 and 
WM1366 (section 4.4.3, Figure 30), it is possible that other repressors or missing 
coactivators can prohibit MIA expression in these melanoma cell lines. An elegant 
strategy to identify such coregulators of SOX10 in melanocytes and melanoma cells 
would be a co-immunoprecipitation with SOX10-specific and control antibodies followed 
by quantitative mass spectrometry. However, this approach has not been further 
pursued as the focus of this study was to discover further SOX10 target genes in 
melanoma. 
The importance of MIA in mediating the pro-invasive effect of SOX10 was demonstrated 
in a rescue experiment (section 4.4.4). Here, MIA overexpression in SOX10-inhibited 
melanoma cells restored the invasion capacity of these cells. However, invasion was 
not increased by MIA overexpression in control cells with high endogenous MIA levels. 
It is likely that extensive amounts of MIA may even reverse its the pro-invasive effects, 
possibly by inhibiting adhesion as shown previously upon exposure to exogenous MIA 
in vitro [17] or by reducing cell viability, which is indicated in Figure 33 section 4.4.4. 
Thus, the results of this study suggest that activation of MIA by SOX10 is a crucial event 
in melanoma progression. Reduced migration in B16 melanoma cells has been 
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attributed to known SOX10 target genes, such as MITF or MC1R [235]. Both have been 
shown to independently regulate melanoma cell migration but the direct correlation to 
SOX10 is missing and MITF has not been found upregulated in cell lines where SOX10 
overexpression enhanced the invasive capacity in this study (section 4.6). 
Notwithstanding, as MIA overexpression in SOX10-inhibited melanoma cells did not 
completely restore their invasion capacity (section 4.4.4, Figure 32) the involvement of 
further SOX10 target genes cannot be excluded. 
5.5.3 Peripheral myelin protein 2 (PMP2) 
An elegant and novel tool to characterize gene expression at a specific time-point is 
RNA sequencing also termed whole transcriptome shotgun sequencing. It is a next 
generation sequencing method in which mRNA of tissues or cells in specific states is 
purified, reverse transcribed in cDNA, and used for library generation including specific 
bar labeling. With these labels several transcriptomes can be analyzed in one 
sequencing cycle. In this study, sequencing was performed with the Illumina Genome 
Analyzer IIx. Two rounds of RNA sequencing were performed, one without and one 
including DNA digestion after mRNA purification. The analysis was performed with 
SOX10 overexpressing and control 1205Lu cells in biological triplicates. The 
significantly regulated genes by SOX10 overexpression were KLF10, NR1D1, H1FX-
AS1, PPP1R15A, PMP2, TIPARP, FTL, RPL27A, and GH1 (section 4.7). Some of these 
factors, i.e., KLF10, NR1D1, PPP1R15A, and TIPARP have been related to 
malignancies before [87], [135], [260], [284].  
As generally regulated factors should be identified, the 
expression of these genes was analyzed in three different 
melanoma cell lines after SOX10 overexpression or control 
transfection by qRT-PCR. Comparing the log2-fold 
changes, the patterns of mRNA expression were most 
similar comparing SOX10 and PMP2 (section 4.7, Figure 
38 and Figure 39). PMP2 expression was substantially 
increased in SOX10-overexpressing cells. 
PMP2 is a small (14.9 kDa) fatty acid binding protein 
(FABP) that is predominantly present in the peripheral 
nervous system’s myelin sheath and is necessary for its 
composition [104], [105]. It is a candidate autoantigene in 
Figure 57: Structure of PMP2 
predicted using the 
Orientation of Proteins in 
Membranes server according 
to Han et al. [96]. 
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the peripheral autoimmune neuropathy Guillain Barré syndrome [170]. Its structure 
forms a compact 10-stranded up-and-down β-barrel that can encapsulate a fatty acid 
molecule [123]. A predicted structure of PMP2 is shown in Figure 57. The helical lid 
segment of PMP2 is partially embedded in the membrane and another membrane-
binding site was suggested to be on the opposite site of the protein. 
The myelin sheath is a unique biological membrane that is essential for the 
development and function of the vertebrate nervous system. It contributes to a 100-fold 
amplification of the nerve impulse along the axon by acting as an isolator and by 
directing the localization of neuronal ion channels to the nodes of Ranvier. The 
myelination process includes a myelinating glial cell that wraps its differentiated plasma 
membrane dozens of times tightly around selected axons. This process requires 
coordinated membrane synthesis, compaction, and maintenance. Myelin-specific 
proteins play a central role in all these processes and are highly abundant in the myelin 
sheath [96]. Many of them are cell adhesion molecules of the immunoglobulin family 
type I transmembrane proteins, such as MPZ. These proteins can mediate extracellular 
interactions between the successive layers of myelin and the neuronal plasma 
membrane. MBP and PMP2 are the only two non-transmembrane proteins that are 
present in high abundance in the region of compact myelin. They are both positively 
charged and this biochemical property facilitates their binding to the negatively charged 
inner leaflet of the myelin membrane. Both are localized at the cytoplasmic position of 
two consecutive layers of the myelin membrane and were shown to act synergistically in 
the compaction and maintenance of the multilayered myelin membrane [262]. It was 
shown that PMP2 can stack membrane bilayers and affect lipid bilayer dynamics [132], 
[133], [168], [262]. In addition to its function on the integrity of the myelin multilayer, it 
has also been suggested to be important for lipid transport to and from the membrane.  
PMP2 mRNA was also found highly expressed in the cerebral cortex according to the 
Human Protein Atlas (section 3.1.12). Interestingly, PMP2 and SOX10 were found 
upregulated in dermal Schwannomas compared to other cutaneous neoplasms of 
peripheral nerve sheath origin [241]. Strikingly, SOX10 is present in both myelinating 
glial cell populations, which are Schwann cells and oligodendrocytes, throughout 
development and after terminal differentiation [139]. SOX10 is required for myelination 
in both cell types [31], [256]. In Schwann cells, SOX10 directly activates the 
transcription factor EGR2 [82]. Together they activate myelin gene enhancers as MPZ, 
PMP-22, MBP, and myelin-associated glycoprotein (MAG) [148], [251].  
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In this study, PMP2 was only found specifically expressed on mRNA and protein level in 
two melanoma cell lines (WM278 and WM239A) out of 13 (sections 4.9.1 and 4.9.2.2). 
The mRNA expression of PMP2 varied highly in melanoma cells and also moderate 
mRNA expression was found in melanocytes.  
PMP2 mRNA expression was strongly reduced upon SOX10 inhibition in all investigated 
melanoma cell lines but reduction on protein level was only found in cell lines WM278 
and WM239A (section 4.8.1, Figure 41 and section 4.9.1, Figure 46). Although SOX10 
overexpression was sufficient to increase PMP2 protein expression in WM278 cells and 
although its mRNA levels were considerably elevated upon SOX10 overexpression, no 
induced or increased PMP2 protein expression was found in cell lines WM3211, 
WM1366, and 1205Lu (section 4.8.1, Figure 42). This discrepancy might be explained 
due to a substantial role for regulatory processes occurring after mRNA transcription 
[278]. Several possible events can restrict PMP2 expression on protein level. In 
mammalian cells, mRNA is produced at a much lower rate than proteins, which means 
two copies of a specific mRNA per hour correlates with dozens of copies of the 
according protein of mRNA per hour. The stability of mRNA is less than that of proteins 
with 2.6-7 hours versus about 46 hours, respectively. Therefore it is possible that the 
PMP2 mRNA is very unstable and a very high amount of mRNA production (as it is the 
case for cell lines WM278 and WM239A) would be necessary for PMP2 protein 
expression. Strikingly, PMP2 ectopic overexpression in the PMP2-negative cell line 
WM3211, which generated high amounts of mRNA, led to strong PMP2 expression on 
protein level (section 4.9.2.4, Figure 54). Regarding the fact that PMP2 mRNA was 
measured in several melanoma cell lines and SOX10 regulation of PMP2 expression 
was also found in these cells (4.8.1), it is possible that cell lines expressing PMP2 
mRNA but not PMP2 protein might miss several specific regulators for PMP2 translation 
or modifications that affect protein stability. Differential regulation of post-transcription 
(RNA processing, alternative splicing or differential splicing, regulatory elements in 5’ 
UTR, or depletion of ternary complexes), translation, and protein degradation together 
with protein modifications could contribute to absent PMP2 protein. Furthermore, the 
presence of micro RNAs - which is certainly differing between the different cell lines - 
could alter protein translation. 
Moreover, PMP2 expression might be regulated epigenetically. The PMP2 promoter 
region as well as 1023 bp upstream of the promoter and 1049 bp downstream were 
analyzed by two different softwares for identification of CpG islands (EMBOSS Cpgplot 
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and CpG Island searcher, section 3.1.12). An island was defined with the following 
parameters: observed GpC/expected GpC > 0.65, percentage GC > 55%, length > 200, 
and distance to next island > 100 bp. As no CpG islands were found DNA methylation 
can be excluded as a potential epigenetic regulatory mechanism for PMP2 expression.  
Not only PMP2 expression but also expression of other SOX10-regulated myelin 
proteins, i.e., MPZ and PLP1, was found in melanocytes and melanoma cell lines 
(section 4.9.1, Figure 47). Strikingly, MPZ and PLP1 mRNA levels were found 
substantially elevated in WM278 cells compared to other melanoma cells. PLP1 mRNA 
levels were also found elevated in WM239A cells. Thus, the restricted expression of 
myelin proteins in some melanoma cell lines seems to be a cell line-specific feature. 
The VGP cell lines WM278 derived from a nodular melanoma stage IV 
(http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-vgp) 
while WM239A were established from a lymph node metastasis [293], which does not 
indicate that the specific expression of myelin proteins in these cell lines is related to 
their original tissue microenvironment. Nevertheless, the expression of myelin proteins 
in melanoma cells could be a forecast where the cells might preferentially metastasize 
according to the seed and soil hypothesis of cancer pathogenesis [68], [193]. Hereby, 
the term “seed” is referred to certain tumor cells that display affinity for the milieu of 
certain organs, denominated as “soil”. 
Reed et al. [210] demonstrated that Schwann cell-resembling melanocytic nevus cells 
express proteins that define the earliest stages of Schwann cell development, i.e., p75, 
neural cell adhesion molecule (N-CAM), and growth-associated phosphoprotein-43 
(GAP-43). Notwithstanding, these proteins were found limited in primary melanoma and 
absent in melanoma in situ. Another research group found histological and molecular 
characteristics of malignant peripheral nerve sheath tumors in amelanotic melanomas of 
their BRAFV600E-Cdk4R24C mouse model that seems to be also present in a subset of 
human melanomas (oral presentation of Jennifer Landsberg, [307], FV28). Therefore, 
expression of myelin proteins might be a specific feature in a subset of melanomas 
contributing to melanoma heterogeneity. 
Due to an early downregulation of PMP2 protein by SOX10 inhibition in WM278 cells, a 
direct transactivation of PMP2 by SOX10 was suggested. In silico analyses identified 
three potential SOX10 binding sites in the PMP2 promoter region and ChIP as well as 
EMSA experiments indicated binding of SOX10 to the proximal PMP2 promoter region 
(section 4.8.2). 
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In order to investigate the role of PMP2 in melanoma cells, gain- and loss-of-function 
experiments were performed (section 4.9.2). PMP2 inhibition via RNA interference with 
two different siRNAs reduced cell number and viability in PMP2-positive but not in 
PMP2-negative cells (section 4.9.2.2, Figure 51). Since caspase 3 was activated by 
siPMP2b but not by siPMP2a, while p21 was induced by both siRNAs, it was suggested 
that PMP2 inhibition might be able to prevent cell cycle progression in PMP2-positive 
melanoma cells.  
Matrigel analysis showed decreased invasion after PMP2 inhibition in WM278 cells, 
which was only significant in case of the caspase 3-activating siPMP2b (section 4.9.2.3, 
Figure 52). Since myelination of neurons by Schwann cells is a highly migratory 
process, the influence of PMP2 on melanoma cell migration was further investigated by 
PMP2 overexpression. Stable PMP2 overexpression significantly increased invasion of 
WM278 cells but it could not rescue the SOX10 knockdown phenotype in these cells 
(section 4.9.2.3, Figure 53). Cell viability was not influenced by PMP2 overexpression. 
Moreover, PMP2 wild type and mutant variants were stably expressed in PMP2-
negative WM3211 cells (section 4.9.2.4). The L27D mutant has been described recently 
by Ruskamo et al. [219] to reduce PMP2 binding to the membrane. The Mut3 mutant 
represents a mutated form of PMP2 where all three amino acids that allow fatty acid 
binding according to Majava et al. [168] were mutated. On mRNA level, expression of 
PMP2 wild type and mutants was highly upregulated compared to control cells while 
only wild type PMP2 and the L27D mutant were also found expressed on protein level. 
It is possible that mutations of the three amino acids in Mut3 affect protein stability and 
thereby cause protein degradation. Notwithstanding, WM3211 stably transfected with 
PMP2 wild type, both PMP2 mutant forms, and control vector were subjected to a three-
dimensional spheroid assay (section 4.9.2.4). Quantification of this assay revealed that 
PMP2 wild type-overexpressing cells substantially increased invasiveness compared to 
the mutant and control cells. Overexpression of the L27D mutant also considerably 
increased the invasive capacity compared to the control cells but to a lesser extent than 
PMP2 wild type-expressing cells. Two explanations are possible for this observation: 
firstly, it is possible that PMP2 has another membrane binding domain that is not 
affected by the L27D mutation. Secondly, the membrane binding function might not be 
required for stimulating the invasive potential in melanoma cells. 
Taken these results together, SOX10 directly transactivates PMP2 and PMP2 plays a 
promigratory role in melanoma cells. PMP2 overexpression increased melanoma cell 
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invasion but the entire functions of PMP2 in melanoma cells remain to be elucidated. 
Due to its roles in the myelinating process of Schwann cells it is possible that PMP2 can 
modify membrane dynamics during migration processes or it might be involved in lipid 
signaling in the migrating cell. 
5.6 SOX10 regulated genes – parallels between Schwann cell, Schwannian 
tumor, and melanoma development 
SOX10 is expressed in NCCs and a subset of NCC-derived lineages. Without SOX10, 
no glia development occurs throughout the peripheral nervous system [31], [139], [248]. 
SOX10 continues to be expressed after lineage segregation, promotes differentiation, 
and is still expressed in melanocytes, glial cells of the central nervous system 
(oligodendrocytes), and glial cells of the peripheral nervous system (Schwann cells) 
[126], [139]. Schwann cell precursors proliferate, migrate along the dorsolateral axis, 
and differentiate for myelination of the peripheral neuronal axons. SOX10 directly 
regulates myelin gene expression in both types of glial cells although it does not control 
ERBB3 expression in oligodendrocytes in contrast to Schwann cells. Thus, SOX10 
functions in peripheral and central glia at different stages and through different 
mechanisms [256]. Another study demonstrated that siRNA-mediated downregulation of 
SOX10 promoted transdifferentiation of Schwannoma cells into myofibroblasts in vitro 
[218]. Thus, SOX10 is not only critical for melanocyte but also for oligodendrocyte and 
Schwann cell development and homeostasis. 
Lee et al. [151] performed RNA interference (SOX10 siRNA and control siRNA) and 
subsequent DNA microarray analysis to identify SOX10 target genes in a rat 
Schwannoma cell line (according to GEO profile GDS3480). ERBB3 and MIA were part 
of the genes that were downregulated more than 4-fold upon SOX10 inhibition. Also 
PMP2 was strongly downregulated by SOX10 inhibition in this array. Therefore, target 
genes of SOX10, which were identified in this study, seem to be also regulated by 
SOX10 in Schwannoma cells. Schwannoma is a benign nerve sheath tumor composed 
of Schwann cells outside the nerve. They grow slowly and only around 1% become 
malignant and form tumors such as neurofibrosarcoma. An immunohistochemical study 
recommended SOX10 as a specific and sensitive marker not only for melanomas but 
also for Schwannian (peripheral nerve sheath) tumors [188]. Moreover, SOX10 seems 
to be a prognostic marker in neuroectodermal tumor cells (including Schwannoma and 
Schwann-like cells in neuroblastoma) as proposed by Gershon et al. [81]. Fujiwara S. et 
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al. suggested that SOX10 transactivates S100B in Schwann cells and the SOX10-
S100B axis critically regulates Schwann cell proliferation and myelination [76]. 
As melanoma cells can be genetically and functionally connected with melanocyte 
precursors, it is interesting that melanocytes can directly evolve from SOX10-positive 
Schwann cell precursor cells during mouse embryonic development [2]. Thus, 
developing melanocytes and Schwann cells as well as their neoplastically transformed 
counterparts share several signaling molecules including SOX10. 
Other target genes of SOX10 that do not only play a key role in melanocyte but also in 
Schwann cell development have been investigated in melanoma cells in the present 
study (sections 4.5 and 4.10). Fate decision of nerve-linked Schwann cell and 
melanocyte precursors is controlled by neuregulin signaling through their ERBB3 
receptor [2]. It was shown that ERBB3 is required for Schwann cell precursor 
proliferation and migration along peripheral axons as well as for myelination in zebrafish 
and mouse models [166], [268]. Complete knockout of ERBB3 results in embryonic 
lethality with a complete loss of Schwann cell precursors and effects similar to various 
peripheral neuropathy symptoms [215]. SOX10 has been shown to regulate ERBB3 in 
NCCs and Schwann cells, where functional ERBB3 is required for differentiation, 
growth, and survival [212], [223]. Furthermore, neoplastic Schwann cells almost 
uniformly express ERBB3 and ERBB2 (with which it forms heterodimers upon 
activation) and they were suggested to promote Schwannoma pathogenesis [259]. 
Thus, ERBB3 is not only essential for Schwann cell differentiation and maintenance but 
also plays a role in neoplastic transformation similar to its function in melanomagenesis.  
Similarly, the endothelin receptor EDNRB is required for melanocyte and enterous 
nerve system development but also related to Schwann cell tumor formation and 
melanoma progression [55]. SOX10 interacts with EDNRB in the enteric nervous 
system as well as in melanocyte development and it was shown that SOX10 regulates 
EDNRB in melanocytes and enteric neuron precursors [253], [303], [306]. EDNRB is 
furthermore related to melanoma progression and also to the development of Schwann 
cell-derived tumors. 
The transcription factor EGR2 is critical for the differentiation of immature into 
myelinating Schwann cells [267]. EGR2 is a common coactivator of SOX10 in the 
regulation of myelin gene transcription and was shown to be regulated by SOX10 in 
Schwann cells [82], [122], [211], [258]. In this study, coregulation of PMP2 by SOX10 
and EGR2 was found in the PMP2-positive melanoma cell line WM278 (section 4.8.3). 
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Moreover, downregulation of expression was found for ERBB3, EDNRB, and EGR2 
upon SOX10 inhibition in different melanoma cell lines (sections 4.5 and 4.10). 
Regarding these data, it is hypothesized that SOX10 regulates common target genes 
and could thereby possess analogous functions in melanocytes and Schwann cell 
precursors but also in their neoplastic counterparts. 
5.7 Conclusion and outlook 
This study provides evidences for a hitherto undescribed regulatory role of SOX10 
during melanoma cell invasion and further highlights its role as a pro-survival factor in 
melanoma. However, the role of SOX10 in melanoma is most likely multifaceted. 
SOX10 is associated with stem cell development and maintenance. During neural crest 
development, SOX10 plays a role as stem cell factor maintaining multipotency and 
preventing premature neurogenesis [128]. SOX10 is not only relevant for the 
differentiation of melanocytes and glial cells, it is also crucial for survival and 
proliferation of multipotent neural crest stem cells [31]. Furthermore, SOX10 was found 
to be relevant for melanocyte stem cell maintenance in the adult organism [103]. A 
recent study revealed important roles of SOX10 promoting stem and EMT-like 
properties in mammary stem cells [62]. Several publications highlight common 
molecular and cellular mechanisms affecting self-renewal, phenotypic, and functional 
similarities between neural crest stem cells and melanoma cells that can be linked to 
SOX10 [237]. Co-expression of SOX10 and the neural crest stem cell marker p75 
correlates with a high metastatic potential and worse patient’s prognosis [49]. Together 
with SOX9, SOX10 regulates the putative stem cell marker nestin [72]. Tumor formation 
of subcutaneously injected SOX10-inhibited melanoma cells in non-obese diabetic-
severe combined immunodeficient and nude mice was impaired completely [239]. 
Cronin et al. [53] suggested that reduced tumor formation in mice that harbor SOX10 
heterozygocity is independent of the function of SOX10 as MITF activator. In summary, 
SOX10 is able to regulate stem cell functions, which seem to be specifically required for 
initiating and propagating melanoma. As suggested in the present and previous studies, 
SOX10 regulates targets genes whose functions have been related to Schwann cell 
differentiation. Therefore, SOX10 might be also relevant for the initiation and 
progression of glial cell tumors. 
In this study novel direct targets genes of SOX10 have been identified, i.e., the secreted 
factor MIA, which directly affects melanoma cell migration, and the cellular membrane-
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attached lipid binding protein PMP2, which entire functions in melanoma still need to be 
elucidated. SOX10 in general and both target genes specifically promote melanoma cell 
invasion (Figure 58). Strikingly, this is an important feature, as tumor metastases are 
the cause of 90% of human cancer deaths [250]. 
 
 
Figure 58 SOX10 regulates migration-associated genes in melanoma cells.  
In this study the direct regulation of MIA and PMP2 by SOX10 has been demonstrated. Both proteins can 
influence melanoma cell invasion and might therefore promote melanoma metastasis. 
This study highlights that transcription factors, which are essential for proliferation and 
migration of developing melanocytes, may contribute to melanoma progression. Curing 
therapies for patients with metastatic melanoma are still missing. Thus, manipulating the 
SOX10 signaling pathway could have a great therapeutical value [159]. To inhibit 
SOX10 in vivo in patients, SOX10-targeting siRNAs attached to nanoparticles could be 
injected. However, this method has not found its way to clinics yet. Another option is to 
search for small molecule inhibitors impairing SOX10 binding to DNA. As the DNA 
binding motif of SOX10, the HMG box, is found in all other SOX and HMG factors, this 
approach would have most likely toxic effects. Another problem is the general 
expression of SOX10 in a variety of tissues and intervention of SOX10 wild type 
functions is related to many severe organic defects. Therefore, targeting SOX10-
regulated genes that directly execute specific functions in melanoma would improve 
tumor-specific therapy. Affecting PMP2 functions might be beneficial in a subset of 
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melanomas but might be most likely a problem due to its essential contribution to 
myelination. 
MIA inhibition is a novel objective in melanoma therapy [230]. Schmidt et al. [231] 
showed that dimerization of MIA is required for its functional activity. The dodecapeptide 
AR71 prevented MIA dimerization and reduced melanoma cell migration and formation 
of metastasis in vitro and in vivo [231]. In conclusion, the analysis of melanoma-specific 
target genes of SOX10 is important for generating novel therapies to prevent melanoma 
cell migration and invasion. 
It further remains to be elucidated, how SOX10 promotes melanoma progression on the 
one hand and regulates differentiation and pigmentation in melanoblasts on the other 
hand. Besides, it would be interesting to determine the molecular mechanisms driving 
SOX10 to regulate the same target genes as PMP2, EDNRB, ERBB3, and EGR2 in 
melanoma and in Schwann or Schwannoma cells. Lineage-specific functions of these 
proteins might be related to altered protein levels, specific post-translational 
modification, the absence or presence of coregulators, or other contextual features. 
In conclusion, this study describes a crucial function of SOX10 in melanoma cell 
survival and invasion and led to the identification of novel target genes that mediate the 
functions of SOX10 in melanoma. 
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7 Supplementary figures 
Figure S1: SOX10 inhibition in the SOX10-
negative cell line WM3211. 
Cell death was analyzed by staining with AN-
Fluos and PI followed by flow cytometry in 
SOX10-negative WM3211 cells 96 hours after 
transfection of siSOX10a, siSOX10b, siControl, 
or no siRNA. AN- and PI-positive cells were 
examined in three independent experiments 
(mean ± SD). No significant increase in AN- and 
PI-positive cell fractions could be detected after 
SOX10 inhibition (one-way ANOVA versus siControl). 
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Figure S2: Expression of integrin α-subunits 3, 4, and V as well as integrin β-subunits 1 and 3 
after SOX10 inhibition. 
Expression of the integrin α-subunits 3 (ITGA3), 4 (ITGA4), and V (ITGAV) and the integrin β-subunits 1 
(ITGB1) and 3 (ITGB3) was analyzed by qRT-PCR in cell lines WM278, WM1232, and 1205Lu (mean ± 
SD of three independent experiments) 48 hours after transfection of siSOX10a, siSOX10b, or siControl 
(siCtrl). ITGA3 and ITGB1 were upregulated in all three cell lines after SOX10 inhibition. ITGA4 was 
downregulated with both SOX10-targeting siRNAs in WM278 and with siSOX10a in WM1232 and 
1205Lu. ITGB3 was downregulated in SOX10-inhibited WM278 and WM1232. No change was found for 
ITGAV after SOX10 inhibition. 
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Figure S3: LIVE/DEAD staining of spheroids after SOX10 inhibition and Matrigel invasion assay 
after blocking cell death with Z-VAD and Nec-1. 
(a) Representative pictures of spheroid formation 54 hours after transfection of siSOX10a, siSOX10b, 
siControl, or no siRNA, staining with calcein AM and EthD-1, and fluorescence microscopy are shown. 
Scale bar = 50 µm. (b) 1205Lu cells were treated with Z-VAD and Nec-1 or DMSO and transfected with 
siSOX10a, siSOX10b, siControl, or no siRNA one hour later. Cell death by staining with Annexin V-Fluos 
and PI and subsequent flow cytometry was investigated after 96 hours. Onset of cell death upon SOX10 
inhibition and with DMSO but not with Z-VAD and Nec-1 treatment was observed (mean ± SD of three 
independent experiments; *P<0.0001, one-way ANOVA versus siControl). (c) Cells were treated and 
transfected as described in (b). Matrigel invasion assays were carried out after 24 hours. SOX10 
inhibition significantly reduced cell invasion as determined in three independent experiments (*P<0.0001, 
one-way ANOVA versus siControl). 
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8 Abbreviations 
°C  degree Celsius 
ABAM  antibiotics and antimycotics 
ABCB5 adenosine triphosphate binding cassette sub-family B member 5 
ADP  adenosine diphosphate 
AHR  aryl hydrocarbon receptor 
AIDS  acquired immune deficiency syndrome 
AIM1  absent in melanoma 1 
ALM  acral lentiginous melanoma 
AN  Annexin V 
AP-2  activator protein 2 
APAF-1 apoptotic protease activating factor 1 
APAAP alkaline phosphatase-anti-alkaline-phosphatase 
APC  antigen presenting cell 
bp  base pairs 
BCA  bicinchoninic acid 
Bcl-2  B-cell lymphoma 2 
BH  Bcl-2 homology 
BMP  bone morphogenetic protein 
BRAF  V-Raf murine sarcoma viral oncogene homolog B 
BSA  bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
CDKs  cyclin-dependent kinases 
cDNA  copy deoxyribonucleic acid 
CMV  Cytomegalovirus 
c-Myc   myelocytomatosis viral oncogene homolog c 
ChIP  chromatin immunoprecipitation 
CREB   cAMP response element-binding protein 
CSH  cold spring harbor 
CtBP1  COOH-terminal binding protein 1 
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 
dT  deoxythymidine 
DCT   dopachrome tautomerase 
DIG  digoxygenin 
DISC  death-inducing signaling complex 
DLX  distal-less homeobox 
DMEM  Dulbecco’s modified Eagle Medium 
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DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonucleotide triphosphate 
ds  double-stranded 
DTT  dithiothreitol 
ECM  extracellular matrix 
EDNRB endothelin receptor type B 
EDTA  ethylenediaminetetraacetic acid 
e.g.  exempli gratia (Latin), for example  
EGR2  early growth response 2  
EHS  Engelbreth-Holm-Swarm 
eIF-2α  eukaryotic translation initiation factor 2 alpha 
EMA  European medicines agency 
EMEM  Eagle’s Minimum Essential Medium 
EMT  epithelial-to-mesenchymal transition 
ERBB3 erb-b2 receptor tyrosine kinase 3 
ERK  extracellular signal-related kinase 
EthD-1  ethidium homodimer-1 
FABP  fatty acid binding protein 
FACS  fluorescence-associated cell sorting 
FADD  Fas-associated protein with death domain 
FBS  fetal bovine serum 
FDA  Food and drug administration 
FGF  fibroblast growth factor 
FGFR  fibroblast growth factor receptor 
FOXD3 forkhead box D3 
FTL   ferritin light polypeptide 1 
G1-phase gap-phase 1 
G2-phase gap-phase 2 
GAP-43 growth-associated phosphoprotein-43 
GF  growth factor 
GH1   growth hormone 1 
GNA11 guanine nucleotide binding protein 11 
GNAQ  guanine nucleotide binding protein Q 
GTP  guanosine triphosphate 
H1FX-AS1 H1FX antisense RNA 1 
hAct Int2 human actin intron 2  
  Abbreviations 
 
181 
HBSS  Hank’s balanced salt solution 
HEPES 4- (2-hydroxyethyl)-1-piperazinethanesulfonic acid 
HMB45  human melanoma black 45 
HMG  high-mobility group 
HMGS-2 human melanocyte growth supplement-2 
HPRT  hypoxanthin-guanine phosphoribosyltransferase 
HRP  horse radish peroxydase 
IARC   International Agency for Research on Cancer 
Id  inhibitor of DNA-binding protein 
i.e.  id est (Latin), that is 
IFN  interferon 
IGF1R  insulin-like growth factor 1 receptor 
IHC  immunohistochemistry 
IL-2  interleukin-2 
ITGA  integrin alpha 
ITGB  integrin beta 
IUPAC  International Union of pure and Applied Chemistry 
kb  kilo base pairs 
kDa  kilo Dalton 
KLF10  Krueppel-like factor 10 
LB  Luria-Bertani broth 
Lef1  lymphoid enhancer-binding factor-1 
M  molar = mol/l 
M-phase mitosis 
MAG  myelin-associated glycoprotein 
MAPK  mitogen-activated protein kinase 
MBP  myelin basic protein 
MC1R  melanocortin 1 receptor 
McSCs melanocyte stem cells 
MEK  mitogen-activated protein kinase kinase 
Mel-CAM  melanoma cell adhesion molecule 
MIA  melanoma inhibitory activity 
MIB1  mindbomb E3 ubiquitin protein ligase 1 
MITF  microphthalmia-associated transcription factor 
MLANA melanoma antigen 
MPZ  myelin protein zero  
mRNA  messenger RNA 
  Abbreviations 
 
182 
MSX  msh homeobox 
NADPH nicotinamide adenine dinucleotide phosphate 
N-CAM neural cell adhesion molecule 
NCBI  National Center for Biotechnology Information 
NCC  neural crest cell 
NF1  neurofibromin 1 
NFκB  nuclear factor kappa B 
NR1D1 Nuclear receptor subfamily 1, group D, member 1 
n.s.  not significant 
p.a.  per analysi 
PARP1 poly (ADP-ribose) polymerase-1 
PAX  paired box protein 
PBS  phosphate-buffered saline 
PCD  programmed cell death 
PCR  polymerase chain reaction 
PCWH Peripheral demyelinating neuropathy, central dysmyelination, Waardenburg 
syndrome, and Hirschsprung disease 
PD-1  programmed cell death 1 receptor 
PD-L1  programmed cell death ligand 1 
PDGFR platelet-dervied growth factor receptor 
PI  propidium iodide 
piRNA  PIWI interacting RNA 
PIWI  P-element induced wimpy testis 
PI3K  phospoinositide 3-kinase 
PIK3CA  phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
PIPES  piperazine-N,N’bis(2-ethanesulfonic acid) 
PKA  protein kinase A 
PLP1  proteolipid protein 1 
PMP2  peripheral myelin protein 2 
PPP1R15A  Protein phosphatase 1 regulatory subunit 15A 
pRB  phosphorylated retinoblastoma protein 
PS  phosphatidyl serine 
PTEN  phosphatase and tensin homolog 
PVDF  polyvinylidene fluoride 
qRT-PCR quantitative real-time PCR 
rel. u.  relative units 
RGP  radial growth phase 
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RISC  RNA-induced silencing complex 
RIP  receptor interacting protein 
RNA  ribonucleic acid 
RNAi  RNA interference 
RPL27a  ribosomal protein 27 a 
rpm  revolutions per minute 
RTK  receptor tyrosine kinase 
RT-PCR reverse transcriptase PCR 
S-phase synthesis phase 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
siRNA  small interfering RNA 
shRNA small hairpin RNA 
SOX  (sex determing region-Y)-box 
SRY  sex determing region-Y 
TBX2  T-box 2 
TCDD  2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin 
TCTAP2α  transcription factor Ap-2 alpha 
TERT  telomerase reverse transcriptase 
TF  transcription factor 
TIPARP TCDD-inducible poly (ADP-ribose) polymerase 
TNF  tumor necrosis factor 
TP53  tumor protein 53 
TRAIL  TNF-related apoptosis-inducing ligand 
Tris  Tris(hydroxymethyl)aminomethane 
TYRP1 Tyrosinase-related protein 1 
UV  ultraviolet 
VGP  vertical growth phase 
Wnt  wingless 
w/v  weight per volume 
ZIC1  zink finger protein 1 
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